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ABSTRACT 
Autism spectrum disorders (ASDs) are a heterogeneous class of 
neurodevelopmental disorders that share the three core behavioral symptoms of 
impaired social interactions, communication deficits, and restrictive and repetitive 
behaviors. Our previous studies identified the novel X-linked ASD gene NEXMIF 
(KIAA2022, KIDLIA). Mutations in NEXMIF leading to loss of its protein product 
are responsible for the development of autistic features and intellectual disability 
in humans. However, the role NEXMIF plays in brain development and ASD 
remains largely unknown. Therefore, I investigated the behavioral impairments 
and cellular and molecular dysregulation that result from loss of NEXMIF in a 
transgenic mouse model. I found that male NEXMIF-/y hemizygous knockout (KO) 
mice replicate the behavioral alterations reported in affected humans and that 
cultured neurons from NEXMIF-/y KO brains show a significant decrease in neurite 
outgrowth, synaptic protein expression, and spine and synapse density. Loss of 
NEXMIF in cultured neurons also leads to altered expression of many genes 
including several involved in synaptic development and function. Reintroduction of 
viii 
some of the downregulated genes in cultured neurons rescued the decreased 
spine density and synaptic AMPAR levels observed from loss of NEXMIF. 
Several clinical reports have indicated that in females, haploinsufficiency of 
the X-linked NEXMIF gene causes symptoms similar to those observed in males 
lacking NEXMIF. Therefore, I examined the behavioral and molecular phenotypes 
in a transgenic mouse model of NEXMIF haploinsufficiency, female NEXMIF+/- 
mice. These animals displayed ASD-like behaviors, including impaired social 
interactions, repetitive self-grooming, and memory deficits. NEXMIF 
haploinsufficiency results in mosaic expression of the protein, resulting in two 
populations of neurons in the brain, those that express NEXMIF and those that do 
not. Interestingly, I found that both types of neurons demonstrated impairments in 
dendritic outgrowth, synaptic density, and the expression of important synaptic 
proteins. Together, these findings provide new insights into the cellular and 
molecular mechanisms of NEXMIF-dependent ASD and the role of NEXMIF in 
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1.1 Overview of brain development and neurodevelopment disorders 
 Basic structure and cellular organization of the brain 
The brain is the most complex organ in the body and is primarily made up of cells 
called neurons and glia. There are approximately 86 billion neurons in the human 
brain, which make trillions of connections, called synapses, resulting in a highly 
complex network (Azevedo et al., 2009). The normal development of this network 
is important for overall functioning of the brain.  
The brain is organized into various regions based on anatomical structure 
and cognitive function. The neocortex makes up 80% of the of the volume of the 
brain and has characteristic folds and fissures (gyri and sulci) to increase its 
surface area (Azevedo et al., 2009; Kaas, 2013). Also known as the cerebral 
cortex, the neocortex is divided by the longitudinal fissure into two hemispheres, 
which remain connected by the corpus callosum. Each hemisphere is subdivided 
by the central sulcus and the lateral sulcus into four sections called the frontal, 
parietal, temporal, and occipital lobes.  
The neurons of the cortex are organized into 6 distinct layers parallel to the 
surface of the brain. These layers vary in cell density and play different roles in 
overall brain function. For example, layer 5 (L5) is the main output layer while L4 
is the main thalamic input layer and L2/3 form intracortical associations between 
the layers (Douglas and Martin, 2004; Feldmeyer, 2012; Schubert et al., 2007). 
Cortical neurons make connections with other neurons throughout the cortex but 
show particularly high interconnectedness with neurons within the same cortical 
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column. Columns are functional units of the cortex oriented perpendicular to the 
surface of the brain and are comprised of neurons from all 6 cortical layers  
(Bonhoeffer and Grinvald, 1991; Molnar, 2013; Rakic, 2008). 
Other important brain regions include the hippocampus and the cerebellum. 
The hippocampus plays key roles in memory formation. The major components of 
the hippocampus include the dentate gyrus, which consists primarily of granule 
cells, and the cornu ammonis (CA), which consists primarily of pyramidal cells and 
is subdivided into four regions (CA1-CA4) (Wible, 2013). The cerebellum is located 
at the back of the brain and is important for movement. In humans, it is the next 
largest portion of the brain in volume after the cerebral cortex, and it too uses 
elaborate folding to increase its surface area (Ackerman, 1992; Herrup and 
Kuemerle, 1997). Thus, even in its complexity, the brain maintains organization 
within its structure to delegate and coordinate its various functions. 
 Neuronal morphology  
Neurons have a complex morphology distinct from other cell types in the body. 
Proper development of neurons’ two distinct domains, the axon and the dendrites, 
is crucial for normal nervous system function. The dendrites form a complex and 
highly branched arbor and are covered in small structures called spines that 
receive and integrate signals from presynaptic axons. The axon is a single, long 
process that extends from the cell body, or soma, of a neuron. The axon 
propagates signals to postsynaptic dendritic spines on a downstream neuron. 
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Neurons can be classified into many different subtypes based on a variety 
of criteria including morphological features, electrophysiological properties, gene 
expression, and connectivity (Van Aerde and Feldmeyer, 2015; Ascoli et al., 2008; 
Boudewijns et al., 2013; Donohue and Ascoli, 2008; Gentet, 2012; Gonchar et al., 
2008; Kubota et al., 2011; Markram et al., 2004; Miyamae et al., 2017; Spruston, 
2008; Tremblay et al., 2016). Most broadly, neurons can be classified based on 
the type of neurotransmitters they release, such as glutamate for glutamatergic 
neurons, or gamma-aminobutryric acid (GABA) for GABAergic neurons. Owning 
to the close relationship between form and function, the different subtypes of 
neurons maintain varied morphologies. One of the most abundant types of neurons 
in the cortex is excitatory pyramidal neurons, which are defined by the pyramidal 
shape of their soma and their distinct apical and basal dendritic arbors (Spruston, 
2008). Even among pyramidal neurons there is diversity in their structure, for 
example with L2 pyramidal neurons maintaining particularly dense apical trees as 
compared to L3 or L5 pyramidal neurons and CA3 pyramidal neurons branching 
closer to the soma than CA1 pyramidal neurons (Van Aerde and Feldmeyer, 2015; 
Spruston, 2008). Likewise, there is variety in the morphology of inhibitory neurons, 
ranging from cerebellar Purkinje cells, which have a characteristic and extensively 
branched fan-shaped dendritic arbor, to chandelier cells, which have dense axonal 
branches with rows of axon terminal boutons resembling the candlesticks of a 
chandelier (Gentet, 2012; Markram et al., 2004; Sultan and Shi, 2018; Tremblay 
et al., 2016). 
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The stages of neurite growth in primary cultured neurons have been well 
characterized, making these neurons an excellent model for studying neurite 
development and growth (Dotti et al., 1988; Namba et al., 2015). Neurons cultured 
in vitro begin as a simple round soma, attach to a substrate, and form lamellipodia. 
Within 12 hours, neurons develop several immature neurites and select one 
neurite to elongate into the axon within 24 hours. After 5-7 days, the remaining 
neurites grow and branch to form the complex dendritic arbor. Both the axon and 
the dendrites continue to mature and, at 14 days in vitro (DIV), dendritic spines 
and synaptic connections to other neurons will form. 
In vivo, excitatory neurons undergo radial migration through the cortex to 
form its six distinct layers. This process begins with neural progenitor cells at the 
ventricles undergoing asymmetrical division to self-renew the progenitor as well as 
produce a post-mitotic neuron. The fate of the daughter cells is highly controlled 
by chromatin regulators, which establish specific gene expression profiles for the 
renewed neural progenitor and the newly formed postmitotic neuron (Daynac and 
Petritsch, 2017; Homem et al., 2015; Kohwi and Doe, 2013; Lessard et al., 2007; 
Sokpor et al., 2017). These new neurons then migrate along radial glial scaffolds 
in an inside-out manner to their final destination in the brain, with the earliest 
neurons forming the deepest layers and the later neurons forming the outer layers 
(Cadwell et al., 2019; Hatanaka et al., 2016). Throughout this process, migrating 
neurons alter their morphology, undergoing a multipolar to bipolar transition 
(LoTurco and Bai, 2006). After arriving at their final destination, neurons will 
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undergo extensive dendritic outgrowth, followed by pruning, to create a mature 
structure (Riccomagno and Kolodkin, 2015). The particular morphology of the 
dendritic arbor is regulated for each neuronal subtype according to its particular 
function. The selective removal of unnecessary dendritic branches, known as 
pruning, is crucial for proper neural network formation. After this refinement period, 
dendrites begin to stabilize, though a small degree of dendritic plasticity is 
observed after early development (Wu et al., 1999). In contrast, cortical inhibitory 
interneurons undergo tangential migration. These neurons are formed from radial 
glial progenitor cells in the medial and caudal ganglionic eminences and migrate 
parallel to the ventricular surface to integrate into cortical circuits (Cadwell et al., 
2019; Faux et al., 2012; Sultan and Shi, 2018).  
 Synaptic structure, function, and plasticity 
Synapses are specialized structures, which connect neurons to form neural 
networks. Crucial for overall cognitive function, synapses transmit electrical signals 
from one neuron to the next using chemical neurotransmitters. Synapses are made 
up of a presynaptic axon terminal, the extracellular space between the neurons 
called the synaptic cleft, and the postsynaptic dendrite. Excitatory synapses are 
formed on the small, physical protrusions of dendrites called spines, while 
inhibitory synapses are generally formed on the dendritic shaft.  
Formation of a functional synapse requires the presynaptic axon and the 
postsynaptic dendrite to come into close enough proximity to make contact. Axons 
are guided to recognize and grow towards their correct target by detecting 
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gradients of chemical cues and interacting with mechanical cues (Chédotal and 
Richards, 2010; Vitriol and Zheng, 2012). The axonal growth cone has receptors 
to detect molecular cues, such as netrins, neurotrophins, semaphorins, and Slits 
(Kolodkin and Tessier-Lavigne, 2011; McAllister, 2002; Raper and Mason, 2010). 
Additionally, axon pathfinding involves interactions with adhesive cues from the 
extracellular matrix or from neuronal surfaces expressing transmembrane 
proteins. These contact dependent cues include ephrins, laminin, fibronectin, and 
cell adhesion molecules (CAMs) (Kerstein et al., 2015; Raper and Mason, 2010). 
Synaptogenesis continues after the initial contact of the axon and dendrite 
with mechanical changes, including stabilization of the connection and maturation 
of the pre- and postsynaptic structures, and recruitment of the functional molecular 
machinery. Synaptic adhesion molecules such as SynCAM, N-cadherin, 
neuroligin/neurexin, and protocadherin-γ localize to synaptic sites and help provide 
a physical link between the pre- and postsynaptic sites (Chamma and Thoumine, 
2018; Missler et al., 2012; Waites et al., 2005; Weiner, 2006). The dynamic finger-
like protrusions, called filopodia, which emerge from the dendritic shaft will mature 
into larger and more stable spines by the polymerization of actin into a stable core  
(Berry and Nedivi, 2017; Kilinc, 2018; Petzoldt and Sigrist, 2014). Mature spines 
have a mushroom shape with a large head for the postsynaptic synaptic machinery 
and a thin neck to act as a barrier for other intracellular components. In addition to 
the cytoskeleton, the pre- and postsynaptic sites organize a physical framework 
for their synaptic machinery using scaffolding molecules. The presynaptic active 
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zone makes use of proteins such as Bassoon, Piccolo, and RIM while the 
postsynaptic density includes proteins such as PSD-95, Shank, and Homer 
(Friedman et al., 2000; Petzoldt and Sigrist, 2014; Ziv and Fisher-Lavie, 2014). 
Functional synapses also require the recruitment of key molecules including 
synaptic vesicle exocytosis machinery such as SNARE proteins, neurotransmitter 
receptors such as NMDA and AMPA receptors, ion channels such as voltage-
gated calcium channels, and  calcium-binding molecules such as calcium 
calmodulin- dependent protein kinase II (CaMKII) (Munno and Syed, 2003; Waites 
et al., 2005). 
In addition to synapse formation, synapse elimination is another key 
component of proper synapse development. In early development, there is an 
excess of synaptic growth and formation (Rakic et al., 1986). Later on, pruning 
occurs, in which many synapses are selectively eliminated in order to refine the 
connections for proper overall brain circuitry (Purves and Lichtman, 1980; Waites 
et al., 2005). One mechanism for synapse elimination is their activity-dependent 
engulfment by microglia, a type of glial cell in the brain capable of phagocytosis 
(Kim et al., 2017; Neniskyte and Gross, 2017; Paolicelli et al., 2011; Thion and 
Garel, 2018). 
Once functional synapses are formed, they are capable of synaptic 
transmission. Transmission begins when an action potential reaches the axon 
terminal, causing an influx of Ca2+ and the subsequent exocytosis of synaptic 
vesicles containing neurotransmitters. The neurotransmitters are released into the 
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synaptic cleft and bind to neurotransmitter receptors on the surface of the dendritic 
spine. This initiates a signaling cascade to excite the post-synaptic neuron and 
propagate the signal with a new action potential (if the neurotransmitters are 
excitatory, such as glutamate) or to prevent excitation (if the neurotransmitters are 
inhibitory, such as GABA).  
The strength of a synaptic connection can change in response to neuronal 
activity. This is a key feature of synaptic connections, known as synaptic plasticity, 
and is the molecular basis underlying learning and memory. There are two major 
types of synaptic plasticity: Hebbian plasticity and homeostatic synaptic plasticity  
(Davis, 2006; Marder and Goaillard, 2006; Turrigiano and Nelson, 2004). 
Hebbian plasticity consists of long term alterations in synaptic strength. An 
enhancement in synaptic strength is known as long-term potentiation (LTP) and a 
reduction in strength, long-term depression (LTD). LTP can be induced by high 
frequency stimulation (50-100 Hz) and LTD by low frequency stimulation (0.1-1Hz). 
In this way, neurons are able to strengthen synaptic connections that are used 
frequently and spend fewer resources on connections that are not used often 
(Abraham et al., 2019; Bear and Malenka, 1994; Humeau and Choquet, 2019; 
Siegelbaum and Kandel, 1991). 
Homeostatic synaptic plasticity (HSP) is a compensatory form of plasticity 
that balances other modulations in synaptic strength to maintain network stability 
using synaptic scaling. If unchecked, the self-reinforcing feedback of Hebbian 
plasticity could lead to runaway excitation and saturated synapses (in the case of 
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LTP) or synapse silencing and loss (in the case of LTD). This unstable state could 
change the overall excitability of the postsynaptic neuron and prevent it from 
effectively storing information through the differences in synaptic strengths 
(Turrigiano, 2012). HSP is therefore an important mechanism for maintaining the 
stability of the network at a set point while preserving the relative differences in 
synaptic strength (Keith and El-Husseini, 2008; Pozo and Goda, 2010). With 
prolonged increases in activity, HSP reduces synaptic strength with downscaling. 
In contrast, under chronic suppression of activity, HSP increases synaptic strength 
with upscaling. Thus, Hebbian and homeostatic plasticity work together to 
dynamically change synaptic strength in response to changes in activity. 
In both forms of synaptic plasticity, changes in synaptic strength are 
mediated by changes in the expression of the excitatory glutamate receptor 
AMPAR at the postsynaptic surface (Diering and Huganir, 2018; Li et al., 2019a; 
Turrigiano, 2012). Strengthening of the synapse, such as in LTP and homeostatic 
up-scaling, involves insertion of more AMPARs into the synaptic surface, while 
weakening of the synapse, such as in LTD and homeostatic down-scaling, involves 
internalization of AMPARs from the surface (Li et al., 2019a; Lledo et al., 1998; 
Lüscher et al., 1999). This trafficking of AMPARs to and from the synaptic surface 
is a tightly regulated mechanism as this process is crucial for functional synaptic 
activity. 
 Neuronal processes vulnerable to neurodevelopmental disorders 
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Development of the brain is very complex and the appropriate regulation of each 
stage is necessary for proper cortical function. Disruption of various developmental 
processes can cause abnormalities in overall brain connectivity and lead to 
neurodevelopmental disorders (NDDs) including cortical malformations, 
intellectual disability, attention-deficit/hyperactivity disorder (ADHD), and autism 
spectrum disorder (ASD) (Morris-Rosendahl and Crocq, 2020; Parenti et al., 2020; 
Thapar and Rutter, 2015). As NDDs can be caused by impairments in various 
stages of development, they are heterogeneous in their clinical manifestations and 
finding a particular molecular mechanism underlying the pathology can be difficult. 
Some of the key developmental processes that are vulnerable to errors leading to 
NDDs include neurogenesis, neuronal migration, neurite extension and 
development, and synaptogenesis (Hu et al., 2014; Klingler et al., 2021; Zoghbi, 
2003). 
The first stage in neuronal development is neurogenesis. Asymmetric 
division of progenitor cells gives rise to neurons. Altered progenitor proliferation 
can change the number of neurons produced and ultimately the size of the brain. 
Changes in brain size are known as macrocephaly and microcephaly, where 
macrocephaly is an increase in brain size and microcephaly is a decrease in brain 
size. For example, microcephaly has been linked to mutations in genes associated 
with the cell cycle such as centrosome proteins (CENPJ, MCHP1) and spindle 
proteins (ASPM, WDR62) (Klingler et al., 2021; Pirozzi et al., 2018). When the 
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neural progenitors can’t undergo normal cell division, there are fewer neurons 
formed resulting in a smaller brain. 
After neuron proliferation, the next critical phase in brain development is 
neuronal migration. Neurons must migrate through the layers of the neocortex from 
their birthplace at the ventricular zone to their final destination at the cortical plate. 
Lissencephaly, a smooth brain, has been shown to be a cortical malformation 
associated with impairments in neural migration. Typically, the human brain has 
folds, known as gyri, creating grooves, known as sulci, which increases the surface 
area of the brain. In lissencephaly, there is a lack of cortical folding and often a 
thickening of the cortex. Lissencephaly has been linked to mutations in genes 
related to microtubule structural proteins or microtubule associated proteins (LIS1, 
DCX) (Hu et al., 2014; Kato and Dobyns, 2003; Tan et al., 2018). For neurons to 
migrate through the cortex, rapid and dynamic rearrangement of the cytoskeleton, 
including microtubules, is necessary. Thus, impairments in microtubule dynamics 
results in the inability of neurons to properly migrate. 
Proper brain development involves the formation of functional neuronal 
connections, thus creating neural networks throughout the brain. This requires 
further maturation of the neurons with the development and maintenance of a 
complex dendritic arbor and dendritic spines. After growth of an extensive dendritic 
arbor and many spines, selective pruning is required to refine the neuronal 
connections. Therefore, in addition to errors in cytoskeletal elements (Lasser et 
al., 2018; Parato and Bartolini, 2021; Spence and Soderling, 2015; Yan et al., 
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2016) and cell adhesion molecules (Cao and Tabuchi, 2017; Gnanapavan and 
Giovannoni, 2013; Parenti et al., 2020) required for the initial formation of neural 
circuits, impairments in pruning mechanisms, such as autophagy (Fleming and 
Rubinsztein, 2020; Lv and Ma, 2020; Neniskyte and Gross, 2017), can result in 
aberrant dendritic growth and synapse formation. This can lead to irregular 
network function, as observed in intellectual disability and ASD (Ameis and Catani, 
2015; Betancur et al., 2009; Gilbert and Man, 2016; Lima Caldeira et al., 2019; 
Turner et al., 2006). 
 
1.2 Autism spectrum disorder (ASD) 
 Introduction to ASD 
Autism spectrum disorder (ASD) is a neurodevelopmental disorder with a strong 
genetic basis. ASDs are commonly characterized by impairments in 
communication, restrictive and repetitive behaviors, and deficits in social 
interactions (American Psychiatric Association, 2013; Chen et al., 2015a). In 
addition to the core ASD behavioral phenotypes, many ASDs also present with 
comorbid developmental, psychiatric, and physical phenotypes. Reports indicate 
that between about 25-70% of individuals with ASD are comorbid for intellectual 
disability  (Chiurazzi et al., 2020; Idring et al., 2015; Maenner et al., 2020; La Malfa 
et al., 2004; Matson and Shoemaker, 2009). Many people with ASD also suffer 
from attention deficit/hyperactivity disorder (ADHD), obsessive compulsive 
disorder (OCD), and anxiety (Hartley et al., 2008; Simonoff et al., 2008). Other 
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common comorbidities include epilepsy, gastrointestinal (GI) issues, motor control 
problems, and sleep disorders (Limoges et al., 2005; Mannion and Leader, 2013; 
Nikolov et al., 2009).  
The prevalence of ASDs is rising with current estimates reaching 1 in 54 
individuals in the United States (Maenner et al., 2020). This increasing prevalence 
emphasizes the growing societal burden due to increased need for resources to 
care for and support individuals with a range of abilities and symptoms (Lavelle et 
al., 2014; Xu et al., 2019). As there is no cure for ASD, the costs of treatment and 
care become substantial as they accumulate over a lifetime (Agrawal et al., 2018; 
Buescher et al., 2014; Horlin et al., 2014). Therefore, scientific discoveries in the 
underlying mechanisms of ASD are essential to provide guidance for improved 
diagnosis and pharmacological intervention of the disorder. 
 ASD genes and genetics 
ASDs are highly heterogeneous with hundreds of genetic variants implicated in its 
development. ASDs have a strong genetic component and are highly heritable, as 
seen in studies of families and twins, which indicate a high concordance rate of 
ASD. Different diagnostic methods result in varied estimates, but most studies 
agree that monozygotic twin concordance rates (~60%-90%) are much higher than 
dizygotic twin concordance rates (~5%-40%) (Castelbaum et al., 2020; Chen et 
al., 2015a; Colvert et al., 2015; Hu et al., 2019; McKernan et al., 2017; Tick et al., 
2016). Additionally, the risk of ASD is higher in siblings of patients with ASD 
compared to that of the general population (McKernan et al., 2017; Ozonoff et al., 
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2011). There also appears to be an increased inheritance of specific autistic traits 
and specific phenotypes (Hu et al., 2019). 
However, most ASD associated genes account for no more than 1% of ASD 
cases (Abrahams and Geschwind, 2008; Fernandez and Scherer, 2017), 
emphasizing the vast genetic landscape underlying ASD pathology. Though these 
risk genes have diverse roles, many converge on similar developmental and 
molecular pathways including synapse structure and function, excitation/inhibition 
balance, axon and dendrite outgrowth, and neuronal connectivity (Varcin and 
Jeste, 2017). Genome-wide association and large-scale sequencing studies have 
demonstrated that the genetic variants associated with ASD risk genes can be 
categorized as de novo mutations, rare inherited variants, and copy number 
variations (Abrahams and Geschwind, 2008; Gaugler et al., 2014; Huguet et al., 
2013; Iossifov et al., 2012; Krumm et al., 2015; Levy et al., 2011; Pinto et al., 2010; 
Ronemus et al., 2014; De Rubeis et al., 2014; Sanders et al., 2012; Sebat et al., 
2007; Takata et al., 2016; Yu et al., 2013; Ziats and Rennert, 2016).  
To make things more complicated, in addition to these monogenic 
disorders, ASD can occur from polygenic variation in which the sum of many small 
effects in risk alleles contribute together to manifest the disease (Iakoucheva et 
al., 2019; De La Torre-Ubieta et al., 2016; Weiner et al., 2017). Indeed, a clear, 
causative genetic variant has only been identified in about 25% of patients 
diagnosed with ASD (Fernandez and Scherer, 2017; Jeste and Geschwind, 2014; 
Quesnel-Vallières et al., 2019). Several studies have shown polygenic effects in 
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patients with ASD with more than one deleterious mutation (Guo et al., 2019; 
Huguet et al., 2013; Schaaf et al., 2011; Weiner et al., 2017; Ziats and Rennert, 
2016). Thus, the variability in the genetics underlying ASD pathology makes 
studying the causative neurobiological pathways for potential treatments a major 
challenge. 
 Cellular and molecular alterations in ASD 
Just as the genetic causes of ASD are diverse, the cellular and molecular 
phenotypes underlying the neuropathology can be quite varied. However, it has 
been observed that many risk genes converge on common molecular pathways 
and cellular phenotypes, which may help explain how similar behavioral 
phenotypes manifest from genetically heterogeneous individuals. Indeed, 
disruptions in the proliferation and positioning of the correct number of neurons, 
the growth of their neuronal processes, and the formation of the correct number of 
functional synapses can all lead to defects in neural network connectivity which 
contribute to ASD etiology (De La Torre-Ubieta et al., 2016).  
1.2.3.1 Neurogenesis and migration in ASD 
One recurring feature observed in ASD is an impairment in overall brain 
growth, leading to structural abnormalities such as micro- or macrocephaly (Chen 
et al., 2015a; Courchesne et al., 2011a; Donovan and Basson, 2017; Fombonne 
et al., 1999; Hazlett et al., 2011; Klingler et al., 2021; Lainhart et al., 1997). 
Microcephaly is defined as a head circumference below the 3rd percentile and 
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macrocephaly as that above the 97th percentile (Fombonne et al., 1999). Estimates 
of the prevalence of microcephaly in ASD range from 3-15% while reported rates 
of macrocephaly in ASD tend to be higher, ranging from 14-34% (Ben-Itzchak et 
al., 2013; Deutsch and Joseph, 2003; Fombonne et al., 1999; Grandgeorge et al., 
2013; Lainhart et al., 2006; Miles et al., 2000; Sacco et al., 2007). Mutations in 
several ASD genes have been reported to cause macrocephaly including PTEN, 
CHD8, PAK1, and WDFY3 (Abghari et al., 2019; Bernier et al., 2014; Butler et al., 
2005; Buxbaum et al., 2007; Le Duc et al., 2019; Harms et al., 2018; Horn et al., 
2019; McBride et al., 2010; Orrico et al., 2009; Prontera et al., 2014; Varga et al., 
2009). Others have been linked to microcephaly including DYRK1A, CDKL5, and 
TRIO (Ba et al., 2016; Van Bon et al., 2016; Ji et al., 2015; Pengelly et al., 2016; 
Russo et al., 2009; Scala et al., 2005). 
The changes in overall brain growth observed in ASD suggest underlying 
impairments in mechanisms such as neuron proliferation and differentiation. 
Indeed, a number of ASD-associated genes converge on neurogenesis as part of 
their underlying pathobiology (Courchesne et al., 2011b, 2019; Kaushik and 
Zarbalis, 2016; Marchetto et al., 2017; Mariani et al., 2015; Packer, 2016; Pinto et 
al., 2010; Stoner et al., 2014). For example, CHD8 deficiency in mice has been 
shown to increase brain weight and volume and to increase proliferation during 
neurogenesis (Gompers et al., 2017; Katayama et al., 2016; Platt et al., 2017). 
Similarly, mice lacking WDFY3 show macrocephaly and excess proliferation of 
neuronal progenitor cells (Le Duc et al., 2019; Orosco et al., 2014). Also, 
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conditional knockdown of BAF170 promoted indirect neurogenesis through the 
increased production of intermediate progenitors from radial glial cells, ultimately 
resulting in an increased number of neurons and an enlarged cortex (Tuoc et al., 
2013). Loss of PTEN is well known for its connection to macrocephaly and has 
been shown to enhance pro-growth pathways leading to enhanced proliferation 
(Amiri et al., 2012; Chen et al., 2015b; Fraser et al., 2004; Gregorian et al., 2009; 
Groszer et al., 2001). Conversely, PAK1 deficiency in mice reduces the number of 
neurons in several layers of the cortex and the pool of proliferating progenitor cells 
(Pan et al., 2015). Thus, altered neuronal proliferation can have a profound effect 
on brain size and overall cortical development in ASD. 
Postmortem studies of brain tissue from individuals with ASD provide 
evidence to support impaired neuronal migration as an underlying neurobiological 
mechanism in ASD. Abnormalities in cytoarchitectural organization have been 
observed including ectopic cell clustering, cortical disorganization, aberrant 
laminar distribution of neurons, and irregular gray-white matter boundaries (Avino 
and Hutsler, 2010; Stoner et al., 2014; Wegiel et al., 2010). Further support for 
migration defects to play a role in ASD pathogenesis comes from the fact that 
several ASD risk genes have been implicated in neuronal migration. Of particular 
note is RELN, which is well known for its role in neuronal migration (Reiner et al., 
2016; Wasser and Herz, 2017). Indeed, loss of RELN in humans has been shown 
to cause lissencephaly with cerebellar hypoplasia (Hong et al., 2000) and the 
RELN KO mouse, reeler¸ demonstrates layer disorganization throughout the 
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cortex due to abnormal neuron migration (Badea et al., 2007; Boyle et al., 2011; 
Curran and D’Arcangelo, 1998; D’Arcangelo et al., 1995; Hirotsune et al., 1995; 
Yabut et al., 2007). Additionally, loss of CNTNAP2 in humans leads to abnormal 
neuron organization in clusters and ectopic neurons in the white matter (Alarcón 
et al., 2008; Rodenas-Cuadrado et al., 2014; Strauss et al., 2006; Whitehouse et 
al., 2011) and in mice leads to abnormal distribution of neurons in groups and 
ectopic neurons in the corpus callosum (Peñagarikano et al., 2011). Loss of 
NCKAP1 has been shown to promote neuronal migration (Guo et al., 2020) while 
premature, ectopic expression inhibits neuronal migration (Yokota et al., 2007). 
Altered migration has also been observed from reduced expression of PTEN (Li et 
al., 2002), PAK1 (Causeret et al., 2009), and TRIO (Peng et al., 2010). These 
studies support a likely role for impaired neuronal migration in improper positioning 
for circuit-level organization in ASD. 
1.2.3.2 Neurite outgrowth and neuronal morphology in ASD  
Disruptions in functional connectivity are considered a major defect in ASD (Carroll 
et al., 2021; Geschwind and Levitt, 2007; Hull et al., 2017). Indeed, functional 
imaging studies suggest there is local hyperconnectivity and long-range 
hypoconnectivity in ASD brains (Belmonte et al., 2004; Cooper et al., 2017; 
Damarla et al., 2010; Ebisch et al., 2011; Hull et al., 2017; Iidaka et al., 2019; Just 
et al., 2012; Di Martino et al., 2011; Mash et al., 2020; Maximo et al., 2014; Moseley 
et al., 2015; Müller et al., 2011; Vissers et al., 2012; Woodward et al., 2017). A 
likely mechanism underlying these impairments in functional connectivity is altered 
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structural connectivity as changes in neuronal morphogenesis and neurite 
outgrowth have a significant impact on circuit function during brain development 
(McFadden and Minshew, 2013). It has even been proposed that long-range 
hypoconnectivity in ASD is in part due to the hyperconnectivity caused by 
excessive local axonal and dendritic processes which outcompete inputs from 
more distal brain regions (Courchesne et al., 2007).  
Evidence supporting altered neurite outgrowth as an underlying cellular 
phenotype in ASD comes from diffusion tensor imaging (DTI) and postmortem 
studies of ASD brains. DTI measurement of fiber tract microstructure in the brains 
of individuals with ASD demonstrate alterations in the morphology of white matter 
tracts, reflecting alterations in axon number, pathfinding, and arborization 
(Alexander et al., 2007; Ameis and Catani, 2015; Kana et al., 2014; Keller et al., 
2007; Lee et al., 2007; Solso et al., 2016; Travers et al., 2012; Zikopoulos et al., 
2010). Furthermore, Golgi staining of hippocampal neurons from patients with ASD 
showed reduced dendritic branching (Raymond et al., 1995), and MAP2 staining 
of the dorsolateral prefrontal cortex revealed reduced dendrite numbers in the 
individuals with ASD (Mukaetova-Ladinska et al., 2004). Additionally, several ASD 
genes have been implicated in the processes of neuronal morphogenesis, axon 
guidance, and dendritic arborization. It has been consistently shown that PTEN 
deficiency results in axon and dendrite overgrowth, as well as neuronal 
hypertrophy (Cupolillo et al., 2016; Fraser et al., 2008; Haws et al., 2014; Jaworski 
et al., 2005; Kwon et al., 2006; Weston et al., 2014; Wong et al., 2020). Loss of 
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TSC1 results in substantial changes in neuron morphogenesis, including ectopic 
axon formation (Choi et al., 2008; Floricel et al., 2007; Meikle et al., 2007; Uhlmann 
et al., 2002). Pak1/Pak3 double knockouts exhibit less complex neuronal 
morphology and introduction of a dominant negative form of PAK1 caused a 
reduction in the dendritic branching (Hayashi et al., 2007; Huang et al., 2011). 
Overexpression of UBE3A in an ASD mouse model reduces dendritic branching 
(Khatri et al., 2018). Reduced neurite outgrowth is also observed from loss of 
NCKAP1, MeCP2, CHD8, DOCK4, PRICKLE2, and TAOK2 (Armstrong et al., 
1995; Calderon de Anda et al., 2012; Durak et al., 2016; Kishi and Macklis, 2004; 
Rietveld et al., 2015; Sowers et al., 2013; Ueda et al., 2008; Xiao et al., 2013; Xu 
et al., 2018; Yokota et al., 2007). 
1.2.3.3 Synapse formation and function in ASD 
Impaired synaptogenesis is one of the most commonly observed cellular 
phenotypes in ASD with alterations in synaptic structure and function considered 
a hallmark of ASD (Bagni and Zukin, 2019; Bourgeron, 2009, 2015; Carroll et al., 
2021; Gilbert and Man, 2017; Guang et al., 2018; Phillips and Pozzo-Miller, 2014; 
Zoghbi and Bear, 2012). Indeed, dendritic spine density is increased on Golgi 
stained cortical neurons from ASD subjects (Hutsler and Zhang, 2010; Tang et al., 
2014). Additionally, many ASD-associated genes have functions which converge 
at the synapse including those involved in actin dynamics, cell-cell adhesion, and 
synaptic scaffolding (Betancur et al., 2009; Joensuu et al., 2018; Lin et al., 2016; 
Martínez-Cerdeño, 2017; Penzes et al., 2011; Verma et al., 2019). For example, it 
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has been consistently shown that PTEN deficiency results in increased synapse 
number (Cupolillo et al., 2016; Fraser et al., 2008; Haws et al., 2014; Jaworski et 
al., 2005; Kwon et al., 2006; Weston et al., 2014). Loss of TSC1 also leads to 
increased dendritic spine density (Tavazoie et al., 2005). SHANK3 deficiency 
results in reduced spine density and, often, increased spine length, indicating less 
mature spines (Durand et al., 2012; Peça et al., 2011; Roussignol et al., 2005; 
Wang et al., 2011b; Zhou et al., 2016). Knockdown of NCKAP1 using shRNA also 
resulted in reduced spine density (Yokota et al., 2007). Also, shRNA knockdown 
or haploinsufficiency of CYFIP1 leads to an increase in the fraction of immature 
spines and filopodia (Pathania et al., 2014; De Rubeis et al., 2013). Similarly, 
MeCP2 deficiency leads to reduced spine density in pyramidal cortical neurons 
and hippocampal CA1 neurons from affected humans and mouse models 
(Armstrong et al., 1995; Belichenko et al., 1994; Chapleau et al., 2009; Fukuda et 
al., 2005; Stuss et al., 2012; Tropea et al., 2009). Haploinsufficiency of SYNGAP1 
leads to premature spine maturation with more mature mushroom type spines and 
fewer less mature stubby type spines, as well as premature pruning (Aceti et al., 
2015; Carlisle et al., 2008; Clement et al., 2012, 2013; Kim et al., 2003; Vazquez 
et al., 2004). The changes in spine number in ASD may be due to impairments in 
not only synapse formation but also synaptic elimination (Ram Venkataraman et 
al., 2017). There is evidence linking some ASD risk genes to synaptic pruning such 
as FMR1, PCDH10, and MEF2C (Pan et al., 2010; Pfeiffer et al., 2010; Tsai et al., 
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2012). Thus, these findings indicate that multiple mechanisms may be involved in 
the synaptopathology of ASD. 
Insight that synaptic functional abnormalities were a common underlying 
pathway in ASD was first gained by the phenotypic overlap ASD shares with similar 
monogenic diseases with synaptopathologies, such as fragile X syndrome and 
tuberous sclerosis complex, as well as the observation that somewhere between 
about 10-30% of patients with ASD have epilepsy (Besag, 2018; Bourgeron, 2009; 
Guang et al., 2018; Jokiranta et al., 2014; Mouridsen et al., 2011; Spence and 
Schneider, 2009; Tuchman et al., 2010; Zhang et al., 2019a). Mutations that lead 
to abnormal synaptic strength or number can lead to impairments in overall 
neuronal network connectivity. Indeed, an imbalance in the excitation to inhibition 
(E/I) ratio in the cortex, leading to altered excitability of cortical circuits, is 
considered to be a key underlying mechanism for ASD pathology (Ajram et al., 
2017; Bozzi et al., 2018; Bruining et al., 2020; Canitano and Pallagrosi, 2017; 
Culotta and Penzes, 2020; Dickinson et al., 2016; Howell and Smith, 2019; Nelson 
and Valakh, 2015; Oliveira et al., 2018; Port et al., 2019; Rubenstein and 
Merzenich, 2003; Sohal and Rubenstein, 2019; Uzunova et al., 2016).  
 Many ASD susceptibility genes seem to converge on altered synaptic 
function and plasticity as the likely underlying pathology for ASD. Several 
demonstrate abnormalities in synaptic transmission including impairments in 
AMPAR-mediated excitatory synaptic transmission as measured by miniature 
excitatory postsynaptic currents (mEPSCs), GABAaR-mediated miniature 
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inhibitory postsynaptic currents (mIPSCs), and basal synaptic transmission as 
measured by field excitatory postsynaptic potentials (fEPSPs). For example, 
SHANK3 mutations show reductions in the amplitude and frequency of mEPSCs 
and the slope of fEPSPs (Bozdagi et al., 2010; Durand et al., 2012; Kouser et al., 
2013; Peça et al., 2011; Yang et al., 2012; Yi et al., 2016). SYNGAP1 deficiency 
also results in disrupted synaptic function as seen by an increase in the amplitude 
and frequency of mEPSC from increased AMPAR-mediated currents and an 
increase in fEPSPs at P14 (Clement et al., 2012; Llamosas et al., 2020; Ozkan et 
al., 2014; Vazquez et al., 2004; Wang et al., 2013). A transgenic mouse model of 
NRXN1 KO showed reduced excitatory synaptic strength with a decrease in 
mEPSC frequency and fEPSP slope (Etherton et al., 2009). Expression of an ASD 
related mutation of NLGN3, R471C, increased the amplitude of mIPSC (Gutierrez 
et al., 2009) and a decreased fEPSP slope, while a NLGN3 KO mouse showed 
increased mIPSC frequency and decreased mEPSC frequency (Etherton et al., 
2011). Similarly, conditional knockout of CYFIP1 leads to an increase in mIPSC 
amplitudes but no change in mEPSCs (Davenport et al., 2019). Furthermore, 
CNTNAP2 KO mice show decreased mEPSC frequency and amplitude with no 
change in mIPSCs and CNTNAP2 knockdown showed a reduced E/I ratio (Lazaro 
et al., 2019; Sacai et al., 2020). The imbalances between excitatory and inhibitory 
transmission observed in several of these studies demonstrate the importance of 
E/I balance for normal brain function and suggest a critical role for these genes in 
maintaining such a balance. 
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Impaired maintenance of experience-dependent synaptic plasticity is also a 
synaptic abnormality commonly observed in models of ASD-linked mutations 
(Hansel, 2019). As synaptic plasticity is the cellular mechanism underlying learning 
and memory consolidation, disturbances in plasticity are consistent with the high 
rates of intellectual disability and impairments in cognitive function observed in 
ASD (Verma et al., 2019). Deficiency in a number of ASD risk genes results in 
impaired LTP. These include NLGN1 (Blundell et al., 2010; Chubykin et al., 2007; 
Kim et al., 2008), SHANK3 (Bozdagi et al., 2010; Jaramillo et al., 2016; Kouser et 
al., 2013; Wang et al., 2011b; Yang et al., 2012), SYNGAP1 (Clement et al., 2013; 
Kim et al., 2003; Komiyama et al., 2002; Ozkan et al., 2014; Vazquez et al., 2004), 
FMR1 (Hu et al., 2008; Lauterborn et al., 2007; Lundbye et al., 2018; Shang et al., 
2009; Tian et al., 2017; Zhao et al., 2005), and MeCP2 (Asaka et al., 2006; Moretti 
et al., 2006; Weng et al., 2011). Interestingly, loss of some ASD risk genes result 
in enhanced mGluR-mediated LTD including FMR1 (Hou et al., 2006; Huber et al., 
2002; Tian et al., 2017; Till et al., 2015) and SYNGAP1 (Barnes et al., 2015; Paul 
et al., 2019), whereas loss of other ASD risk genes decreases LTD such as in 
MeCP2 (Moretti et al., 2006), NLGN3 (Baudouin et al., 2012), PTEN (Takeuchi et 
al., 2013), and TSC1 (Bateup et al., 2011). These abnormalities in LTD may also 
have consequences for synaptic pruning, underscoring the potential of aberrant 
synaptic plasticity to disturb synaptic connectivity (Hansel, 2019). Thus, the 
impaired synaptic function and plasticity which occur during the critical 
developmental period of synapse formation in ASD seem to result in abnormal 
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neuronal connectivity that persists into adulthood and leads to the observed 
alterations in behavior. 
 Sex differences and the X chromosome in ASD  
It has been noted that ASD is more prevalent in males compared to females. 
Indeed, studies indicate that males are between 3-5 times more likely to be 
diagnosed with ASD than females (Fernell and Gillberg, 2010; Fombonne, 2009; 
Loomes et al., 2017; Nicholas et al., 2009). It is possible that a contributing factor 
to this gender bias is a bias in diagnosis. It has been suggested that current ASD 
diagnostic tools may overlook or misdiagnose females due to lack of sensitivity to 
the symptoms that manifest in women compared to men, thus contributing to the 
lower prevalence of ASD in women (Bargiela et al., 2016; Dworzynski et al., 2012; 
Giarelli et al., 2010; Lai and Baron-Cohen, 2015; Loomes et al., 2017; Mandy and 
Tchanturia, 2015; Murray et al., 2017; Navarro-Pardo et al., 2021; Trubanova et 
al., 2014).  
Findings from recent studies support that there may also be a biological 
component to the gender bias. It has been proposed that there is a male 
vulnerability, or a female protective effect, in the development of ASD. This female 
protective model, also known as the multiple threshold liability model, states that 
multiple genetic variants contribute to the overall risk of developing ASD and 
females require a higher threshold of liability to manifest ASD (Jacquemont et al., 
2014; Robinson et al., 2013; Werling et al., 2016; Zhang et al., 2020b). Supporting 
this hypothesis, there is evidence of a higher frequency of deleterious variants 
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disrupting more genes in females with ASD than in males with ASD (Desachy et 
al., 2015; Gilman et al., 2011; Jacquemont et al., 2014; Levy et al., 2011; Sanders 
et al., 2011; Satterstrom et al., 2020; Zhang et al., 2020b). There are a few theories 
to explain why females are able to withstand more mutations than males before 
developing ASD. One is the extreme male brain theory, in which differences in 
hormone exposure during development, specifically higher levels of fetal 
testosterone, may cause the gender differences seen in ASD (Auyeung et al., 
2006; Baron-Cohen, 2002; Baron-Cohen et al., 2011; Baruah et al., 2018; 
McCarthy and Wright, 2017; Werling and Geschwind, 2013).  
The differential inheritance of X-linked ASD genes provides another 
explanation for the male bias in ASD susceptibility. Males only carry one copy of 
the X chromosome, inherited from their mother, compared to the two copies in 
females. Thus, hemizygous loss of function (LOF) variants would result in a 
complete knockout of expression in males while females would still have another 
functional copy, contributing to the larger proportion of males observed in ASD. 
Indeed, there are several examples of ASD associated X-linked genes including 
MeCP2, FMR1, NLGN3, SLC6A8, CDKL5, PCDH19, ARHGEF9, TBL1X, IQSEC2 
(Amir et al., 1999; Carney et al., 2003; Jamain et al., 2003; Marco and Skuse, 
2006; Reddy, 2005; Zipper et al., 2017). Although X-linked LOF mutations 
contribute to the male gender bias observed in ASD, statistically they alone cannot 
explain the overall male bias (Lim et al., 2013; Mandel and Chelly, 2004; Nava et 
al., 2012; Sanders et al., 2015; Stone et al., 2004; Werling et al., 2016; Zhang et 
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al., 2020b). Yet, they are still important to study for improving our understanding 
of the pathogenesis of ASD, particularly for affected females. 
For females with ASD carrying a hemizygous LOF variant, epigenetic 
factors such as X chromosome inactivation (XCI) can play a key role in disease 
severity. One X chromosome is inactivated in each cell in females to balance the 
expression of X-linked genes between the sexes. XCI occurs early in development 
and which of the two X chromosomes will be inactivated is typically random, 
resulting in mosaic expression of paternally and maternally inherited X-linked 
genes. However, when one of the two X chromosomes is preferentially inactivated, 
the cellular mosaicism is skewed (Bittel et al., 2008; Gribnau and Barakat, 2017; 
Morleo and Franco, 2008; Payer, 2016; Ribeiro and MacDonald, 2020; Taherian 
et al., 2016; Tan et al., 1995; Tukiainen et al., 2017; Wu et al., 2014). This 
preferential inactivation is known as primary skewing. Secondary skewing can 
occur as a result of a genetic variant on one of the X chromosomes giving a survival 
advantage to cells expressing that variant or negative selection against cells 
expressing a deleterious variant. In this way, heterozygous females carrying X-
linked mutations may have some protective compensation from skewed 
inactivation of the mutant allele. However, the opposite can also occur, where 
skewed inactivation of the wild type allele results in an increased risk, or severity, 
of disease. Thus, the varied XCI pattern in individual females can have a dramatic 
effect on disease pathogenesis for women and, indeed, skewed XCI has been 
observed in heterozygous women with various neurological disorders (Fieremans 
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et al., 2016; Godler et al., 2015; Heine-Suñer et al., 2003; Migeon, 2020; Plenge 
et al., 2002; Vacca et al., 2016; Zhang et al., 2020a; Zweier et al., 2013).  
XCI skewing has also been observed in females heterozygous for several 
ASD risk genes (Braunschweig et al., 2004; Dibbens et al., 2008; Huppke et al., 
2006; Jackson et al., 2019; Knudsen et al., 2006; Patel et al., 2020; Sikora et al., 
2016; Snijders Blok et al., 2015; Young and Zoghbi, 2004a). Several studies have 
investigated the contribution of XCI patterning in ASD with inconsistent results. 
One study found an increase in skewing in females with ASD (33%) compared to 
female controls (11%) (Talebizadeh et al., 2005). However, another study using a 
larger sample of both affected girls and mothers of affected children found no 
significant excess of XCI skewing in females with ASD (Gong et al., 2008). A 
subsequent study in an Italian cohort of patients also failed to find any altered XCI 
pattern in the ASD females (Cannelli et al., 2011). These results overall suggest 
there is no correlation with XCI skewing and development of, or escape from, ASD; 
however, XCI patterns are assessed using peripheral blood cells which may not 
reflect the XCI patterning of the brain.  
 
1.3 NEXMIF ASD gene and Thesis Rationale 
 Expression and Genetics 
NEXMIF (also known as KIDLIA, KIAA2022, or Xpn) is an X-linked gene 
associated with ASD and X-linked intellectual disability (XLID). Located at Xq13.2, 
NEXMIF is a 192 kb gene containing 4 exons with a large 180 kb intron between 
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exons 1 and 2. Exon 3 spans over 4 kb and contains the majority of the coding 
region for the 170 kDa protein product, NEXMIF, made of 1516 amino acids.  
Though little is known about NEXMIF’s function and it has no significant 
homology to other proteins, work from our lab and others has established that 
NEXMIF is expressed in the nucleus of neurons in fetal and adult brains (Cantagrel 
et al., 2009; Gilbert and Man, 2016; Gilbert et al., 2020; Ishikawa et al., 2012; 
Magome et al., 2013). mRNA levels of NEXMIF are first detectable at embryonic 
day 10.5 (E10.5) with a peak at postnatal day 3 (P3) and decreased expression to 
low levels in adulthood (Cantagrel et al., 2009; Ishikawa et al., 2012). Using 
immunostaining, we are able to detect NEXMIF protein expression from the 
perinatal period into adulthood (Gilbert and Man, 2016; Gilbert et al., 2020; 
Ishikawa et al., 2012). NEXMIF is expressed in the nuclei of neurons, colocalizing 
with nuclear marker Hochest and neuronal marker NeuN, and purifying in nuclear, 
not cytosolic, fractions from cell lysates (Cantagrel et al., 2009; Gilbert and Man, 
2016; Gilbert et al., 2020; Ishikawa et al., 2012; Magome et al., 2013). However, 
lacking colocalization with GFAP, NEXMIF is not expressed in glia (Cantagrel et 
al., 2009; Gilbert and Man, 2016; Ishikawa et al., 2012). NEXMIF expression is 
detected in the hippocampus, olfactory blub, cerebellum, and cerebral cortex 
(Cantagrel et al., 2009; Gilbert and Man, 2016; Ishikawa et al., 2012). 
The first pathogenic variants in NEXMIF were observed in two male 
members of a family with autistic phenotypes and intellectual disability (Cantagrel 
et al., 2004). We followed this initial report with an investigation into the genetic 
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basis of the disorder in 8 male patients from 3 families with inherited autistic 
characteristics and intellectual disability, in which we established the novel gene 
NEXMIF as the etiological factor for the syndrome (Van Maldergem et al., 2013). 
Subsequently, dozens of pathogenic variants have been identified in 87 male and 
female patients from 78 families (Alarcon-Martinez et al., 2019; Athanasakis et al., 
2014; Borlot et al., 2017; Cantagrel et al., 2004; Charzewska et al., 2015; Farach 
and Northrup, 2016; Kuroda et al., 2015; Lambert et al., 2018; de Lange et al., 
2016; Lorenzo et al., 2018; Van Maldergem et al., 2013; Moysés-Oliveira et al., 
2015; Panda et al., 2020; Samanta and Willis, 2020; Stamberger et al., 2020; 
Webster et al., 2017; Wu et al., 2020). Patients acquired these variants by de novo 
mutation or X-linked maternal inheritance. The genetic variants include nonsense 
mutations, frameshift mutations, and deleterious structural variants, all of which 
were predicted to decrease NEXMIF protein expression through nonsense- 
mediated decay leading to loss of function (Alarcon-Martinez et al., 2019; 
Athanasakis et al., 2014; Borlot et al., 2017; Cantagrel et al., 2004; Charzewska et 
al., 2015; Farach and Northrup, 2016; Kuroda et al., 2015; Lambert et al., 2018; 
de Lange et al., 2016; Lorenzo et al., 2018; Van Maldergem et al., 2013; Moysés-
Oliveira et al., 2015; Panda et al., 2020; Samanta and Willis, 2020; Stamberger et 
al., 2020; Webster et al., 2017; Wu et al., 2020). Thus far, no missense pathogenic 
variants have been reported. The majority of mutations occur within the large exon 
3 however, these span the length of exon 3, so no clear mutational hot spot with 
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clues to protein function has been identified (de Lange et al., 2016; Panda et al., 
2020; Stamberger et al., 2020).  
Given its spatiotemporal expression pattern and the increasing number of 
pathogenic variants identified, NEXMIF clearly plays an important role in early 
brain development. 
 Clinical phenotypes 
Observations from our study, as well as others’, revealed individuals with 
phenotypic NEXMIF variants demonstrate developmental delay and cognitive 
impairments (Alarcon-Martinez et al., 2019; Athanasakis et al., 2014; Borlot et al., 
2017; Cantagrel et al., 2004; Charzewska et al., 2015; Farach and Northrup, 2016; 
Kuroda et al., 2015; Lambert et al., 2018; de Lange et al., 2016; Lorenzo et al., 
2018; Van Maldergem et al., 2013; Moysés-Oliveira et al., 2015; Panda et al., 
2020; Samanta and Willis, 2020; Stamberger et al., 2020; Webster et al., 2017; 
Wu et al., 2020). Often they have autistic features including impaired language, 
difficulty with social interactions, and repetitive stereotypies. Frequently, patients 
present with epilepsy, the majority showing generalized seizures including 
myoclonic, absence, atonic, and tonic-clonic seizures. Additional comorbidities 
include behavioral problems, such as hyperactivity, attention deficit disorder, and 
aggression, as well as gastroesophageal reflux, mild dysmorphic facial features, 
hypotonia, and microcephaly.   
In general, males have more severe impairments than females, who range 
in phenotype from completely asymptomatic to severe intellectual disability and 
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drug-resistant epilepsy. Initially, only affected male were reported with their 
requisite related female carriers reporting as asymptomatic (Alarcon-Martinez et 
al., 2019; Cantagrel et al., 2004; Charzewska et al., 2015; Kuroda et al., 2015; 
Lambert et al., 2018; Lorenzo et al., 2018; Van Maldergem et al., 2013; Panda et 
al., 2020; Stamberger et al., 2020). Subsequently, several reports have identified 
symptomatic females (Athanasakis et al., 2014; Borlot et al., 2017; Farach and 
Northrup, 2016; Lambert et al., 2018; de Lange et al., 2016; Moysés-Oliveira et al., 
2015; Samanta and Willis, 2020; Stamberger et al., 2020; Webster et al., 2017; 
Wu et al., 2020). Comparison of the individuals affected with NEXMIF variants 
across sex reveals males have a more severe degree of intellectual disability, while 
females have more frequently have epilepsy. Additionally, males have a more 
severe language impairment and more frequently show microcephaly. The onset 
of developmental delay is recognized earlier in males, with females being on 
average a greater age when their genetic diagnosis was established (Panda et al., 
2020; Stamberger et al., 2020). 
The differences between sexes and the phenotypic diversity observed in 
females might be explained by X chromosome inactivation (XCI). Located on the 
X chromosome, NEXMIF is subject to XCI (Cantagrel et al., 2004) and compared 
with the total loss of function from lack of protein expression in hemizygous males, 
heterozygous NEXMIF mutation in females combined with random XCI results in 
partial loss of function due to a decrease in protein expression. However, of the 32 
female patients on which XCI analysis is available, 24 show a random XCI pattern, 
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4 are skewed, 2 are borderline skewed, and 2 are 100% skewed (Stamberger et 
al., 2020). And interestingly, comparing sisters with skewed versus random XCI 
(which occurs in 2 of the reported families) showed no correlation between XCI 
status and severity of the phenotype (Stamberger et al., 2020). Therefore, the 
hypothesis that the phenotypic variation is due to XCI pattern is not supported as 
there is not a genotype-phenotype correlation between the degree of skewed XCI 
and NEXMIF symptoms.  
The severity of clinical phenotypes that occur from loss of NEXMIF function 
underscores its importance for normal brain development. 
 Cellular and molecular phenotypes 
As a novel gene, NEXMIF initially had no formal name and was referred to as 
KIAA2022. In 2017, we worked with the HUGO Gene Nomenclature Committee 
(HGNC), aiming to assign the gene an official name. Because we, and others, had 
shown that the gene is involved in neurite growth and neuron migration, HGNC 
approved NEXMIF (Neurite EXtension and MIgration Factor) as the official name 
for the gene (Gilbert and Man, 2016; Gilbert et al., 2020; Ishikawa et al., 2012; 
Magome et al., 2013; Van Maldergem et al., 2013). Indeed, we have found that 
NEXMIF plays a role in neuronal morphogenesis, neuronal migration, and synapse 
formation. 
We, and others, found that siRNA mediated knockdown of NEXMIF in 
cultured mouse neurons and PC12 cells resulted in reduced neurite and axon 
length and number (Ishikawa et al., 2012; Van Maldergem et al., 2013). We also 
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found that shRNA mediated knockdown in cultured neurons showed a decrease in 
dendritic growth and branching (Gilbert and Man, 2016). Additionally, our RNAi 
mediated knockdown of NEXMIF altered migration (Gilbert and Man, 2016; 
Magome et al., 2013). While our work, and that of others, supports a major role for 
NEXMIF in neuron development and brain function, further work is needed to fully 
understand its molecular mechanism of action underlying the phenotypes 
observed at both the clinical and cellular levels. 
 Thesis Rationale  
NEXMIF is a novel X-linked ASD gene, however its role in brain development 
remains largely unknown. An increasing number of reports indicate that NEXMIF-
dependent ASD results in severe ASD phenotypes, intellectual disability, and 
seizures in both males with complete loss-of-function and females with 
haploinsufficient loss-of-function. As a monogenetic cause of ASD with intellectual 
disability, NEXMIF represents an excellent opportunity to examine ASD 
pathogenesis at the cellular and molecular levels with clarity and certainty. To date, 
the molecular details underlying the lack, or haploinsufficiency, of NEXMIF in ASD 
remain unknown. The goal of my thesis is to systematically investigate the function 
of NEXMIF in neurobiology and to characterize the cellular and molecular 
dysregulation, and ASD behavioral impairments, which arise from loss of NEXMIF. 
First, I aimed to understand the cellular and molecular mechanisms underlying 
NEXMIF-dependent ASD pathogenesis. Second, I aimed to characterize 
behavioral phenotypes, and investigate phenotypic cellular mosaicism, due to 
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NEXMIF haploinsufficiency. Findings from this study provide important original 
knowledge of this new ASD gene and will help with the future development of 
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2.1  Materials 
 Plasmids 
A list of plasmids used and their relevant information can be found in Table 2.1. 
 Antibodies 
A list of antibodies used and their relevant information can be found in Table 2.2. 
 Drugs 
A list of drugs used and their relevant information can be found in Table 2.3. 
 Human brain tissue 
Human brain tissues from control and AD patients were provided by, and used with 
approval from, the Boston University Alzheimer’s Disease Center. Samples were 
collected from both males and females aged from 54 to 96 years old. 
 Preparation and use of Aβ peptides 
β-Amyloid (Aβ) [1-42] oligomeric peptides (Invitrogen, cat # 03-112) were prepared 
according to manufacturer’s instructions. Briefly, lyophilized peptide was dissolved 
in HPLC grade water and diluted to 1 mg/ml with phosphate buffered saline (PBS). 
Peptides were then incubated at 37°C for at least 24 h. Aliquots were made and 
stored at -20°C. Aliquots were thawed once directly prior to use. Neuronal cultures 
were treated with Aβ oligomers or water at a comparable volume as a control. 
 
2.2 Cell culture 
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 Primary culture of rat and mouse neurons 
Hippocampal and cortical brain tissues were dissected out of postnatal day 0-1 
(P0- P1) mouse brains of transgenic NEXMIF mice and WT littermate controls or 
embryonic day 18 (E18) rats of either sex to be used for primary culture. Mice 
brains were individually digested, and rat brains collectively digested, in papain (1 
mg/ml in Hanks balanced salt solution, Sigma-Aldrich; cat. # 4762) for 15 min at 
37 °C, then triturated in a trituration buffer [0.1% DNase (cat. # PA5-22017 RRID: 
AB_11153259), 1% ovomucoid (Sigma-Aldrich; cat. # T2011)/1% bovine serum 
albumin (Sigma-Aldrich; cat. #05470) in Dulbecco’s modified eagle medium 
(DMEM, Corning)] to fully dissociate neurons. Dissociated neurons were counted 
and plated on 18-mm circular coverslips (Carolina, Burlington, NC; cat. # 633013, 
No. 0) in 60-mm Petri dishes (five coverslips/dish) that had been coated in poly-l-
lysine (Sigma-Aldrich; cat. # P2636; 100 μg/ml in borate buffer) overnight at 37°C 
then washed three times with sterile deionized water and left in plating medium 
[minimal essential medium (500 mL) containing 10% fetal bovine serum (FBS; 
Atlanta Biologicals, Flowery Branch, GA; cat. # S11550), 5% horse serum (HS; 
Atlanta Biologicals; cat. # S12150), 31 mg l-cysteine, 1% penicillin/streptomycin 
(P/S; Corning, Corning, NY; cat. # 30-002-Cl), and l-glutamine (Corning; cat. # 25-
005-Cl) before cell plating. The day after plating, plating medium was replaced by 
feeding medium (neurobasal medium supplemented with 1% horse serum, 2% B-
27, and 1% penicillin/streptomycin and l-glutamine) which was supplemented with 
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5′-fluoro-2′-deoxyuridine (10 μm; Sigma-Aldrich; cat. # F0503) after 7 d in vitro (DIV 
7) to suppress glial growth. 
 Culture of human embryonic kidney cell line (HEK293) 
An aliquot of frozen HEK293T cells (ATCC® CRL-3216™) stored at -80°C was 
thawed at 37°C for 2 min. The thawed cells were placed in a 10 cm Petri dish with 
10 ml of pre-warmed culture media (DMEM with 10% fetal bovine serum and 1% 
penicillin/streptomycin. The cells were incubated 37°C with 5% CO2 until at least 
80% confluency was reached. Confluent cells were split by removing the culture 
media and incubating with 1 ml of trypsin-EDTA (Invitrogen) at 37°C for 1 min to 
free adherent cells from the surface of the dish. 10 ml of culture media was added 
to neutralize the trypsin and gently triturated to dissociate the cells into individual 
cells. Cells were then re-seeded at the desired density into a cell culture dish with 
pre-warmed culture media and maintained at 37°C until further use. To freeze cells 
for long-term storage, cells were isolated as described above, resuspended in 
DMEM with 10% FBS and 10% DMSO, aliquoted into cryovials (Nalgene), and 
frozen overnight at -20°C before transferring to -80°C. 
2.3 Plasmid transfection 
Neurons or HEK293T cells that were split and cultured overnight were transfected 
respectively with lipofectamine 2000 (Life Technologies) or polyethylenimine (PEI) 
reagent (Polysciences, Warrington, PA; cat. # 23966) along with the target 
plasmids. Target plasmids were mixed with lipofectamine 2000 (1:1 ratio) or PEI 
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(1:3 ratio) in 1X DMEM for 20 minutes at room temperature to form the transfection 
complex. The transfection complex was then incubated with the cells in culture 
medium for another 3-4-h at 37℃ in the cell culture incubator. Afterward, the 
medium with the transfection complex was replaced with fresh culture medium. For 
neurons, half of the fresh feeding medium was supplemented with conditioned 
feeding medium to minimize cell death. HEK 293T cells were cultured in the 
following medium: 1X DMEM with 10% FBS, 1% P/S and 1% L-Glutamine.  
 
2.4 Viral infection 
 Production of adenovirus and lentivirus 
For AAV GluA1 constructs, GFP-GluA1-WT and GFP-GluA1-4KQ in the adeno-
associated virus vector (AAV2) (Addgene #50954) under the human synapsin 1 
promoter were transfected in HEK293T cells along with viral packaging and 
envelope protein plasmids (XR2 and XX6.80) as described above. After incubation 
at 37°C for 72 h, the cells were scrapped from the dish surface and subjected to 
four freeze/thaw cycles to lyse the cells and release the virus. The lysate was 
centrifuged at 3000 g for 30 min at 4°C and the supernatant was combined with 
conditioned medium containing AAV from the culture dish, filtered through a 0.45-
μm filter, and combined with PEG-it virus purification solution (System Bioscience) 
at a 1:4 dilution. This mixture was left at 4C overnight, followed by centrifugation 
at 1500 g for 30 min at 4°C .The viral particles were resuspended in 500 mL sterile 
1x PBS, aliquoted, and stored at −80°C until use. 
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For lentiviral shRNA, two NEXMIF shRNA sequences 
(CAGGAGCTACTAAGAATCAC and CAGGTAGCTTTGAGGTGTCA), which 
recognize NEXMIF transcripts from mouse, rat and human, as well as a control 
scrambled shRNA sequence (CCGCAGGTATGCACGCGT) in the pLKO.1-TRC 
cloning vector (Addgene; cat. # 10878, RRID: SCR_005907) were transfected in 
HEK293T cells along with viral packaging and envelope protein plasmids 
(pRSV/REV, pMDLg/RRE, and pVSVG) as described above. After incubation at 
37°C for 72 h, conditioned medium containing lentivirus was collected, centrifuged 
at 1000 × g for 10 min, filtered through a 0.45-μm filter, and combined with the 
PEG-it solution at a 1:4 dilution. This mixture was left at 4°C overnight, followed by 
centrifugation at 1500 g for 30 min at 4°C The viral particles were resuspended in 
500 mL sterile 1x PBS, aliquoted, and stored at −80°C until use.  
 Intracerebroventricular viral injection 
For AAV injection, the APP/PS1 mice were deeply anesthetized with isoflurane; 
AAV particles (1.0 µL at 0.1 µL/min) were injected into the lateral ventricle (1.8 mm 
antero-posterior, 1.06 mm medio-lateral, 2 mm dorso-ventral). After the injection, 
the mice were placed on a heating plate for recovery, and then were kept under 
standard laboratory conditions. The AAV of Control, GluA1-WT and GluA1-4KQ 
were constructed and prepared by Obio Technology (Shanghai, China). 
 
2.5 Cellular techniques 
 Immunocytochemistry 
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Cortical or hippocampal neurons were fixed for 8 min in a 4% 
paraformaldehyde/4% sucrose solution at room temperature (RT). Cell 
membranes were permeabilized for 5 min in 0.3% Triton-X-100 (Fisher Biotech) in 
phosphate buffered saline (PBS) and rinsed three times in PBS. Cells were 
blocked in 10% goat serum in PBS for 1 h at RT. After blocking, cells were 
incubated with primary antibodies (in 5% goat serum PBS) for 2 h at RT, washed 
three times with PBS, and incubated with Alexa Fluor-conjugated fluorescent 
secondary antibodies (1:500, Life Technologies) for 1 h at RT. Cells were then 
mounted to microscopy glass slides with Prolong Gold anti-fade mounting reagent 
(Life Technologies) for subsequent visualization. Mounted coverslips were kept 
overnight in the dark at RT before imaging. 
 Immunohistochemistry 
Adult mice underwent transcardial perfusion with ice cold PBS prior to collection 
of the brain. Brains were fixed in 4% paraformaldehyde for 4-6 h and cryoprotected 
in 30% sucrose/PBS. Brains were then placed in molds to be rapidly frozen in OCT 
(Tissue-Tek) and stored at -80°C until they were cut into 20 μm sections using a 
LEICA CM1850 cyrostat (LEICA Biosystems). Sections were mounted onto 
SuperFrost microscope slides (Fisher Scientific) and stored at −20°C until staining. 
To prepare for immunostaining, sections were hydrated in PBS for at least 2 h and 
underwent antigen retrieval by microwaving in sodium citrate buffer (10 mM, pH 6) 
at 800 watts for 1 min followed by 80 watts for 10 min. Sections were cooled to RT 
for 20 min and then blocked in 10% goat serum, 0.3% Triton X-100/PBS for 1 h. 
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Sections were then incubated in primary antibodies (5% goat serum PBS) 
overnight at 4°C, washed three times with PBS, and incubated in Alexa Fluor-
conjugated fluorescent secondary antibodies (1:500, Life Technologies) for 1 h at 
RT. Brain slices were then washed three times with PBS, with the first wash 
containing Hoescht (1:10,000, Thermo Fisher) and mounted under a coverslip with 
Prolong Gold anti-fade mounting reagent (Life Technologies). Slides were allowed 
to dry at room temperature overnight and stored at −20°C for subsequent 
visualization. 
 AMPA receptor internalization assay 
Neurons were incubated with an N-terminal specific GluA1 (GluA1Nt) antibody 
(Neuromab, 1:100) or GFP antibody (Synaptic Systems, 1:100) for GluA1-4KQ-
GFP experiments at 37°C for 10 min and then washed twice with feeding medium 
to get rid of extra antibody. After replacing the treatment with the cells’ original 
culture medium, cells were placed at 37°C for 20 min. Neurons were then fixed in 
4% paraformaldehyde/4% sucrose solution for 8 min. Neurons were blocked with 
10% GS and further incubated with a secondary antibody (Alexa Fluor dye 488 or 
HRP, 1:500, 1 h) to bind all the AMPARs remaining on the cell surface. Neurons 
were permeabilized with 0.3% Triton X-100/PBS for 5 min, blocked in 10% goat 
serum for 1 h and incubated with another secondary antibody of a different color 
(Alexa Fluor dye 555, 1:500, 1 h) to specifically label the internalized AMPARs.  
 AMPA receptor insertion assay 
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Neurons were incubated with GluA1Nt antibody (Neuromab, 1:80) at 37°C for 10 
min and then washed twice with feeding medium to get rid of extra antibody. 
Neurons were further incubated with a secondary antibody (Alexa Fluor dye 488 
or HRP, 1:100 in ACSF with no Mg2+) for 45 min at RT to bind all the AMPARs 
initially on the cell surface. To induce insertion in chem-LTP assays, neurons were 
treated with 200 µM Glycine and 1 µM Strychnine, 20 µM Biccuculine, 1 µM TTX 
in ACSF with no Mg2+ for 3 min at 37°C. After replacing the treatment with the cells’ 
original culture medium, cells were placed at 37°C for 20 min. Neurons were then 
fixed in 4% paraformaldehyde/4% sucrose solution for 8 min. Neurons were 
blocked with 10% GS and incubated again with GluA1Nt antibody (1:200, RT for 2 
h) followed by a secondary antibody of a different color (Alexa Fluor dye 555, 
1:500, 1 h) to specifically label the newly inserted AMPARs. Total surface AMPARs 
were calculated as the initial surface expressing AMPARs plus the newly inserted 
AMPARs.  
 
2.6 Biochemical techniques 
 Sample collection 
Brains regions were dissected on ice immediately after sacrificing animals at the 
appropriate time points. Tissues were lysed in RIPA buffer (50 mM Tris-Cl, 150 
mM NaCl, 1% NP40, 1% sodium deoxycholate (SDOC)) with 1% SDS and a 
protease inhibitor cocktail (Complete tablets, Roche). Samples were 
homogeneneized mechanically with a pestle, followed by sonication (10X for 10 s 
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each), and head-to-toe rotation for at least 2 h at 4°C. Brain lysates were then 
centrifuged for 20 min at 13,000 rpm in a 4°C microcentrifuge to collect the 
supernatant fraction. Protein concentrations were determined with a BCA assay 
according to the manufacturer’s protocol (Pierce) and were normalized to the same 
total protein concentration with RIPA lysis buffer cells. Each sample was given an 
equal volume of 2X Laemmli sample buffer (4% SDS, 10% 2-mercaptoethanol, 
20% glycerol, 0.004% bromophenol blue, 0.125 M Tris HCl) and was boiled for 15 
min at 95°C. Cultured cells were lysed in 2X Laemmli sample buffer and boiled for 
15 min at 95°C. Samples were then stored at -20°C until use in immunoblotting 
assays. 
 Immunoprecipitation 
Cultured neurons or brain tissues were lysed on ice in 1x radioimmunoprecipitation 
assay (RIPA) buffer (50 mM Tris-HCl [pH 7.4], 50 mM NaCl, 1% NP-40, 1% sodium 
deoxycholate [SDoC], and 0.1%-1% SDS) supplemented with protease inhibitor 
cocktail tablets (11697498001, Roche) to reduce protein degradation. For IP 
experiments, stringent RIPA buffer (1% SDS) was used to ensure specificity of 
immunoprecipitation. After collection, cells were lysed by pipetting, followed by 5 
bursts of sonication. Samples were then rotated head-to-toe for 30 min and 
centrifuged at 13,000 rpm at 4°C for 20 min. The protein concentration of the 
supernatant was balanced using a BCA assay while the pellets were discarded. A 
small portion of each sample was saved as a total cell lysate while the remainder 
was incubated with specific antibodies for 1 h, rotating, at 4°C, then incubated 
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overnight after the addition of protein A-agarose beads (sc-2001, Santa Cruz 
Biotechnology). Agarose beads were rinsed at least three times with the lysis 
buffer used for that assay. The samples were finally boiled with Laemmli 2X 
sample buffer (4% SDS, 10% 8 2-mercaptoethanol, 20% glycerol, 0.004% 
bromophenol blue, and 0.125 M Tris HCl) for 10-15 min at 95°C before being used 
in immunoblotting assays. 
 Immunoblotting 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed to separate 
proteins of interest using standard procedures. Proteins were transferred to PVDF 
membranes and blocked for one hour in 10% milk prepared in Tris buffered saline 
supplemented with 0.05% Tween (TBST). Following blocking, membranes were 
probed with the appropriate primary antibody (in 5% milk in TBST) overnight at 
4°C, then washed 3X in TBST for 5-10 min, and incubated with the appropriate 
secondary antibody tagged with horse radish peroxidase (HRP) for 1 h at RT. 
Membranes were washed 3x with TBST and visualized using a 
chemiluminescence detection system (GE Healthcare) and exposed on Fuji 
medical X-ray films (Fisher Scientific). The film was scanned and analyzed using 
ImageJ. 
 Post-translational modification assays 
Acetylation assays were designed as in Wang et al., 2017, and ubiquitination 
assays as in Huo et al., 2015. To detect the post-translational modification signal 
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of endogenous AMPARs in brain (in vivo) or neuronal culture (in vitro), the GluA1 
subunit was first immunoprecipitated from whole-brain extracts or homogenized 
cortical neuron lysates following the Immunoprecipitation procedure described 
above, using a specific antibody bound by Protein A-agarose beads. Lysis buffer 
(RIPA buffer with 1% SDS) was used to homogenize the brain tissue. The buffer 
was supplemented with a cocktail of deacetylase inhibitors (100 μM trichostatin A, 
50 mM sodium butyrate, and 50 mM nicotinamide), to sufficiently block 
deacetylase activity, and deubiquitination inhibitors (5 µM ubiquitin aldehyde) as 
needed. The acetylation signal was then assessed by immunoblotting with an 
antibody that detects general acetylated lysine residues (1:1000; ab80178, Abcam 
or 32268, Santa Cruz). Ubiquitination signals were detected by immunoblotting 
with an antibody targeting ubiquitin (1:1000; ab19247, Abcam) and smear signals 
above 100 kDa were measured and quantified. 
 GST assay 
The GST assay was adapted from Einarson et al., 2007. The BL21 E.coli bacteria 
were transformed with GST-GluA1-Cterm plasmid then grown at 37°C to show 
single colonies (diameter <1mm) before the experiments. For each experiment, 
one colony of transformed BL21 bacteria was inoculated into 2-ml aliquot of LB 
containing appropriate antibiotic selection then grew overnight at 37°C with 
shaking at 250 rpm. One liter of LB containing the antibiotic selection was then 
inoculated with the 2-mL aliquot of transformed BL21 bacteria and grown at 19°C 
with shaking for a few hours untill the OD600 reached 0.5-1.0. Isopropyl β-D-1-
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thiogalactopyranoside (IPTG) was then added to the concentration of 0.1 mM to 
induce the expression of GST-GluA1-Cterm recombinant protein for another 3 
hours. The bacteria were centrifuged at 3500 g for 20 min at 4°C to be 
concentrated then lysed in 20 mL of PBS for lysis with repeated sonication. Lysed 
bacteria were centrifuged again at 12,000 g for another 15 min at 4°C to keep the 
supernatant. GST-GluA1-Cterm recombinant protein in the supernatant was then 
purified with GST beads and resuspended in acetylation assay buffer [RIPA buffer 
(50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 1% SDOC, and 0.1% SDS) 
supplemented with a protease inhibitor cocktail (Roche, cat# 11697498001) and a 
protein deacetylase inhibitor cocktail (100 mM trichostatin A, 50 mM sodium 
butyrate, and 50 mM nicotinamide)]. Resuspended GST beads were equally 
divided into several aliquots for protein acetylation assay. 
 Synaptosome purification 
For brain tissues, the hippocampus or cortex of APP/PS1 mice were washed with 
cool artificial cerebral spinal fluid (aCSF: 140 mM NaCl, 3 mM KCl, 10 mM HEPES, 
2 mM CaCl2, 1 mM MgCl2, and 10 mM glucose) and suspended in 300 µL (per 30 
mg tissue) solution A containing 0.32 M sucrose,1 mM NaHCO3, 1 mM MgCl2, 0.5 
mM CaCl2 • 2H2O, 10 mM sodium pyrophosphate, and protease inhibitors on ice. 
The suspension was collected and mixed up and down with a pipette up to 12 
times, centrifuged at 710 g for 10 min, and the supernatant was collected. The 
pellet (P1) was re-suspended in 50 mL of solution A, and following pipetting up 
and down three times, centrifuged at 1,400 g for 10 min. The supernatant was 
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collected together with the previously collected supernatant as whole-cell lysate 
(S1, whole). S1 was further centrifuged at 13,800 g for 10 min; supernatant (S2, 
cytosolic fraction) and pellet (P2, containing synaptosome and mitochondria) were 
separated. Pellet was resuspended in RIPA buffer, sonicated on ice, and rotated 
at 4°C for 30 min.  
For cultured neurons, synaptic fractions were purified using Syn-PER 
Synaptic Protein Extraction Reagent (87793, Thermo Scientific). The protein 
concentrations in whole, cytosolic, and crude synaptosomal fractions were 
measured by BCA assay. Samples were then boiled with 4X loading buffer for 
Western blotting detection. 
 
2.7 Golgi impregnation 
Whole brains from adult female C57BL/6J wild-type and NEXMIF Heterozygous 
mice were subjected to Golgi neuron staining using the FD Rapid GolgiStain Kit 
(FD Neurotechnologies, catalog #PK401) according to the manufacturer’s 
instructions. Mice were sacrified in a 4% CO2 chamber and brains were collected 
and rinsed in cold PBS. Brains were immersed in a Golgi-Cox solution containing 
potassium dichromate, mercuric chloride, and potassium chromate. The solution 
was replaced after 1 d of immersion with fresh solution and stored at RT in the 
dark for 2 weeks. After immersion, the brains were rapidly frozen and stored at -
80°C prior to cutting. Brain slices were sectioned in the coronal plane at 100 um 
thickness on a cryostat and were mounted on gelatin-coated slices (FD 
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Neurotechnologies, catalog #PO101) and air dried at RT before further processing. 
Sections were then rinsed in distilled water, incubated in staining solution for 10 
min, and dehydrated with 50%, 75%, 95%, and finally 100% ethanol. Sections 
were defatted in xylene and mounted onto coverslips with Permount mounting 
medium (Thermo Fisher Scientific). Sections were stored at RT in the dark for 
subsequent visualization. 
 
2.8 Acute brain slice preparation and LTP recording 
Mice were decapitated under anesthesia with isoflurane, the brain was quickly 
removed and placed in ice-cold oxygenated artificial cerebral spinal fluid (aCSF) 
containing 119 mM NaCl, 2.5 mM KCl, 26.2 mM NaHCO3, 1 mM NaH2PO4, 11 
mM glucose, 1.3 mM MgSO4, and 2.5 mM CaCl2 (pH 7.4). Horizontal 350 µm thick 
brain slices were cut in ice-cold aCSF using a vibrating microtome (Leica, 
VT1000S, Germany). Slices were transferred to a recovery chamber at least 1.5 h 
with oxygenated aCSF at room temperature until recordings were performed. 
For LTP recording, acute brain slices were transferred to a recording 
chamber and submerged in aCSF. Slices were laid down in a chamber with an 8 
× 8 microelectrode array (Parker Technology, China) on the bottom plane (each 
50 × 50 μm in size, with an interpolar distance of 150 μm) and kept submerged in 
aCSF. Signals were acquired using the MED64 System (Alpha MED Sciences, 
Panasonic). The fEPSPs in CA1 neurons were recorded by stimulating CA3 
neurons. LTP was induced by applying three trains of high-frequency stimulation 
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(HFS; 100 Hz, 1s duration). The LTP magnitude was quantified as the percentage 




Exposure time for the fluorescence signals was adjusted manually so the signals 
were within a full dynamic range. Either the glow scale look-up table or the 
histogram was used to monitor the saturation level. Once the parameters were set, 
they were fixed and used throughout image acquisition for the experiment.  
For ICC: fluorescent images were collected with a 40x air-objective 
(numerical aperture, 0.95) on a DS-Fi2 Color Camera on a Nikon Eclipse NiE using 
NIS-Elements software or with a either a 40× (numerical aperture, 1.3) or 63x 
(numerical aperture, 1.4) oil-immersion objective on a Zeiss Axiovert 200M using 
Axiovision 4.5 software. Neuron images were quantified in using NIH ImageJ 
software.  
For IHC: Brain sections were imaged with 10x and 20x air-objectives using 
a Nikon C2+ Si spectral laser scanning confocal microscope using NIS-Elements 
software. 
For Golgi staining: images were acquired using brightfield transmitted light 
with a 40x air-objective (numerical aperture, 0.95) on a DS-Qi1 Monochrome 
Cooled Digital Camera on a Nikon Eclipse NiE using NIS-Elements software. Each 
neuron was scanned by varying the depth of the Z plane to ensure that all parts of 
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the cell (especially dendrites) were intact. The number of basal spines on neurons 
was measured with ImageJ software. 
 
2.10 Transgenic animals 
 Animal care and use 
For NEXMIF mice: All the procedures involving animal use were in compliance 
with the policies of the Institutional Animal Care and Use Committee (IACUC) at 
Boston University. Mouse colonies were maintained in the Laboratory Animal Care 
Facility (LACF) at Boston University, Charles River Campus in a C57BL/6J genetic 
background. Female mice heterozygous for NEXMIF were crossed with wild-type 
male mice. All WT (NEXMIF+/+) mice were randomized female littermate controls 
for experiments with the heterozygous mice (NEXMIF+/-), or male littermate 
controls for experiments with the knockout mice (NEXMIF-/y). Adult mice were used 
in all behavioral studies to avoid variability due to changes during adolescent 
periods. Transgenic mice were backcrossed to C57Bl/6J mice >10 times prior to 
use. 
For APP/PS1 mice: All animal experiments were approved by the Animal 
Care and Use Committee of Huazhong University of Science and Technology, and 
performed in compliance with the National Institutes of Health Guide for the Care 
and Use of Laboratory Animals. The Tg(APPswe,PSEN1dE9)85Dbo (APP/PS1) 
mice and littermates were from Jackson Lab. The mice were kept under standard 
laboratory conditions: 12 h light and 12 h dark with water and food ad libitum. 
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 Genotyping 
DNA was isolated from tail snips for genotyping using the Hot Shot Method. A 
single tail snip was collected from each mouse at the time of weaning on postnatal 
day 21 (P21) and placed in an Eppendorf tube. Tail snips were incubated for 30 
min at 95°C in 75 ul of alkaline lysis buffer (25 mM NaOH, 0.2 M EDTA). The tubes 
were allowed to cool at room temperature for 5 min before 75 ul of neutralization 
buffer (40 mM Tris-HCl, pH 5) was added. The tubes were vortexed to mix and 1 
ul of DNA extract was used in the following PCR protocol run on a Biorad DNA 
engine Tetrad 2 Peltier Thermal Cycler: 
 Initial Denaturation 94 °C 5 min 
30 cycles { 
Denature 98 °C 15 s 
Anneal 
55 °C  (WT) 
or 
59 °C  (KO) 
30 s 
Extend 72 °C 1 min 
 Final Extension 72 °C 5 min 
 Hold 4 °C ∞ 
The resulting PCR fragments were run on a 1% agarose gel with ethidium bromide 
to label and visualize DNA under ultraviolet light. 
 Two sets of primers were used to genotype NEXMIF Het animals. One set 
(WT) was targeted against the deleted exon 4 region using the primers: 
5’−AGGACTTGCTTAGGTTGCTTCATGGAA−3’ and 
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5’−CTTAAATTGCTCTACCTCAAGACCACCA−3’ with an expected PCR 
fragment of 949 bp. The other set (KO) was targeted against the KO cassette 
using the primers: 5’−CACACCTCCCCCTGAACCTGAAAG −3’ and 
5’−CCCACGAAGGGATCATACCCTGTA−3’ with an expected PCR fragment of 
794 bp. 
 Novel object recognition test 
The mice were put in to the arenas (50 cm × 50 cm ×50 cm wooden container) for 
5 min to adapt to the empty arenas 24 h before the test. 70% ethanol was used to 
clean arenas between each habituation period. On the first training day, the mice 
re-entered the arenas from the same starting point and were granted 5 min to 
familiarize themselves with the A object and B object. The 70% ethanol was used 
to clean arenas and objects after each familiarization period. One hour after the 
familiarization period, B object was replaced with C object, and the mice were 
granted 5 min to explore both objects; Twenty-four hours after the familiarization 
period, C object was replaced with D object, and the mice were granted 5 min to 
explore both objects. The recognition index was calculated by TA/(TA+TB), 
TB/(TA+TB),TC/(TA+TC), TD/(TA+TD). The discrimination index was calculated 
by (TC-TA)/(TA+TC), (TD-TA)/(TA+TD). TA, TB, TC, TD were respectively the time 
mice exploring the object A, B, C, D. 
 Three chamber social test 
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A three-chambered box measuring 65 × 28 × 28 cm was constructed from 0.75 in 
thick white plastic board with 4 × 4 in cut-out doors in the walls to the center 
chamber allowing movement between chambers. A small wire cage was placed 
in each of the side chambers to later house stranger mice. For 3 d before the test, 
test mice were habituated to the apparatus with empty cages in both side 
chambers and allowed to move freely between all three chambers for 5 min each 
day. On the testing day, the side doors were blocked with white plastic boards and 
test mice were singly placed into the center chamber with a stranger WT mouse 
(Mouse 1) placed under the wire cage in either of the side chambers. Once the 
doors were unblocked, the test mouse was allowed to move freely within the 
apparatus for 5 min. The test mouse was then returned to the center chamber, the 
doors were blocked again, and a second mouse (Novel Mouse) was placed in the 
wire cage of the other side chamber. The center doors were unblocked again and 
the test mouse was allowed to move freely within the apparatus for another 5 min. 
Between test mice, the entire apparatus was wiped with 70% ethanol to eliminate 
odor cues. Animals’ movement was analyzed for the time spent interacting with 
each mouse or empty cage (nose ≤ 2 cm) and the time spent in each chamber. 
 Ultrasonic vocalization recordings 
To record USVs, pups were separated from the dam and littermates and isolated 
in a recording chamber. Mouse vocalizations were recorded every 2 days (P5, P7, 
P9) in a random order for each litter using a CM16/CMPA microphone (Avisoft 
Bioacoustics, Berlin, Germany) placed 15 cm above the pups. The recording 
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chamber was cleaned with 70% ethanol and dried between each pup. Audio 
recordings were done at a sampling rate of 300 kHz in 16-bit format. The 
microphone was connected to a pre-amplifer UltraSoundGate 116Hb (Avisoft 
Bioacoustics, Berlin, Germany) and digitized sonograms were stored in a 
computer. Recordings were analyzed using SASLab Pro 5.2.12 (Avisoft 
Bioacoustics, Berlin, Germany). Spectrograms were generated using fast Fourier 
transform (256 FFT length, 100% frame, FlatTop window, and 50% window 
overlap) and a high-pass filter was applied to eliminate background noise below 
30 kHz. USVs were detected automatically (threshold: -47 ± 10 dB, hold time: 7 
ms) followed by manual inspection to ensure all detected calls were legitimate. 
Several acoustic parameters of calls were measured including number of calls, 
mean call duration, total time spent calling, peak frequency, and peak amplitude. 
Calls were classified based on their acoustic features into the following groups; 
simple: short, flat, upward, downward, chevron, U shape, and complex: 
modulated, frequency jump, multiple jumps, harmonic. 
 Marble burying 
The marble burying was conducted in a square plastic bin with a 3 in thick layer 
of fresh pine chip bedding. Twenty-five shiny glass marbles (0.25 in diameter) 
were arranged in a 5 × 5 grid on top of the bedding. Mice were singly placed into 
the bin and allowed to move freely and bury marbles for 30 min. The number of 
marbles buried after 5, 10, 15, 25 and 30 min were manually counted. 
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 Grooming test 
Grooming was assessed in the animal’s home cage with a 3 in thick layer of fresh 
pine chip bedding. Mice were singly placed back into the cage and allowed to 
move freely for 20 min. Video recordings were captured from the side of the cage. 
The amount of time spent grooming and the number of grooming instances were 
manually quantified. The number of unsupported rearing instances was all 
quantified. 
 Open field test 
The open field test was conducted in a chamber constructed from 0.75 in thick 
white plastic box with a base measuring 28 × 28 × 28 cm. Lights in the testing 
room were dimmed for comfort of the animal with only a small desk lamp in the 
corner for the experimenter. Mice were habituated to the testing room over three 
days and handled for 5 min each session. On the test day, each mouse was singly 
placed into the center of the box and allowed to freely explore the chamber for 15 
min. Animals’ movement was analyzed for the movement speed, entries to open 
center, and track lengths. 
 Barnes maze spatial memory test 
The Barnes maze consisted of a 48 in diameter, 0.75 in thick, circular white plastic 
board with twenty 2 in diameter holes evenly distributed around the board 1 in 
from the edge. The maze was mounted 30 in above the ground on a pedestal that 
allowed it to rotate from the center. A plain curtain with a few shapes attached as 
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spatial cues surrounded the maze to simplify the cues for the mice. The escape 
cage beneath the escape hole consisted of a black plastic box with a ramp to allow 
for easy access.  
 For each session, the test mouse was placed in the center of the maze 
under an opaque container. The aversive stimuli of four bright ceiling lamps and 
a loud alarm were turned on when the mouse was released from the container 
and allowed to roam freely about the maze. The ceiling lights and loud noise 
remained on while the mouse was exploring the maze and turned off immediately 
after they entered the escape hole. The maze and escape cage were thoroughly 
cleaned with 70% ethanol between testing sessions to avoid any olfactory cues 
and the maze was rotated randomly after every mouse to avoid intra-maze odor 
or visual cues. The escape hole remained in the same location relative to the 
spatial cues. 
 On day 1 of the procedure, the mice were habituated to the maze. After 3 
min of exploring the maze, the mouse was gently nudged into the escape hole. 
The mouse was then allowed to stay in the escape hole without the aversive 
stimuli for 2 min. All mice were adapted to the maze in this way. On days 2-5, the 
mice were trained 3 times each day (12 times total) to learn to enter the escape 
hole by themselves and ensure a strong memory for the escape hole location. For 
each training trial, if the mice did not enter the escape hole on their own after 3 
min, they were gently nudged into the hole. After the entered the escape hole, the 
aversive stimuli were turned off and the mice remained in the escape chamber for 
60 
1 min. On days 6 and 10 (1 d and 5 d post-training), the mice were tested for their 
memory of the escape hole location. During the memory probes, the escape hole 
was covered and the mice were allowed to roam freely for 3 min. Recordings of 
the animals’ movement were analyzed to test the spatial memory of the mice. 
Primary latency to the escape hole, distance traveled to the escape hole, 
percentage of erroneous nose pokes, and time spent in each quadrant of the maze 
were quantified. 
 
2.11 Statistical analysis 
Statistical analysis for parametric data was performed using the two-population 
student's t test, one-way ANOVA with Tukey post-hoc test, or repeated measures 
two-way ANOVA with Sidak’s multiple comparison test as appropriate. 
Kolmogorov–Smirnov test was used to analyze cumulative probabilities of mEPSC 
frequency and amplitude. All data are expressed as mean ± SEM and were 
analyzed using GraphPad Prism 6 statistical software (USA, GraphPad Software). 
p < 0.05 is considered statistically significant. p values are presented as p > 0.05 
(ns, not significant), ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001. 
For Western blots: Values of band immunointensity were measured using 
ImageJ and normalized to their corresponding tubulin or GAPDH loading control 
in the same lane, or to the total amount of pulled-down protein for 
immunoprecipitation assays. Data was then normalized to the control group by 
dividing all conditions and their SEMs by the value of the control condition. Data 
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from multiple trials were averaged to obtain the mean for each experiment. Multiple 
means of the same conditions were averaged to obtain the standard error of the 
mean, as indicated by the error bars in histograms. 
For ICC: Synaptic puncta were analyzed using NIH FIJI (ImageJ) Software. 
Images were manually thresholded to select synaptic puncta. To obtain intensity 
values, raw integrated density measurements were acquired using the Analyze 
Particles function. Colocalization of pre-synaptic and post-synaptic fluorescent 
puncta was assessed using the “Puncta Analyzer” plugin. Measurements from at 
least three segments of secondary dendrites from different neurites were analyzed 
to represent one neuron. Control conditions were normalized to 1 by dividing all 
conditions and their SEMs by the value of the control condition. 
For IHC: Mosaic expression of NEXMIF in brain slices was analyzed using 
the Spots protocol in IMARIS 9.5.1 (Bitplane AG, Zurich, Switzerland). Images 
underwent deconvolution according to the parameters of the microscope objective 
used for capture. Neurons were identified and labelled based on NeuN expression. 
Neurons were then sorted as NEXMIF+ and NEXMIF- based on NEXMIF 
expression. 
For behavioral tests: Video recordings were captured with a Logitech c920 
webcam during each test. Locomotion tracks were generated using idtracker.ai 
software (Romero-Ferrero et al., 2018). These tracks were used in custom scripts 
written in Python to quantify the desired aspects of the animals’ movement. 
 Sholl Analysis 
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Complexity of dendritic arborization was quantified using IMARIS 9.5.1 (Bitplane 
AG, Zurich, Switzerland). The dendrites of each neuron were manually traced 
using the Filament Tracer AutoPath protocol. The tracings were used to obtain 
measurements of the total dendritic length, mean dendritic length, and dendritic 
complexity evaluated by Sholl analysis. Sholl analysis within IMARIS measured 
dendritic branching complexity by counting the number of intersections between 
the dendritic filaments and concentric circles set at 1 µm intervals from the soma. 




Table 2.1 Plasmids 






shRNA pLKO.1 TRC Ampicillin Addgene 10878 
pLKO NEXMIF 




shRNA 368 pLKO.1 TRC Ampicillin 
Cloned In 
House - 
GFP Lentivirus pLVX Ampicillin Weifeng Xub, MIT - 
Nrgn-GFP lentivirus pLVX Ampicillin Weifeng Xu, MIT - 
SynDig1-HA pHM6 Amipcillin Elva Diaz, UC Davis - 
p300-myc pCMVβ Ampicillin Addgene 30489 
CBP-HA pRc/RSV Ampicillin Addgene 16701 
GCN5-flag pAdEasy Kanamycin Addgene 14106 
PCAF-flag pCI Ampicillin Addgene 8941 





GluA1-4KQ-GFP pRK5 Ampicillin Cloned In House - 
GluA1-4KR-GFP pRK5 Ampicillin Cloned In House - 
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Table 2.2 Antibodies 
Primary Antibodies 
Name Dilution Host Source Catalog Number 
Acetyl-Lysine 1:1000 (WB) mouse Santa Cruz sc-32268 
GABARα1 1:100 (ICC)   rabbit Abcam Ab33299 
GAD65 1:100 (ICC) mouse Santa Cruz sc-377145 
GAPDH 1:5000 (WB) mouse Abcam ab8245 
Gephyrin 1:100 (ICC) 1:1000 (WB) rabbit Abcam ab3220066 
GluA1-C 1:100 (ICC) rabbit OriGene Tech 
Custom-
made 
GluA1-N 1:100 (ICC) mouse Millipore MAB2263 
GluA2 1:1000 (WB) mouse Millipore MAB397 
HDAC1 1:1000 (WB) mouse Cell Signaling 5356P 
MAP2 1:100 (ICC) mouse Abcam ab70218 
NEXMIF 1:100 (slice IHC) 1:500 (ICC) rabbit 
Sigma-
Aldrich HPA000404 
NeuN 1:250 (slice IHC) mouse Millipore MAB377 
Neurogranin 1:1000 (WB) rabbit Abcam ab23570 
PSD-95 1:400 (ICC) 1:1000 (WB) mouse 
Synaptic 
Systems 124 011BT 
Synapsin I 1:1000 (WB) rabbit Millipore AB1543 
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SynDig1 1:1000 (WB) mouse Neuromab 75-251 
Tau-1 1:100 (ICC) mouse Millipore MAB3420 
α-tubulin 1:5000 (WB) rabbit Sigma-Aldrich 20911 
Ubiquitin 1:2000 (WB) rabbit Abcam ab7780 
VGlut1 1:250 (ICC) mouse Santa Cruz sc-377425 
VGat 1:200 (ICC) mouse Neuromab 75-457 
Phalloidin 1:50 (ICC) dye in methanol 
Cell 
Signalling 8953 




Name Dilution Host Source Catalog Number 
Rb IgG-HRP 1:5000 (WB) rabbit BioRad 170-6515 
Ms IgG-HRP 1:5000 (WB) mouse BioRad 170-6516 
Rb Alexa Fluor 488 1:500 (ICC) rabbit Molecular Probes A11094 
Rb Alexa Fluor 555 1:500 (ICC) rabbit Molecular Probes A21428 
Ms Alexa Fluor 488 1:500 (ICC) mouse Molecular Probes A21121 
Ms Alexa Fluor 555 1:500 (ICC) mouse Molecular Probes A21127 
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Table 2.3 Drugs 
Drug Name Solvent Final Concentration Source 
Catalog 
Number 
Glycine Water 200 μM Fisher BP381-5 
Strychnine Water 1 μM Sigma-Aldrich s8753 
Biccuculine DMSO 20 μM Sigma-Aldrich 14340 
TTX Water 1 μM Tocris 1069 
APV Water 25 μM Sigma-Aldrich A5282 
Aβ PBS 0.5 μM Invitrogen 03-112 
C646 DMSO 20 mM Millipore SML0002 
CTPB DMSO 20 mM Santa Cruz sc-202558 
B2 DMSO 2 mM Santa Cruz sc-202486 
Trichostatin A DMSO 100 μM Sigma-Aldrich T8552 
Sodium 
butyrate Water 50 mM Sigma-Aldrich B5887 















CHAPTER THREE: INVESTIGATION OF BEHAVIORAL AND MOLECULAR 




Autism spectrum disorders (ASDs) comprise a heterogeneous class of disorders 
characterized by impaired social interactions, diminished language and 
communication, and the tendency for repetitive behaviors. Our previous work 
identified the novel ASD gene NEXMIF and provided the first study of the 
associated cellular phenotypes. However, the molecular mechanism underlying 
NEXMIF function in brain development and ASD remains largely unknown. Here 
we investigate the cellular and molecular mechanisms underlying NEXMIF 
dependent ASD using a transgenic NEXMIF mouse model established by our 
group. We show that loss of NEXMIF in NEXMIF-/y animals leads to ASD-like 
behavioral alterations as well as impairments in neuronal development, such as 
reduced neurite growth, decreased synapse formation, and impaired synaptic 
plasticity. We also show loss of NEXMIF leads to downregulation of neurogranin 
(Nrgn) and SynDig1, which play roles in synaptic development and function. 
Reintroduction of Nrgn or SynDig1 in vitro rescues the decreased spine density 
and synaptic AMPAR levels observed from loss of NEXMIF. These findings 
indicate the NEXMIF-/y mouse faithfully models the human condition and Nrgn and 
SynDig act as downstream regulators of NEXMIF function to affect synaptic 
development. Use of the NEXMIF-/y mouse, particularly for potential rescue of 
behavioral impairments by Nrgn and SynDig1 in vivo, will allow for a better 





Autism spectrum disorders (ASD), estimated to affect 1 in 54 individuals in the 
United States (Maenner et al., 2020), are characterized by reduced social 
interactions, impaired language and communication, and stereotyped, repetitive 
behaviors (American Psychiatric Association, 2013; Chen et al., 2015a; Lord et al., 
1989). ASD often presents with other co-morbid psychiatric and medical conditions 
such as intellectual disability (ID), epilepsy, gross and fine motor deficits, anxiety, 
gastrointestinal issues, and attention-deficit/ hyperactivity disorder (ADHD) 
(Chiurazzi et al., 2020; Reiersen and Todd, 2008; Storch et al., 2012; Towbin et 
al., 2005; Tye et al., 2019; Zafeiriou et al., 2007).  
ASD is among the most heritable neuropsychiatric disorders, and the 
genetic influences implicated in ASD are highly heterogeneous (Fernandez and 
Scherer, 2017; Geschwind, 2011; Grove et al., 2019; Jeste and Geschwind, 2014; 
Krumm et al., 2015; Persico and Bourgeron, 2006; Pinto et al., 2010; Ziats and 
Rennert, 2016). Analysis of the Simons Foundation Autism Research Initiative 
(SFARI) gene database identifies a vast diversity of hundreds of ASD associated 
genes (Abrahams et al., 2013; Banerjee-Basu and Packer, 2010a). Amongst these 
genes, a large number play roles in the development and function of synapses, 
such as neuroligin 3 (NLGN3), neuroligin 4X (NLGN4X), neurexin 1 (NRXN1), and 
SH3 and multiple ankyrin repeat domains 3 (SHANK3) (Durand et al., 2007; Feng 
et al., 2006; Jamain et al., 2003; Tabuchi et al., 2007). These and other reports 
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show that synaptic dysregulation and imbalances in neuronal activity are among 
the most common cellular alterations in ASD (Bagni and Zukin, 2019; Berkel et al., 
2010; Bourgeron, 2015; Pfeiffer et al., 2010; Romero-Garcia et al., 2019; Schwede 
et al., 2018; Zoghbi, 2003).  
The NEXMIF gene (also known as KIDLIA, KIAA2022, or Xpn) is a novel 
gene, localized on the X chromosome at Xq13.2, with little known biological 
function. Previous studies have demonstrated that NEXMIF mRNA expression 
starts as early as E10.5, increases throughout development with a peak at P3, and 
continues at a lower level into adulthood (Cantagrel et al., 2009; Ishikawa et al., 
2012). NEXMIF mRNA shows notably strong expression in the cortex, 
hippocampus, cerebellum, and olfactory bulb (Allen Institute for Brain Science, 
2004; Cantagrel et al., 2009). At the protein level, NEXMIF is specifically 
distributed in the nucleus of post-mitotic neurons but not in glia. Strong protein 
expression can be detected from E17 through adulthood in mice (Gilbert and Man, 
2016), indicating a role for NEXMIF in brain development.  
The NEXMIF gene was first implicated in ASD as one of the candidate 
genes in two male members of a family who had autistic phenotypes and ID 
(Cantagrel et al., 2004). That original report and others established that individuals 
with mutations in NEXMIF show repetitive behaviors, impaired language, seizures, 
and ID, with several cases of microcephaly (Cantagrel et al., 2004, 2009; Van 
Maldergem et al., 2013). Multiple additional reports have confirmed the loss of 
NEXMIF by gene mutation or deletion in individuals diagnosed with ASD (Alarcon-
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Martinez et al., 2019; Charzewska et al., 2015; Farach and Northrup, 2016; Kuroda 
et al., 2015; Lambert et al., 2018; de Lange et al., 2016; Lorenzo et al., 2018; 
Webster et al., 2017). NEXMIF has been listed as an ASD gene in the SFARI 
database. We have recently shown that NEXMIF knockdown in rat hippocampal 
neurons impairs neurite outgrowth via a disruption of N-cadherin/δ-catenin 
signaling and actin dynamics, and loss of NEXMIF caused defects in neuron 
migration in vivo (Gilbert and Man, 2016; Van Maldergem et al., 2013). However, 
to date little is known regarding the function of NEXMIF or the cellular and 
molecular mechanisms underlying the disorder caused by the loss of NEXMIF.  
Therefore, we utilized our transgenic NEXMIF-/y knockout mouse to 
investigate the role of NEXMIF in neuronal and synaptic development. We 
hypothesized that NEXMIF is involved in synaptogenesis and that the absence of 
NEXMIF in neurons from NEXMIF-/y brains would result in synaptopathy, thus 
causing ASD-like behaviors in these animals. 
 
3.3 Results 
 NEXMIF-/y mice show typical autistic features in social behavior† 
Loss of NEXMIF expression in humans produces behavioral deficits typical of 
ASD, including repetitive behavior, decreased social behavior and ID (Cantagrel 
et al., 2004, 2009; Farach and Northrup, 2016; Kuroda et al., 2015; de Lange et 
al., 2016; Van Maldergem et al., 2013; Webster et al., 2017). We therefore sought 
to characterize the knockout NEXMIF-/y mouse (KO) to determine its suitability as 
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a model for studying the human disorder. First, we looked for any deficits in social 
behavior, one of the core ASD behavioral impairments. To do this, we used the 
three-chamber social task, a test broadly used for assessing mouse sociability and 
interest in social novelty (Crawley, 2007; Moy et al., 2009). Animals were 
habituated to the apparatus by allowing the animals to explore all three chambers, 
including the empty cages, prior to testing (Fig. 3.1A-3.1C). To examine 
sociability, first a stranger mouse (Mouse 1) was placed into one of the chambers 
and the test mouse was allowed to freely navigate within the three-chamber 
apparatus (Fig. 3.1D). Representative track lengths during the test show that 
NEXMIF-/y mice spent significantly less time interacting with Mouse 1 compared 
to the empty cage (Fig. 3.1E). A significant decrease in the preference index for 
Mouse 1 was observed, indicating an impairment in sociability (Fig. 3.1F). To 
examine the NEXMIF-/y animal’s interest in social novelty, a second mouse (Novel 
Mouse) was placed into the empty cage after the test mouse had been allowed to 
interact with Mouse 1 (Fig.  3.1G). Strikingly, NEXMIF-/y animals showed no 
preference for the Novel Mouse as shown in the representative track lengths (Fig. 
3.1H) with a preference index significantly smaller compared to the WT animals, 
indicating a lack of interest in social novelty (Fig. 3.1I). 
 Impaired spatial memory in NEXMIF-/y animals† 
Humans with loss of function mutations or genetic deletions of NEXMIF show 
autistic phenotypes accompanied by severe ID. We therefore sought to investigate 
whether our NEXMIF-/y mouse showed learning and memory deficits to 
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recapitulate the human condition. To do this, we used the Barnes maze for spatial 
memory. In this task, mice were trained over a period of 4 days to learn the location 
of a target escape hole, using spatial cues placed within the testing room, on a 
board containing 20 holes around its circumference. NEXMIF-/y animals showed 
the ability to learn the target escape hole location during acquisition training 
periods (Fig. 3.2A). After spatial acquisition training, the target hole was covered 
and the number of nose pokes made at each hole location was quantified 24 h and 
5 d later (Fig. 3.2B). In the 24 h probe for spatial memory, NEXMIF-/y animals did 
not show significant differences in the number of nose pokes made at the target 
hole (Fig. 3.2C). Probing spatial memory 5 d after training showed that NEXMIF-/y 
animals had impairments in memory of the target hole location, with significantly 
less nose pokes at the target and adjacent holes and a broader search of the board 
(Fig. 3.2D). Quantification of the primary latency to find the target hole showed 
that NEXMIF-/y animals took much longer to find the target hole and traveled much 
longer prior to making an initial nose poke at the target hole in both the 24 h and 
the 5 d tests (Fig. 3.2E- 3.2F). These findings suggest that loss of NEXMIF impairs 
spatial memory, which may be a contributing factor to the ID observed in humans 
with loss of NEXMIF and ASD with ID. 
 Impairments in communication by ultrasonic vocalization in NEXMIF-
/y mice 
To further assess the behavioral characteristics of this model, we tested NEXMIF-
/y animals for impaired communication, a core ASD behavioral deficit present in 
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humans with NEXMIF variants. To examine the communication behavior, we 
recorded and analyzed ultrasonic vocalizations (USVs) in pups isolated from their 
mother and littermates. Pups at P5, P7, and P9 were placed in a recording 
chamber for 5 min in which a microphone recorded any vocalizations (Fig. 3.3A). 
Quantification of the number of calls showed that NEXMIF-/y animals made 
significantly fewer calls overall (Fig. 3.3B) and fewer calls within each minute of 
the 5-minute recording period, at all time points measured (Fig. 3.3C-3.3E). Calls 
made by the NEXMIF-/y animals were also of shorter length (Fig. 3.3F) resulting in 
a reduced total time spent calling (Fig. 3.3G). There was no change in average 
peak amplitude or peak frequency of vocalizations between the WT and KO 
animals (Fig. 3.3H-3.3I). Further analysis of the call syllable types (Fig. 3.4A) 
revealed that NEXMIF-/y animals generally made simpler USV calls than WT 
animals (Fig. 3.4B), making significantly more short and flat calls and fewer 
modulated and multiple jump calls (Fig. 3.4C-3.4E). These findings suggest that 
loss of NEXMIF results in an impairment in normal communication. In addition, we 
found that NEXMIF-/y animals demonstrate repetitive self-grooming, decreased 
marble burying, and increased activity in an open field (data not shown), further 
establishing this as an ASD model. 
 Neurons from NEXMIF-/y mice show deficits in neurite extension 
Having established that the NEXMIF-/y mice are a good model of the human 
disorder, we wanted to use this model to investigate the molecular mechanisms 
underlying the observed behavioral phenotypes. To directly study the effect of 
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complete knockout of NEXMIF on neuron morphological development, we used 
primary mouse neurons cultured from NEXMIF-/y mice. To measure changes in 
dendritic arborization, NEXMIF-/y cortical neurons were fixed at DIV 8 and 
immunostained for MAP2 to label dendrites (Fig. 3.5A). At this time point, the 
dendrites are undergoing much of their initial branching. Sholl analysis revealed a 
significant reduction in dendritic branching complexity for neurons from NEXMIF-
/y animals compared to those from male WT littermates (Fig. 3.5B). NEXMIF-/y 
neurons also showed a decrease in the total number of dendrites, number of 
branch points, number of terminal points, and the sum length of the dendrites 
compared to WT neurons (Fig. 3.5C-3.5F). We also assessed dendritic 
phenotypes at DIV 14, when a great deal of the dendritic extension has taken 
place (Fig. 3.5G). Similarly, DIV 14 NEXMIF-/y neurons have a dramatically 
reduced dendritic arbor with fewer dendrites, branch points, terminal points, and 
a decreased sum length of dendrites compared to WT neurons (Fig. 3.5H-3.5L). 
These findings are consistent with our earlier work using shRNA knockdown of 
NEXMIF in cultured rat neurons (Gilbert and Man, 2016).  
 We also examined the effect of NEXMIF knockout on axon extension. To 
do this, cortical neurons from NEXMIF-/y mice were fixed at DIV 3 and 
immunostained for Tau1 to label axons (Fig 3.6A). At this time point, the axon has 
recently differentiated from the other neurites. Tracing the axons revealed that 
axons from NEXMIF-/y neurons were shorter and branched less than those from 
WT neurons (Fig. 3.6B-3.6C). We also assessed axonal development after 
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several days of growth and branching at DIV 6 (Fig 3.6D). Interestingly, there was 
no difference in total axon length or number of branches between WT and 
NEXMIF-/y neurons at this later time point (Fig. 3.6E-3.6D). Together, these results 
support a role for NEXMIF in neurite formation and extension.  
 Loss of NEXMIF results in alterations in synaptic protein composition 
To examine synaptic changes due to loss of NEXMIF, we first used an in vitro 
model using lentiviral-mediated shRNA knockdown of NEXMIF, and analyzed 
GluA1 and PSD-95 synaptic puncta via ICC at DIV 14 in primary hippocampal 
neurons (Fig. 3.7A). Strikingly, a 45% reduction in GluA1 puncta density and 20% 
reduction in GluA1 puncta intensity were observed after shRNA-mediated 
knockdown of NEXMIF compared to scrambled shRNA treatment (Fig. 3.7B-
3.7C). Analysis of the immunostaining of PSD-95 showed a 60% reduction in 
puncta density with no change in synaptic intensity (Fig. 3.7D-3.7E). Analysis of 
GluA1 puncta in primary cortical neurons showed similar reductions in puncta 
density of 20% and in puncta intensity of 37%, (Fig. 3.7F-3.7G) while PSD-95 
puncta showed a 45% reduction puncta density and a 40% reduction in puncta 
intensity (Fig. 3.7H-3.7I).  
We then immunostained the presynaptic marker VGluT1 (Fig. 3.8A). After 
shRNA-mediated knockdown of NEXMIF, VGluT1 puncta density was reduced by 
38% with no change in puncta intensity (Fig. 3.8B-3.8C). To examine changes in 
inhibitory GABAergic synaptic proteins, we used lentiviral-mediated shRNA 
knockdown of NEXMIF and immunostained for gephyrin (Fig. 3.8D). We found 
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that, compared to scrambled shRNA, knockdown of NEXMIF resulted in a 27% 
reduction in the intensity and a modest reduction in density of gephyrin puncta 
(Fig. 3.8E-3.8F). We further characterized the effect of loss of NEXMIF on 
GABAergic synaptic proteins by immunostaining for GAD65 (Fig. 3.8G). Analysis 
of GAD65 immunostaining revealed a significant reduction in both puncta intensity 
and puncta density (Fig. 3.8H-3.8I). Collectively, these results demonstrate a 
reduced in the level of synaptic proteins from loss of NEXMIF, which is suggestive 
of a change in synapses. 
 Confirmation of synaptic impairment in neurons from NEXMIF-/y mice 
To confirm the changes in synaptic proteins observed from transient knockdown 
of NEXMIF, we further examined synaptic development in neurons from the 
NEXMIF-/y mice. We cultured cortical neurons from transgenic knockout NEXMIF-
/y mice and WT male littermates and immunostained them at DIV 14 for the 
excitatory postsynaptic receptor subunit GluA1 (Fig. 3.9A). Strikingly, in NEXMIF-
/y neurons, GluA1 puncta density was reduced by 70% and puncta intensity was 
reduced by 40% compared to that in WT neurons (Fig. 3.9B-3.9C). Similarly, in 
hippocampal neurons, GluA1 demonstrated deficits in NEXMIF-/y neurons 
compared to WT neurons with a 55% decrease in puncta density and a 15% 
decrease in puncta intensity (Fig 3.9D-3.9E). Cortical neurons cultures from WT 
or NEXMIF-/y mice were also immunostained at DIV 14 for the inhibitory 
postsynaptic receptor subunit GABARα1 (Fig. 3.9F). Analysis of GABARα1 
immunostaining revealed a 60% reduction in puncta density and a 26% reduction 
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in puncta intensity in NEXMIF-/y neurons compared to WT neurons (Fig. 3.9G-
3.9H). GABARα1 in hippocampal NEXMIF-/y neurons, however, showed no change 
in puncta intensity compared to WT neurons but maintained the 60% reduction in 
puncta density observed in cortical neurons (Fig. 3.9I-3.9J).  
We also investigated spine density in our transgenic culture. Consistent with 
the phenotype we observed from Golgi staining of WT and NEXMIF-/y brain slices, 
Phalloidin staining for actin-rich spines in DIV 13 neurons cultured from WT or 
NEXMIF-/y mice showed a significant decrease in spine density for NEXMIF-/y 
neurons compared to WT neurons (Fig. 3.9K-3.9L). 
 Loss of NEXMIF results in deficits in synapse formation 
To further investigate the effect of NEXMIF knockdown on synaptic formation, we 
quantified the number of functional synapses by colocalization of presynaptic axon 
terminals with postsynaptic spines. For excitatory glutamatergic synapses, we 
used lentiviral-mediated shRNA knockdown of NEXMIF and co-immunostained 
the presynaptic marker VGluT1 with the postsynaptic marker PSD-95 (Fig. 
3.10A). After shRNA-mediated knockdown of NEXMIF, glutamatergic synapse 
density was reduced by 30% (Fig. 3.10B). To examine changes in GABAergic 
synapses, we co-immunostained gephyrin and VGAT to analyze colocalized 
GABAergic synaptic puncta (Fig. 3.10C). We found that, compared to scrambled 
shRNA, knockdown of NEXMIF resulted in a 60% reduction in GABAergic 
synapse density (Fig. 3.10D).  
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As these results are due to transient knockdown of NEXMIF expression, 
we confirmed the changes in synapse density in neurons cultured from NEXMIF-
/y mice. Similar to the knockdown result, complete loss of NEXMIF in NEXMIF-/y 
neurons resulted in a significant decrease in the density of VGluT1 and PSD95 
colocalized glutamatergic synaptic puncta compared to WT neurons (Fig. 3.10G-
3.10H). Additionally, NEXMIF-/y neurons showed a significant decrease in the 
density of VGat and gephyrin colocalized GABAergic puncta compared to WT 
neurons (Fig. 3.10I-3.10J). These findings demonstrate that loss of NEXMIF 
expression has a profound effect on both glutamatergic and GABAergic synapse 
formation, with a large decrease in synapse number.  
 Neurons from NEXMIF-/y animals show impairments in synaptic 
plasticity 
To determine the functional consequences of the impaired synapse development 
that occurs in NEXMIF-/y neurons, we investigated the AMPA receptor dynamics 
underlying both Hebbian and homeostatic synaptic plasticity in these neurons. 
First, we tested the ability of neurons from NEXMIF-/y mice to undergo LTP by 
using a standard protocol that chemically induces LTP (chem-LTP) by treating 
neurons with glycine (150 µM) (Lu et al., 2001). In DIV 14 neurons, an N-terminal 
specific GluA1 antibody was used to label surface expressing AMPARs before 
and after treatment to identify newly inserted AMPARs (Fig. 3.11A). As expected, 
neurons from WT mice showed an increase in GluA1 surface expression after 
chem-LTP (Fig. 3.11B). However, chem-LTP failed to increase the surface 
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expression of GluA1 in neurons from NEXMIF-/y mice (Fig. 3.11B). Additionally, 
we tested homeostatic synaptic plasticity (HSP) in NEXMIF-/y neurons using an 
established protocol that induces chronic inactivation to stimulate HSP. DIV 14 
neurons were treated with TTX (1 µM) and APV (25 µM) for 24 h and then 
immunostained with an N-terminal specific GluA1 antibody to label the surface 
expressing AMPARs (Fig. 3.11C). When WT neurons had HSP induced, a 
significant increase in surface expressing GluA1 was observed (Fig. 3.11D). 
However, HSP induced NEXMIF-/y neurons failed to show an increase in GluA1 
surface expression compared to those without HSP treatment (Fig. 3.11D). 
 Loss of NEXMIF leads to reduced expression of Nrgn and SynDig1† 
Given the nuclear localization of NEXMIF, we hypothesized that NEXMIF may 
function as a transcriptional regulator. Therefore, our group performed an RNAseq 
to examine changes gene expression from loss of NEXMIF. Mouse neuronal 
cultures were infected with lentiviral NEXMIF shRNA or a scrambled control on 
DIV 0. Total RNA was collected at DIV 14 and analyzed in RNAseq for changes 
in gene expression.  A total of 1,097 significantly up-regulated and 961 
significantly down-regulated genes were identified, with more dramatic 
downregulation dominating (Fig. 3.12A). Ingenuity Pathway Analysis (IPA) 
identified glutamatergic signaling, synaptogenesis signaling, and synaptic 
plasticity processes such as LTP and LTD among the top dysregulated signaling 
pathways (Fig. 3.12B). Additionally, gene ontology (GO) enrichment analysis of 
the RNAseq dataset identified many synapse or neurodevelopment related genes 
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participating in processes such as neuron development and differentiation 
(3.12C). Among the top downregulated, genes, two emerged as top candidates 
for effecting synapse development downstream of NEXMIF. The first was 
neurogranin (Nrgn), the top downregulated gene, which is a calmodulin-binding 
protein enriched in dendritic spines and plays a role in synaptic plasticity and 
synaptogenesis (Díez-Guerra, 2010; Garrido-García et al., 2019; Ryoo et al., 
2015; Zhabotinsky et al., 2006; Zhong and Gerges, 2010). The second was 
SynDig1, which was in the top 10% of downregulated genes, is enriched in 
synapses, and promotes synapse formation (Díaz, 2012; Kalashnikova et al., 
2010; Lovero et al., 2013). To confirm the reduced mRNA transcript levels of these 
candidates, we used lentiviral shRNA to knockdown NEXMIF in cultured neurons 
and performed qPCR on their cell lysates. Quantification of NEXMIF mRNA levels 
after shRNA treatment confirmed successful knockdown compared to use of a 
scrambled (SCR) shRNA control (Fig. 3.13A). Similar to the findings from 
RNAseq, shRNA knockdown of NEXMIF lead to a 72% decrease in Nrgn mRNA 
levels as well as a 60% decrease in SynDig1 mRNA levels (Fig. 3.13B-3.13C). 
To determine whether these decreases in mRNA lead to changes in protein 
expression, hippocampal brain lysates were collected from P30 WT and NEXMIF-
/y mice for western blot analysis (Fig. 3.13D). Immunostaining of synaptic proteins 
revealed no change in total PSD95 levels but a significant decrease in total GluA1 
levels (Fig. 3.13E-3.13F). Additionally, we observed a significant reduction in the 
82 
total protein expression of both Nrgn and SynDig1, confirming the findings from 
qPCR (Fig. 3.13G-3.13H).  
 Reintroduction of Nrgn and/or SynDig1 rescues synapse formation in 
NEXMIF null neurons 
We next wanted to determine whether reintroduction of Nrgn or SynDig1 could 
rescue the synaptic deficits observed from loss of NEXMIF. To do this, we 
transfected rat hippocampal neuron cultures at DIV 9 with GFP or GFP and 
NEXMIF shRNA, together with an empty vector plasmid, Nrgn, SynDig1, or Nrgn 
and SynDig1. Neurons were then fixed and immunostained for GluA1 at DIV 16 
(Fig. 3.14A). Similar to that observed previously, there was a decrease in the 
GluA1 puncta density in neurons with NEXMIF knockdown. However, neurons 
with co-transfection of Nrgn, SynDig1, or both showed a rescue of GluA1 puncta 
density to levels similar to those of the control neurons (Fig. 3.14B). We performed 
a similar transfection at DIV 6 in neurons that were fixed on DIV 14 and stained 
with Phalloidin to label actin-rich spines (Fig. 3.14C). As seen previously, loss of 
NEXMIF resulted in a significant decrease in spine density. Co-transfection with 
Nrgn, SynDig1, or both was able to significantly increase the spine density in these 
neurons compared to NEXMIF shRNA alone. However, only treatment with Nrgn 
was able to rescue spine density to a level similar to that of control neurons as 
neurons treated with SynDig1 or Nrgn and SynDig1 together only demonstrated 




In this study, we successfully established a mouse model for NEXMIF-dependent 
ASD and ID. The NEXMIF-/y mouse displays the characteristics observed in 
humans with loss of NEXMIF and can therefore be used as an animal model. 
NEXMIF-/y mice display significant impairments in the three-chamber social task, 
with decreased sociability and decreased interest in social novelty. NEXMIF-/y mice 
spent significantly less time interacting with a novel mouse. Additionally, NEXMIF-
/y animals showed significant communication impairments shown by USVs, with 
increased use of simpler and shorter call types as well as fewer calls and less total 
time spent making calls. We also found significant impairments in the marble-
burying test, with NEXMIF-/y animals burying significantly fewer marbles during the 
task, a phenotype that suggests a decreased interest in their surrounding 
environment. NEXMIF-/y mice also displayed significantly increased repetitive 
grooming and hyperactivity, common phenotypes observed in ASD mouse models 
(Kalueff et al., 2016; Silverman et al., 2010). NEXMIF-/y mice also displayed major 
deficits in spatial memory, which is consistent with findings of moderate-to-severe 
ID in humans with NEXMIF mutations, (Cantagrel et al., 2004, 2009; Kuroda et al., 
2015; Lambert et al., 2018; Lorenzo et al., 2018; Van Maldergem et al., 2013). 
NEXMIF-/y mice were able to learn the target hole location over the course of the 
Barnes maze training but, showed impairments when probing their memory of the 
location 5 d later.  
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Our group has previously shown loss of NEXMIF impairs neurite outgrowth 
and actin dynamics (Gilbert and Man, 2016), work which helped in the naming of 
NEXMIF (neurite extension and migration factor). However, the previous findings 
were for loss of NEXMIF due to transient shRNA-mediated knockdown. Here we 
confirm the dysregulation of neurite formation in neurons from NEXMIF-/y mice. 
NEXMIF-/y neurons have less complex dendritic arbors with shorter dendrites and 
less branches than WT neurons at DIV 8 and DIV 14. NEXMIF-/y neurons also have 
shorter and less branched axons at DIV 3. Interestingly, this difference in axon size 
is no longer visible at DIV 6. This may indicate that loss of NEXMIF impairs initial 
axon specification but there is no deficit in axon extension. It would be interesting 
for future studies to examine the effect of loss of NEXMIF on the axon initial 
segment, for its roles in both neuronal polarity and excitability (Buffington and 
Rasband, 2011; Leterrier, 2018). 
ASD is classified among other neurodevelopmental disorders, such as 
fragile X syndrome, Rett syndrome, and Angelman syndrome, as a synaptopathy 
due frequently observed alterations in synaptic structure and function among its 
cellular phenotypes (Bagni and Zukin, 2019; Guang et al., 2018; Phillips and 
Pozzo-Miller, 2014; Della Sala and Pizzorusso, 2014; Yang, 2020). Such 
irregularities in synaptogenesis and synaptic function are a shared underlying 
neurobiological mechanism that results in the social and cognitive deficits 
observed in these disorders (Carroll et al., 2021; Won et al., 2013; Zoghbi and 
Bear, 2012). We observed a major dysregulation in synaptic protein expression 
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with a reduction in both glutamatergic and GABAergic synaptic proteins including 
AMPARs, PSD-95, and gephyrin from neurons of NEXMIF knockdown and 
NEXMIF-/y brain tissue. Additionally, neurons from NEXMIF-/y mouse brains 
revealed significantly decreased spine and both glutamatergic and GABAergic 
synaptic densities. It will be valuable for future studies to explore changes in spine 
and synapse formation throughout developmental stages to clarify whether 
synaptic and spine deficits result from aberrant structural growth or pruning, and if 
NEXMIF plays a role in synapse maintenance and function after synaptogenesis.  
In addition to these structural changes, we also observed functional 
changes in synaptic plasticity. Synaptic plasticity is mediated by exocytosis of 
AMPARs onto the synaptic surface from recycling endosomes (Ju et al., 2004; 
Park et al., 2004, 2006; Sutton et al., 2006). NEXMIF-/y neurons failed to enhance 
surface AMPAR expression in response to NMDAR-dependent chemical LTP. 
NEXMIF-/y neurons also failed to increase surface AMPAR expression in response 
to HSP treatments. These findings indicate impairments in both Hebbian and 
homeostatic synaptic plasticity. While the exact mechanisms remain to be 
elucidated, it is possible that loss of NEXMIF results in impaired exocytosis, or 
enhanced endocytosis, of AMPAR, thus preventing stable AMPAR insertion during 
both LTP and HSP. These major abnormalities in synapse formation and function 
may underlie the behavioral deficits of this animal model. Additional studies of LTD 
and AMPAR endocytosis in NEXMIF-/y neurons would be of interest to further our 
understanding of the role NEXMIF plays in synaptic plasticity. 
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Our previous work indicated that NEXMIF is distributed exclusively in the 
nucleus of neurons but not glia, indicating that NEXMIF may function as a 
transcriptional regulator (Gilbert and Man, 2016). Our RNAseq data from neurons 
with NEXMIF knockdown revealed a large population of genes being up- or down-
regulated in expression. The significantly dysregulated genes include those 
involved in neuron development, glutamatergic signaling, synapse formation, and 
synaptic plasticity. This suggests that NEXMIF may function to enhance synaptic 
gene expression during development. Among the top down-regulated genes 
involved in synapse formation and function, we identified the candidate molecules 
neurogranin (Nrgn) and SynDig1 (Garrido-García et al., 2019; Kalashnikova et al., 
2010; Zhabotinsky et al., 2006). We found that overexpression of either Nrgn or 
SynDig1 could rescue the density of AMPAR puncta and spines after loss of 
NEXMIF expression. Further studies to explore the potential rescue effect of Nrgn 
and SynDig1, particularly on synaptic plasticity and ASD-related behaviors, would 
be of interest. Additionally, future work to elucidate NEXMIF’s role in the nucleus 
would help to clarify whether NEXMIF functions as a transcription factor or a 
component of regulatory complexes in gene expression. 
In conclusion, neurons from the NEXMIF-/y mouse reveal potential roles for 
NEXMIF in multiple steps of neuron development including morphogenesis, 
synapse formation, and synaptic plasticity. Additionally, preliminary rescue 
experiments suggest downstream roles for Nrgn and SynDig1 in mediating 
NEXMIF’s effects on synapse development. Further work is needed to elucidate 
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the direct function of NEXMIF as well as the mechanistic pathway leading from 
NEXMIF to each of its phenotypes. Future studies should make use of the 
NEXMIF-/y mouse for continued investigations of NEXMIF function and for ASD 
rescue approaches by molecular therapies, such as genetic restoration or 






Figure 3.1 NEXMIF knockout mice show impaired social behavior in the 
three-chamber social test† 
(A) Habituation to the three-chamber apparatus. Mice were released from the 
center chamber, with empty cages in the adjacent chambers, and allowed to move 
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freely within the apparatus for 5 min prior to beginning the sociability and social 
novelty tests. (B) Traces of animal track paths in the habituation phase for WT 
and KO mice. (C) Neither WT or KO animals showed any preference for either 
side chamber during habituation. (Left vs Right: WT: t(32) = 0.61, p = 0.55; KO: t(32) 
= 0.29, p = 0.77). (D) Paradigm for the sociability test. An unfamiliar mouse 
(Mouse 1) was placed into either of the side chambers and the test mouse was 
allowed to move freely within the apparatus. (E) Traces of animal track paths in 
the sociability test for WT and KO mice. (F) Quantification of the preference index 
(see methods) showed a decrease in preference for Mouse 1 in NEXMIF KO 
animals compared to WT controls. (WT = 55.57 ± 7.37, n = 8; KO = 28.38 ± 
6.46, n = 8; t(6) = 2.71, p = 0.035) (G) Paradigm for the social novelty test.  A 
second mouse (Novel Mouse) was placed into the remaining empty chamber 
opposite to Mouse 1, and the test mouse was allowed to interact with both mice. 
(H) Traces of animal track paths in the social novelty test for WT and KO mice. (I) 
In the social novelty test, KO animals showed no preference for the novel animal. 
(WT = 42.30 ± 8.00, n = 9; KO = -7.93 ± 7.81, n = 9; t(8) = 3.84, p = 0.005). WT: 
wild type littermate, KO: NEXMIF-/y. Data are represented as mean ± SEM. 






Figure 3.2 NEXMIF knockout mice show impairments in Barnes maze spatial 
learning and memory† 
(A) Quantification of the primary latency (s) to find the target hole across all 
training trials (4 trials per day over 4 days) for WT and KO animals. (B) Traces of 
track paths in the Barnes spatial memory maze during the 5 d memory probe for 
WT and KO animals. (C) The distribution of nose pokes on the board showed no 
difference 24 h after training. (D) Quantification of the distribution of nose pokes 
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across different holes on the board showed a significant decrease for the target 
and adjacent holes in the 5 d memory probe. (E, F) Primary latency to the target 
hole (E) (24 h: WT = 6.94 ± 1.41 s, n = 9; KO = 17.22 ± 3.5 s, n = 9; t(32) ⫽= 
2.64, p = 0.013; 5 d: WT = 8.06 ± 0.90 s, n = 9; KO = 23.78 ± 3.91 s, n = 9; t(32) 
= 4.04, p = 0.00032) and total track length (F) (24 h: WT = 0.11 ± 0.021 m, n = 
9; KO = 0.48 ± 0.0.81 m, n = 9; t(16) = 4.41, p = 0.00044; 5 d: WT = 0.11 ± 0.017 
m, n = 9; KO = 0.86 ± 0.16 m, n = 9; t(16) = 4.65, p = 0.00027) were increased in 
the KO animals probing both 1 d and 5 d after training. WT: wild type littermate, 
KO: NEXMIF-/y. Data are represented as mean ± SEM. *p<0.05, **p<0.01, 




Figure 3.3 NEXMIF knockout mice show impairments in communication 
(A) Representative vocalizations from P7 recordings for WT and KO mice. Top: 
the raw USV signals. Bottom: the associated spectrograms; all are 1.5 s in length. 
Dashed line depicts the 30 kHz frequency threshold for eliminating noise. (B) 
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Quantification of the call rate shows a decrease in the number of calls made by 
NEXMIF KO animals compared to WT controls at each developmental time point 
recorded. (P5: t(18) = 5.37, n = 10, p < 0.0001; P7: t(20) = 4.71, n = 11, p = 0.00013; 
P9: t(20) = 2.78, WT: n = 12, KO: n = 10, p = 0.012). (C-E) Mean number of calls 
emitted across the 5 min recording period at each developmental time point P5 
(C: WT, n =10; KO, n =10), P7, (D: WT, n =11; KO, n =11), and P9 (E: WT, n =12; 
KO, n =11). (F, G) NEXMIF KO mice showed a decreased mean call syllable 
duration (F) (P5: t(16) = 3.06, p = 0.0075; P7: t(20) = 2.86, p = 0.0097; P9: t(20) = 
2.98, p = 0.0074) and a decrease in total time spent calling (G) (P5: t(18) = 4.02, 
p = 0.0008; P7: t(20) = 4.18, p = 0.00047; P9: t(20) = 3.43, p = 0.0027) at each time 
point. (H, I) Quantification of the peak amplitude (H) and peak frequency (I) of calls 
shows no change between NEXMIF WT and KO animals at any time point. WT: 
wild type littermate, KO: NEXMIF-/y. Data are represented as mean ± SEM. 





Figure 3.4 Syllable classification of USV calls in NEXMIF mice 
(A) Representative calls of each type used in syllable characterization. (B) KO 
animals showed an increase in Simple type calls and a decrease in Complex type 
calls compared to WT animals at each time point. (P7: WT = 57.12 ± 7.86%, n = 
6; KO = 83.72 ± 3.69%, n = 5; F(1,9) = 19.27, p = 0.002, ANOVA). (C) Call syllable 
classification at P5 shows an increase in short and flat calls and a decrease in 
modulated and harmonic calls made by KO animals compared to WT animals. (D) 
KO mice made significantly more short and flat calls compared to WT mice and 
significantly less modulated and multiple jump calls at P7. (P7: Short: t(9) = 4.9, p 
= 0.0018; Flat: t(9) = 2.86, p = 0.019; Mod.: t(9) = 2.60, p = 0.029; Multi. Jump: t(8) 
= 3.14, p = 0.014). (E) Call syllable classification at P9 shows an increase in short 
calls and decrease in modulated, multiple jump, and harmonic calls made by KO 
animals compared to WT animals. (WT, n =6; KO, n = 5). WT: wild type littermate, 
KO: NEXMIF-/y. Data are represented as mean ± SEM. *p<0.05, **p<0.01, 





Figure 3.5 Neurons from NEXMIF-/y mice show a decrease in dendritic 
arborization 
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(A) Representative images of MAP2 immunostained primary cortical neurons from 
WT or NEXMIF-/y brains at DIV 8. (B) Sholl analysis reveals a decrease in dendritic 
arbor complexity for NEXMIF-/y neurons compared to WT neurons at DIV 8 
(repeated measures two-way ANOVA followed by Bonferroni’s multiple 
comparison test; F(1,70) = 28.47, p < 0.0001 between genotypes; F(173, 12110) = 156.9, 
p < 0.0001 between radius). (C-F) The number of dendrites (C) (t(68) = 5.375, p < 
0.0001), branch points (D) (t(68) = 5.244, p < 0.0001), terminal points (E) (t(68) = 
4.969, p < 0.0001), and sum length of dendrites (F) (t(68) = 6.660, p < 0.0001) were 
decreased in NEXMIF-/y neurons compared to WT neurons at DIV 8. n = 34 
neurons/ group. (G) Representative images of MAP2 immunostained primary 
cortical neurons from WT or NEXMIF-/y brains at DIV 14. (H) Dendritic complexity 
is decreased in NEXMIF-/y neurons compared to WT neurons at DIV 14 as 
measured by Sholl analysis (repeated measures two-way ANOVA followed by 
Bonferroni’s multiple comparison test; F(1,89) = 63.21, p < 0.0001 between 
genotypes; F(200, 17800) = 166, p < 0.0001 between radius). (I-L) The number of 
dendrites (I) (t(87) = 7.492, p < 0.0001), branch points (J) (t(87) = 7.251, p < 0.0001), 
terminal points (K) (t(87) = 7.918, p < 0.0001), and the sum length of dendrites (L) 
(t(88) = 8.074, p < 0.0001) were decreased in NEXMIF-/y neurons compared to WT 
neurons at DIV 14.  n = 44 neurons/ group. Scale bars = 20 μm. WT: wild type 





Figure 3.6 NEXMIF-/y neurons show impaired early axonal outgrowth 
(A) Representative images of Tau immunostained primary cortical neurons from 
WT or NEXMIF-/y brains at DIV 3. (B, C) The sum length of axons (B) (t(167) = 6.295, 
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p < 0.0001) and the number of axon branches (C) (t(153) = 8.808, p < 0.0001) were 
decreased in NEXMIF-/y neurons compared to WT neurons at DIV 3. n = 85 
neurons/ group. (D) Representative images of Tau immunostained primary cortical 
neurons from WT or NEXMIF-/y brains at DIV 6. (E, F) Quantification of the sum 
length of axons (E) (t(67) = 1.040, p = 0.3022) and the number of axon branches (F) 
(t(68) = 1.248, p = 0.2162) showed no difference between WT and NEXMIF-/y 
neurons at DIV 6. n = 40-68 neurons/ group. Scale bars = 60 μm. WT: wild type 






Figure 3.7 Altered synaptic protein composition in cultured neurons with 
shRNA mediated NEXMIF knockdown 
(A)† Representative images of immunohistochemistry for GluA1 and PSD-95 at 
DIV15 in rat hippocampal cultures after infection with scrambled (SCR shRNA) or 
NEXMIF shRNA at DIV 0. Scale bars = 15 μm (full picture); 5 μm (enlarged area). 
(B, C)† Quantification of GluA1 immunostaining in hippocampal neurons showed 
a decrease in puncta density and puncta intensity. (Density: t(22) = 7.59, p < 
0.0001; Intensity: t(22) = 2.50, p = 0.021; n = 10–12 cells). (D, E)† Quantification of 
PSD-95 immunostaining in hippocampal neurons showed a decrease in PSD-95 
density with no significant change in PSD-95 intensity. (Density: t(18) = 9.05, p < 
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0.0001; Intensity: t(18) = 0.75, p = 0.46, n =10–12 cells). (F, G) Quantification of 
GluA1 immunostaining in cortical neurons showed a decrease in puncta density 
and intensity from shRNA mediated NEXMIF knockdown. (H, I) Quantification of 
PSD-95 immunostaining in cortical neurons showed a decrease in puncta density 
and intensity from shRNA mediated NEXMIF knockdown. n = 10 cells. Data are 
represented as mean ± SEM. *p<0.05, ***p<0.001, ns = not significant. † With 




Figure 3.8 Additional synaptic protein composition in cultured neurons with 
shRNA mediated NEXMIF knockdown 
(A) Representative images of immunocytochemistry for VGlut1 in DIV 15 rat 
hippocampal cultures after infection with scrambled (SCR shRNA) or NEXMIF 
shRNA at DIV 3. (B, C) Quantification of VGlut1 immunostaining showed a 
decrease in VGlut1 density with no significant change in VGlut1 intensity from 
shRNA mediated NEXMIF knockdown. (D) Representative images of 
immunocytochemistry for gephyrin in DIV 15 rat cortical cultures after infection with 
103 
SCR or NEXMIF shRNA at DIV 3. (E, F) Quantification of gephyrin immunostaining 
showed no change in puncta density and a decrease in puncta intensity from 
shRNA mediated NEXMIF knockdown. (G) Representative images of 
immunocytochemistry for GAD65 in DIV 15 rat cortical cultures after infection with 
SCR or NEXMIF shRNA at DIV 3. (H, I) Quantification of GAD65 immunostaining 
showed a decrease in both puncta density and intensity from shRNA mediated 
NEXMIF knockdown. n = 10 neurons/ group. Scale bars = 5 μm. Data are 




Figure 3.9 Aberrant synaptic protein composition and dendritic spines in 
NEXMIF KO mice 
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(A) Representative images of DIV 14 cortical neurons from WT and NEXMIF-/y 
mice immunostained with antibodies against GluA1. (B, C) Quantification of GluA1 
immunostaining in cortical neurons showed a decrease in puncta density and 
intensity in NEXMIF-/y neurons compared to WT neurons. (Density: t(154) = 16.87, 
p < 0.0001; Intensity: t(147) = 8.400, p < 0.001, n = 74-80 neurons/ group). (D, E) 
Quantification of GluA1 immunostaining in hippocampal neurons showed a 
decrease in puncta density and puncta intensity in NEXMIF-/y neurons compared 
to WT neurons. (Density: t(176) = 14.94, p < 0.0001; Intensity: t(168) = 3.004, p = 
0.0031, n = 73-99 neurons/ group). (F) Representative images of DIV 14 cortical 
neurons from WT and NEXMIF-/y mice immunostained for GABARα1. (G, H) 
Quantification of GABARα1 immunostaining in cortical neurons showed a 
decrease in puncta density and intensity in NEXMIF-/y neurons compared to WT 
neurons. (Density: t(61) = 7.728, p < 0.0001; Intensity: t(60) = 3.317, p = 0.0015, n 
= 29-34 neurons/ group). (I, J) Quantification of GABARα1 immunostaining in 
hippocampal neurons showed a decrease in puncta density with no significant 
change in puncta intensity in NEXMIF-/y neurons compared to WT neurons. 
(Density: t(54) = 6.783, p < 0.0001; Intensity: t(55) = 0.4454, p = 0.6577, n = 28-29 
neurons/ group). (K) Representative images of DIV 13 primary cortical neurons 
from WT or NEXMIF-/y mice treated with actin dye Phalloidin to label spines. Spines 
marked by red arrows. (L) Spine density was decreased in NEXMIF-/y neurons 
compared to WT neurons. (t(98) = 8.618, p < 0.0001, n = 42-58 dendrites from 12-
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15 neurons/ group). Scale bars = 5 μm. WT: wild type littermate, KO: NEXMIF-/y. 




Figure 3.10 Reduced synaptic density from loss of NEXMIF 
(A) Glutamatergic synapses were identified from colocalized VGluT1 and PSD95 
puncta florescent signals in DIV 15 rat hippocampal cultures after infection with 
108 
scrambled (SCR shRNA) or NEXMIF shRNA at DIV 0. Scale bar = 5 μm (B) 
Quantification showed shRNA mediated NEXMIF knockdown resulted in a 
decrease in glutamatergic synapse density. (t(28) = 3.8, p = 0.0007, n = 15 cells). 
(C) GABAergic synapses were identified from colocalized VGAT and gephyrin 
puncta florescent signals in DIV 15 rat hippocampal cultures after infection with 
SCR or NEXMIF shRNA at DIV 0. Scale bar = 5 μm (D) Quantification showed 
shRNA mediated NEXMIF knockdown resulted in a decrease in GABAergic 
synapse density. Examples of colocalization are marked by arrows. (t(28) = 9.26, p 
< 0.0001, n = 15 cells). (G) Glutamatergic synapses were identified from 
colocalized VGluT1 and PSD95 puncta florescent signals in DIV 14 cortical 
neurons cultured from WT or NEXMIF-/y P0 mice. Scale bar = 7 μm (H) 
Quantification showed glutamatergic synapse density is decreased in NEXMIF-/y 
neurons compared to WT neurons. (t(185) = 5.429, p < 0.0001, n = 90 dendrites 
from 30 neurons/ group). (I) GABAergic synapses were identified from colocalized 
VGAT and gephyrin puncta florescent signals in DIV 14 cortical neurons cultured 
from WT or NEXMIF-/y P0 mice. Scale bar = 5 μm. (J) Quantification showed 
GABAergic synapse density is decreased in NEXMIF-/y neurons compared to WT 
neurons. (t(146) = 2.381, p = 0.0185, n = 73 dendrites from 25 neurons/ group). 




Figure 3.11 Synaptic plasticity fails in NEXMIF-/y neurons 
(A) Representative images DIV 14 cortical neurons cultured from WT or NEXMIF-
/y P0 mice immunostained for initial surface expressing GluA1 and newly inserted 
surface GluA1 after control or chem-LTP treatments. (B) Quantification of newly 
inserted surface GluA1 shows an increase in surface expression from chem-LTP 
treatment in WT neurons but not in NEXMIF-/y neurons. (F(3, 74) = 16.11, p < 0.0001, 
n = 19-20 neurons/ group). (C) Representative images DIV 14 cortical neurons 
cultured from WT or NEXMIF-/y P0 mice immunostained for total and surface 
expressing GluA1 after control or homeostatic synaptic plasticity (HSP) 
treatments. (B) Quantification of surface GluA1 shows an increase in surface 
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expression from HSP treatment in WT neurons but not in NEXMIF-/y neuronsc n = 
15-20 neurons/ group). Scale bars = 5 μm. Data are represented as mean ± SEM. 






Figure 3.12 Neurogranin and SynDig1 are among the most down-regulated 
genes from an RNAseq of neurons with loss of NEXMIF 
 (A) Selected top downregulated genes identified in RNAseq after knockdown of 
NEXMIF in mouse cortical cultures ranked based on fold change. (B) Percentage 
of down-regulated (green) and up-regulated (red) signaling genes in Ingenuity 
Pathway Analysis after NEXMIF knockdown. Asterisk indicates those of particular 
interest. (C) Gene ontology enrichment analysis of top dysregulated molecular 
functions, cell components, and biological processes after knockdown of NEXMIF. 





Figure 3.13 Expression of neurogranin and SynDig1 is reduced from loss of 
NEXMIF† 
(A-C) qPCR after shRNA medicated knockdown of NEXMIF confirms decrease in 
mRNA transcripts of NEXMIF (A), Nrgn (B), and SynDig1 (C) compared to 
scrambled (SCR) shRNA. n = 3 neuron cultures performed in triplicate. (D) 
Western blot of synaptic-related proteins, PSD95 and GluA1, and candidate 
proteins, Nrgn and SynDig1, from P30 WT and NEXMIF KO hippocampal lysates. 
(E-H) Quantification of western blot data showed no change in PSD-95 (E) and a 
significant reduction in the total protein levels of GluA1 (F), Nrgn (G), and SynDig1 
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(H). n = 5 animals. Data are represented as mean ± SEM. *p<0.05, ** p<0.01, 







Figure 3.14 Overexpression of neurogranin or SynDig1 can rescue synaptic 
deficits after loss of NEXMIF expression 
(A) Representative images of GluA1 staining in DIV 16 rat hippocampal neurons 
after transfection with scrambled (SCR) shRNA or NEXMIF shRNA, together with 
GFP and empty vector control, Nrgn, SynDig1, or both Nrgn and SynDig1 at DIV 
9. (B) Overexpression of Nrgn alone, SynDig1 alone, and Nrgn and SynDig1 
together was sufficient to rescue GluA1 puncta density. (F(6, 203) = 33.67, p < 
0.0001, n = 30 dendrites from 10 neurons/ group). (C) Representative images of 
Phalloin staining of actin-rich spines in DIV 14 rat hippocampal neurons after 
transfection with SCR or NEXMIF shRNA, together with GFP and empty vector 
control, Nrgn, SynDig1, or both Nrgn and SynDig1 at DIV 6. (D) Overexpression 
of Nrgn alone was sufficient to rescue spine density while overexpression of 
SynDig1 alone or Nrgn and SynDig1 together achieved partial rescue. (F(6, 467) = 
57.92, p < 0.0001, n = 59-79 dendrites from 15-20 neurons/ group). Scale bars = 
5 μm. KD: NEXMIF shRNA mediated knockdown; Ng: Nrgn, neurogranin; SD: 
SynDig1. Data are represented as mean ± SEM. *** p<0.001 compared to control, 










CHAPTER FOUR: CHARACTERIZATION OF AUTISM-LIKE BEHAVIORS AND 





Autism spectrum disorder (ASD) is a neurodevelopmental disorder with a strong 
genetic basis. ASDs are commonly characterized by impairments in 
communication, restrictive and repetitive behaviors, and deficits in social 
interactions. Although ASD is a highly heterogeneous disease with many different 
genes implicated in its etiology, many ASD associated genes converge on 
common cellular defects, such as aberrant neuronal morphology and synapse 
dysregulation. Our previous work revealed that, in mice, a complete loss of the 
ASD-associated X-linked gene NEXMIF results in a reduction in dendritic 
complexity, a decrease in spine and synapse density, altered synaptic 
transmission, and ASD-like behaviors. Interestingly, human females of NEXMIF 
haploinsufficiency have recently been reported to demonstrate autistic features; 
however, the cellular and molecular basis for this haploinsufficiency-caused ASD 
remains unclear. Here we report that heterozygous female mice demonstrate 
behavioral impairments similar to those of knockout male mice. In the brains of 
NEXMIF+/- female mice, NEXMIF shows a mosaic expression pattern in neurons. 
In the mosaic mixture of neurons cultured from NEXMIF+/- mice, cells that lack 
NEXMIF have impairments in dendritic arborization and spine development. 
Remarkably, the NEXMIF-expressing neurons from NEXMIF+/- mice also 
demonstrate similar defects in dendritic growth and spine formation. These 
findings establish a novel mouse model of NEXMIF haploinsufficiency and provide 
new insights into the pathogenesis of NEXMIF dependent ASD.  
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4.2 Introduction 
Autism spectrum disorders (ASD) comprise a heterogeneous class of disorders 
characterized by impaired social interactions, reduced communication, and 
restrictive interests and repetitive behaviors (American Psychiatric Association, 
2013; Landa, 2008). In up to 25% of individuals diagnosed with ASD, an 
identifiable or genetic variant can be identified, providing valuable insights into the 
mechanisms involved in proper neurodevelopment (Fernandez and Scherer, 
2017; Huguet et al., 2013). Of the hundreds of ASD related genes in the Simmons 
Foundation Autism Research Initiative (SFARI) database, a large number of rare 
genetic variants in protein-coding genes are causative for ASD (Abrahams et al., 
2013; Banerjee-Basu and Packer, 2010b) however, none of these individually 
account for more than 1% of the total number of ASD diagnoses, demonstrating 
the complex landscape of autism genetics (Abrahams and Geschwind, 2008; 
Happé et al., 2006; Rylaarsdam and Guemez-Gamboa, 2019; Yoo, 2015).  
NEXMIF was first implicated as one of the candidate genes in two male 
members of a family who showed autistic features with intellectual disabilities (ID) 
(Cantagrel et al., 2004). Since this original diagnosis, more cases have been 
reported, confirming that a loss of NEXMIF protein due to NEXMIF gene mutation 
or deletion leads to ASD (Alarcon-Martinez et al., 2019; Charzewska et al., 2015; 
Kuroda et al., 2015; Lambert et al., 2018; Lorenzo et al., 2018; Panda et al., 2020; 
Stamberger et al., 2020). The reported individuals affected with NEXMIF variants 
show repetitive behaviors, impaired language, ID, seizures, and several cases of 
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microcephaly. Interestingly, although only male cases were reported in earlier 
studies, recent clinical reports indicate that autistic characteristics are also 
observed in females with NEXMIF mutations (Athanasakis et al., 2014; Farach 
and Northrup, 2016; de Lange et al., 2016; Moysés-Oliveira et al., 2015; 
Stamberger et al., 2020; Webster et al., 2017; Wu et al., 2020). Due to infertility of 
affected males, females with inherited NEXMIF mutations are heterozygous and 
therefore haploinsufficient in NEXMIF. The pathogenicity of single copy NEXMIF 
gene mutation indicates that brain development and function are sensitive to the 
proper gene dosage of NEXMIF.  
Notably, as an X-linked gene NEXMIF presents a particular genetic 
situation contributing to protein haploinsufficiency. In females, one of the two X 
chromosomes is inactivated (XCI) to balance gene dosage between sexes. XCI is 
typically random, and as a result, heterozygous female individuals become 
mosaics of cells expressing either the normal or mutant allele. This creates two 
populations of neurons in the brains of heterozygous females: those that express 
NEXMIF (NEXMIF+) and those that have inactivated the X chromosome carrying 
the normal allele and thus do not express NEXMIF (NEXMIF-). Under this 
condition, despite expression of the gene product remaining in a portion of 
neurons in the brain, the overall neural network can be compromised by the 
aberrant assembling of NEXMIF+ and NEXMIF- neurons. Due to randomness of 
XCI, the extent of NEXMIF expression can vary in the affected individuals and at 
the level of specific organs or tissues, resulting in a broad range of disease 
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severity. In some X-linked gene disorders, one parental-specific X chromosome is 
preferentially inactivated, leading to skewed XCI activity. It has been reported that 
the majority of females with NEXMIF-dependent ASD had random XCI, 
suggesting a lack of compensatory regulation in XCI in these females 
(Athanasakis et al., 2014; Farach and Northrup, 2016; Lambert et al., 2018; de 
Lange et al., 2016; Moysés-Oliveira et al., 2019; Panda et al., 2020; Stamberger 
et al., 2020). 
Here we characterize the behavioral and cognitive abnormalities of, and 
investigate the related cellular defects in, the NEXMIF heterozygote (NEXMIF+/-) 
female mouse model. Female NEXMIF+/- mice demonstrate representative ASD 
behavioral phenotypes including reduced social interactions, repetitive behaviors, 
and impaired memory, but with intact development of communication. NEXMIF 
haploinsufficiency results in mosaic cellular expression of NEXMIF in the brains 
of these mice resulting in mixed coexistence of both NEXMIF+ and 
NEXMIF- neurons due to random XCI. Haploinsufficient NEXMIF expression 
results in impairments in neuronal structural development in dendritic arborization 
and synaptic connectivity. These findings validate the mouse model for NEXMIF 
haploinsufficiency ASD, and provide new insights in our understanding of the role 
of NEXMIF in brain development and the pathobiological mechanisms underlying 




 NEXMIF+/- mice demonstrate autistic features in social behavior 
Individuals affected with NEXMIF mutations present with autistic behaviors, poor 
to absent speech, ID, and often epilepsy (de Lange et al., 2016; Van Maldergem 
et al., 2013; Panda et al., 2020; Stamberger et al., 2020; Webster et al., 2017). 
Additionally, NEXMIF-/y KO mice demonstrate decreased sociability, reduced 
communication, increased repetitive behaviors, and impaired spatial memory 
(Gilbert et al., 2020). We therefore sought to characterize the extent of behavioral 
changes that result from NEXMIF haploinsufficiency. We first examined the social 
behavior of the NEXMIF+/- mice using the three-chamber test, which assesses 
general sociability and preference for social novelty (Silverman et al., 2010). 
Animals were habituated to the three-chambered apparatus before testing by 
letting them explore all three areas (Fig. 4.1A). Neither female WT nor female 
NEXMIF+/- mice showed a preference for a particular side of the testing apparatus 
(Fig. 4.1B-4.1D). For the sociability test, an unfamiliar female mouse (Mouse 1) 
was placed into a cage in one of the side chambers and the test mouse was 
allowed to move throughout the three-chambers (Fig. 4.1E). WT mice spent a 
significant amount of time investigating and interacting with Mouse 1 relative to 
the empty chamber; however, NEXMIF+/- mice failed to show a preference toward 
Mouse 1 in either the amount of time spent in the chamber of Mouse 1 or in close 
proximity to the cage housing Mouse 1 (Fig. 4.1F-4.1H), indicating NEXMIF+/- 
mice have impairments in sociability. We then tested animals for preference for 
social novelty by placing a second unfamiliar female mouse (Novel Mouse) into 
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the remaining empty cage in the other side chamber and allowing the test mouse 
to roam freely (Fig. 4.1I). NEXMIF+/- mice showed no preference toward the Novel 
mouse (Fig. 4.1J) as demonstrated by similar times spent in either side chamber 
(Fig. 4.1K) and in close proximity to either mouse’s cage (Fig. 4.1L), whereas the 
WT mice spent significantly more time in the side chamber with the Novel mouse 
(Fig. 4.1K) and in close proximity to the Novel mouse’s cage (Fig. 4.1L). These 
findings indicate that the NEXMIF+/- mice have a lack of interest in social novelty. 
 Increased repetitive behavior and hyperactivity in NEXMIF+/- mice 
We further investigated changes in the behavior of NEXMIF+/- mice using the 
marble burying test. We placed WT and NEXMIF+/- mice in a square cage with 25 
evenly spaced marbles on top of fresh bedding. Over 30 min, the WT animals 
began to bury the marbles under the bedding with a digging behavior (Fig. 4.2A). 
The NEXMIF+/- animals however, buried significantly fewer marbles at all time-
points after the first 10 min of observation (Fig. 4.2B). This finding is consistent 
with previous reports showing altered burying behaviors in ASD mice (Amodeo et 
al., 2019; Spencer et al., 2011; Sungur et al., 2014; Wang et al., 2018a, 2018b; 
Wong et al., 2019; Wurzman et al., 2015).  
 In our previous study, we found that the male NEXMIF-/y mice perform 
excessive self-grooming (Gilbert et al., 2020). This repetitive behavior has been 
observed in ASD and is linked to anxiety (Kalueff et al., 2016). We therefore 
assessed the grooming behavior in the NEXMIF+/- females. Similar to the NEXMIF-
/y males, we found that NEXMIF+/- females spent a significantly longer time 
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grooming with a significantly greater number of grooming episodes (Fig. 4.2C-
4.2D). We also investigated the rearing behavior of the mice, which has been 
linked to anxiety with increases in unsupported rearing indicating reduced anxiety 
(Sturman et al., 2018). We quantified unsupported rearing as the number of 
instances in which the mice reared up onto their hind legs without leaning on the 
wall of the cage. NEXMIF+/- mice performed significantly fewer rearing instances 
than the WT controls (Fig. 4.2E). 
 We next examined the NEXMIF+/- mice in the open field test. Consistent 
with the hyperactivity observed in NEXMIF-/y males, NEXMIF+/- females had a 
significant increase in their movement during the open field test compared to WT 
females, as shown by the representative traces (Fig. 4.2F). Quantification of the 
track lengths revealed that NEXMIF+/- mice traveled a further distance during the 
test (Fig. 4.2G) with a significantly greater maximum velocity, average velocity, 
and average acceleration (Fig. 4.2H-4.2J). Further quantification revealed that 
there is no change in time spent in the center of the open field between WT and 
NEXMIF+/- mice (Fig. 4.2K). All together, these results show that NEXMIF+/- mice 
are hyperactive with an increased level of anxiety. 
  NEXMIF+/- mice show moderate changes in communication by 
ultrasonic vocalization 
Impaired or delayed communication is a defining phenotype in ASD (American 
Psychiatric Association, 2013), and indeed, both males and females affected with 
NEXMIF variants have shown poor or absent speech (Alarcon-Martinez et al., 
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2019; Charzewska et al., 2015; Kuroda et al., 2015; de Lange et al., 2016; Lorenzo 
et al., 2018; Van Maldergem et al., 2013; Panda et al., 2020; Stamberger et al., 
2020; Webster et al., 2017). In order to assess communication behavior in 
NEXMIF+/- mice, we recorded and analyzed their ultrasonic vocalizations. Wild 
type and NEXMIF+/- female pups were separated from their dam and littermates to 
induce calling and vocalizations were recorded for 5 mins. The same animals were 
tested at P5, P7, and P9. Both groups of animals made calls within the ultrasonic 
range as depicted in representative 1.5 s of recording at P5 (Fig. 4.3A). The total 
number of calls, the number of calls per minute, average duration of calls, total 
time spent calling, average peak amplitude of calls, and average peak frequency 
of calls (Fig. 4.3B-4.3I), as well as the frequency of call types (Fig. 4.3J-4.3L), 
were analyzed at all time points. Unlike their hemizygous KO male counterparts, 
which showed a dramatic reduction in ultrasonic vocalization (Gilbert et al., 2020), 
the NEXMIF+/- females showed moderate communication deficits compared to that 
WT controls. In line with this, it has been observed that in human NEXMIF patients, 
males have a more severe language impairment than females (Panda et al., 2020; 
Stamberger et al., 2020). 
 NEXMIF+/- mice show impairments in spatial memory 
Intellectual disability is a comorbidity in individuals affected with NEXMIF variants, 
and consistently, the NEXMIF-/y KO mice show learning and memory deficits that 
recapitulate this human condition. To test whether haploinsufficient loss of 
NEXMIF is sufficient to result in this phenotype, we examined spatial memory 
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using the Barnes maze test. Mice were trained over 4 days to use spatial cues to 
locate a target escape hole on a circular maze containing 20 holes around its 
circumference. Over the acquisition training period, the NEXMIF+/- mice showed a 
reduction in the primary latency to the target hole, indicating their ability to learn 
its location (Fig. 4.4A). After training, the target hole was covered and the ability 
of the mice to remember its location was assessed both 1 d and 5 d later. 
NEXMIF+/- mice traveled a significantly longer distance than WT mice before 
making an initial nose poke at the target hole in the 5 d test but not the 1 d test 
(Fig. 4.4B), as shown by representative traces (Fig. 4.4C-4.4D). NEXMIF+/- mice 
also took a longer amount of time than WT mice to find the target hole in the 5 d 
test, as measured by the primary latency (Fig. 4.4E). Quantification of the number 
of investigative nose pokes at the target hole versus incorrect holes showed that 
NEXMIF+/- mice made a significantly greater number of nose poke errors than WT 
mice in both the 1 d and 5 d tests (Fig. 4.4F). We separated the maze into four 
quadrants to allow quantification of the amount of time the animals spent looking 
for the target hole in the correct area (Fig. 4.4G-4.4H). This revealed that in both 
the 1 d and 5 d tests NEXMIF+/- mice did not spend significantly more time 
exploring the target quadrant of the maze as compared to the other three 
quadrants, in contrast to WT mice, which did spend more time in the target 
quadrant (Fig. 4.4I-4.4J). These findings indicate that NEXMIF haploinsufficiency 
causes defects in spatial memory, which may contribute to the cognitive 
impairments observed in females. 
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  Heterozygous NEXMIF mice demonstrate mosaic expression of 
NEXMIF 
Due to the random inactivation of either X chromosome, the X-linked gene 
NEXMIF is predicted to be expressed in a mosaic manner in heterozygous female 
mice, leading to either normal expression or complete loss of NEXMIF in individual 
neurons. This type of mosaic expression has been observed in other 
haploinsufficient X-linked genes (Compagni et al., 2003; Hayashi et al., 2017; 
Sikora et al., 2016; Smrt et al., 2011; Tan et al., 1995; Wu et al., 2014). To 
determine the NEXMIF expression pattern in the brain, we used a NEXMIF 
specific antibody to immunolabel NEXMIF both ex vivo and in vivo. 
First, we generated primary neuronal cultures from NEXMIF+/- mice or WT 
littermate controls. These neuron cultures were maintained for 6 days (Days in 
vitro 6; DIV 6) and were probed for NEXMIF expression. As previously observed, 
NEXMIF was expressed in the nuclei as seen by colocalization with the nuclear 
dye Hoechst (Fig. 4.5A). Consistent with random XCI, we found that some 
neurons from NEXMIF+/- mice expressed NEXMIF while others did not (Fig. 4.5A). 
Quantification of the NEXMIF+/- neurons revealed approximately 70% of cells 
expressed NEXMIF (Fig. 4.5B) to the same level as WT neurons (Fig. 4.5C), 
whereas the remaining 30% of cells were NEXMIF negative.  
As the XCI patterning varies between individuals, we quantified the mosaic 
expression of NEXMIF in vivo from adult NEXMIF+/- mice and WT littermate 
controls. To do this we used immunohistochemistry to probe for NEXMIF, as well 
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as the neuronal marker NeuN, in brain slices of both the hippocampus (Fig. 4.5D) 
and L2/3 of the somatosensory cortex (Fig. 4.5G and 4.5J). We found mosaic 
expression of NEXMIF in both hippocampus (Fig. 4.5E) and somatosensory 
cortex (Fig. 4.5H) with NEXMIF expressed respectively in 60% and 65% of NeuN 
positive neurons from NEXMIF+/- brain slices. Consistent with the in vitro data, the 
level of NEXMIF expression in these NEXMIF positive neurons was similar to that 
of neurons from WT mice in both the hippocampus (Fig. 4.5F) and the 
somatosensory cortex (Fig. 4.5I). When the ratio of NEXMIF+ vs. NEXMIF- 
neurons was analyzed in individual animals, we found no cases of skewing 
(>75:25 ratio) in our haploinsufficient mice (Fig. 4.5K). 
  Mosaic loss of NEXMIF impairs the development of neuronal 
morphology 
One of the key phenotypes observed in neurons lacking NEXMIF is impairments 
in neurite extension (Gilbert and Man, 2016; Ishikawa et al., 2012; Van Maldergem 
et al., 2013). We therefore investigated the effect of mosaic loss of NEXMIF on the 
development of neuronal morphology. To do this, we cultured primary cortical 
neurons from WT or NEXMIF+/- brains and immunostained for MAP2 to label the 
dendrites at DIV 8 (Fig. 4.6A). Given the mosaic expression of NEXMIF in 
heterozygote females, we also immunostained for NEXMIF to identify neuron cell 
types in the NEXMIF+/- cultures. Consistent with our previous study of NEXMIF 
knockdown (Gilbert and Man, 2016), Sholl analysis revealed a decrease in 
dendritic arbor complexity for NEXMIF- neurons in the NEXMIF+/- cultures (Fig. 
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4.6B). Further analysis demonstrated that the NEXMIF-lacking (NEXMIF-) neurons 
had a significant reduction in total number of dendrites, number of branch points, 
and number of terminal points, as well as a decrease in the total sum length of 
dendrites (Fig. 4.6C-4.6F). Similar changes were also detected in NEXMIF- 
neurons at DIV 14 (Fig. 4.6G-4.6L). Strikingly, NEXMIF-expressing (NEXMIF+) 
neurons from the NEXMIF+/- culture also showed a reduction in dendritic 
morphology when compared to WT controls (Fig. 4.6B and 4.6H-4.6L). These 
impairments in dendrite morphology were also observed in primary hippocampal 
neurons from WT or NEXMIF+/- animals (Fig. 4.7). 
To further examine the effect of NEXMIF haploinsufficiency on neurite 
extension, we examined axon outgrowth in primary neuronal cultures from WT or 
NEXMIF+/- brains. DIV 3 cortical (Fig. 4.8A) or hippocampal (Fig. 4.8D) were 
immunolabeled for Tau to label axons. Quantification of axonal length and the 
number of axon branches revealed reduced axonal outgrowth in both NEXMIF+ 
and NEXMIF- neurons from the cortex (Fig. 4.8B-4.8C) and the hippocampus (Fig. 
4.8E-4.8F). Collectively, this data demonstrates that in a mosaic network of mixed 
cell types, the loss of NEXMIF in some neurons not only causes developmental 
defects in those neurons themselves, but also in trans affects the neighboring 
neurons which have intact NEXMIF expression.  
 NEXMIF haploinsufficiency results in reduced spine density 
Dysregulation of spine and synapse formation has been recognized as one of the 
most common cellular defects in ASD. Indeed, a dramatic reduction in spine 
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density was observed in the hippocampi of adult NEXMIF-/y KO mice (Gilbert et 
al., 2020). To determine possible changes in spine development in neurons from 
NEXMIF+/- mice in vitro, we cultured primary cortical neurons from WT or 
NEXMIF+/- brains and applied phalloidin at DIV 12 to label actin-rich spines (Fig. 
4.9A). In line with the NEXMIF-/y results, we observed a significant decrease in 
spine density for NEXMIF- neurons compared to neurons from WT brains (Fig. 
4.9B-4.9C). Interestingly, NEXMIF+ neurons in the NEXMIF+/- culture showed a 
decrease in spine density similar to that of the NEXMIF- neurons. By 
immunocytochemistry, we then examined the expression and localization of major 
synaptic proteins including GluA1, PSD95, VGlut1, GABARα1, gephyrin, and 
VGat. We found that puncta density of each of these synaptic proteins was 
significantly reduced in both NEXMIF+ and NEXMIF- neurons from the NEXMIF+/- 
culture, as compared to neurons from the WT culture (Fig. 4.9D). 
In order to observe changes in spine density in vivo, we performed Golgi 
staining on brains of adult WT and NEXMIF+/- mice. Because Golgi staining 
randomly labels neurons, the specific cell type regarding NEXMIF expression 
could not be determined. Therefore, the Golgi stained neurons were combined for 
structural analysis. Compared to WT controls, a significant decrease in spine 
density was detected in neurons from NEXMIF+/- brains (Fig. 4.9E-4.9P). This 
change was apparent in all brain regions measured, including L2/3 (Fig. 4.9E-
4.9G) and L5 (Fig. 4.9H-4.9J) from the somatosensory cortex and CA1 (Fig. 4.9K-
4.9M) and the dentate gyrus (Fig. 4.9N-4.9P) from the hippocampus. Closer 
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examination of this data revealed that the neurons from NEXMIF+/- brains did not 
fall into two distinct groups as predicted to result from the two subsets of NEXMIF+ 
and NEXMIF- neurons, suggesting that the NEXMIF+ cells were likely also 
affected, as we found in cultured neurons (Fig. 4.9A-4.9C). 
 
4.4 Discussion 
In this study, we successfully established a haploinsufficient NEXMIF+/- mouse 
line. The behavioral phenotypes of the haploinsufficient female mice faithfully 
recapitulate those of the human disease. The NEXMIF+/- female mice 
demonstrated reduced sociability and preference for social novelty compared to 
wild-type female controls. They also showed significant changes in marble 
burying, grooming, and rearing behaviors. We also found that the NEXMIF+/- 
females displayed increased activity in an open field and significant impairments 
in spatial memory as measured by the Barnes Maze. In line with findings of milder 
communication phenotypes in females with NEXMIF-dependent ASD (Panda et 
al., 2020; Stamberger et al., 2020), NEXMIF KO male mice showed significant 
impairments in ultrasonic vocalizations from isolated pups, while NEXMIF+/- 
female mice showed moderate changes. Thus, our findings validify this transgenic 
line as a model for NEXMIF-dependent ASD in females. 
We also investigated cellular and molecular phenotypes in the brains of 
NEXMIF+/- mice. We found the heterozygous brains demonstrate a mosaic mixture 
of wild-type and null mutant neurons caused by random X-inactivation in both the 
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hippocampus and the somatosensory cortex. In primary neuronal cultures from 
the brains of transgenic females, we found that both NEXMIF+ and NEXMIF- 
neurons demonstrated aberrant dendritic arborization and reductions in spine and 
synapse density. Both groups of neurons also showed reductions in the puncta 
density of key synaptic proteins including GluA1, PSD95, and VGlut1 at excitatory 
synapses, and GABARα1, gephyrin, and VGat at inhibitory synapses. Thus, the 
loss of NEXMIF affects not only the mutant cells themselves, but also the 
neighboring NEXMIF+ cells. These surprising findings indicate a non-cell 
autonomous effect from loss of NEXMIF. It is possible that NEXMIF 
haploinsufficiency causes a reduction of secretory molecules in the extracellular 
milieu, leading to developmental defects in all cells.     
Studies of humans with NEXMIF-dependent ASD have demonstrated a 
significant difference in disease phenotypes between hemizygous knockout male 
and heterozygous females. Males tend to have more severe impairments in 
language (58% nonverbal) and cognition (74% severe to profound ID) than 
females (10% nonverbal; 32% severe to profound ID) (Stamberger et al., 2020). 
Consistently, our data shows the NEXMIF-/y KO male mice have dramatic 
impairments in communication, while the haploinsufficient NEXMIF+/- females 
show only moderate changes. Interestingly, females are significantly more likely 
to have a seizure phenotype than males (Panda et al., 2020; Stamberger et al., 
2020). We have observed seizures in both male and female mice, though the 
differences between male and female mice remain to be investigated. In 
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haploinsufficient females, variations in phenotypic severity could result from 
skewed XCI (Gribnau and Barakat, 2017; Heine-Suñer et al., 2003; Migeon, 2020; 
Ribeiro and MacDonald, 2020; Taherian et al., 2016; De Vries et al., 1996; Young 
and Zoghbi, 2004b; Zhang et al., 2020a). Of the 32 female NEXMIF patients who 
have been tested for XCI skewing, 25 showed random (<75:25) XCI patterning 
without skewing. Additionally, when comparing sisters within patient families, no 
correlation was found between extent of XCI skewing and disease phenotype, 
indicating skewing itself is unlikely to be responsible for phenotypic variations 
(Stamberger et al., 2020). Although these findings were from peripheral blood 
cells, it is in agreement with our findings in the female mouse model, which shows 
no signs of significant skewing in NEXMIF expression in the brains of 
heterozygous female mice.  
In the brain, mosaic expression of NEXMIF could lead to structural and 
functional abnormalities via multiple potential mechanisms. While the most direct 
causal factor is the loss of NEXMIF in the NEXMIF- neurons, the unbalanced 
NEXMIF expression among mosaic neurons in the brain can lead to further 
disruptions. To compensate for the overall reduction of NEXMIF in the brain, 
NEXMIF expression may be up regulated in NEXMIF+ cells. This global 
compensation would result in overexpression and a hyper-dosage of the protein 
in the NEXMIF+ neurons. Our findings indicate that this scenario did not occur in 
the NEXMIF haploinsufficient females. Second, if the effect of loss of NEXMIF is 
mediated, at least partially, via secretory signaling molecules, changes in NEXMIF 
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expression could affect all neurons in the brain. In fact, we found comparable 
defects in dendritic structure and spine formation in both NEXMIF+ and NEXMIF- 
neurons. Interestingly, the impaired dendritic arborization phenotype became 
more severe in NEXMIF+ cortical neurons at DIV 14 than at DIV 8. It is possible 
that, at the early stage, a lack of NEXMIF only affects NEXMIF- neurons, and at a 
later phase, the NEXMIF+ neurons are affected from neighboring NEXMIF- 
neurons, probably due to changes in extracellular cues. 
Given the mutual innervation between NEXMIF+ and NEXMIF- neurons, the 
trans effects on NEXMIF+ neurons could also result from aberrant interneuronal 
communication. Not only might this account for the phenotypes in the NEXMIF+ 
neurons, but cell-cell interactions between wild type and mutant neurons in the 
brain of heterozygotes could disrupt the overall neuronal circuitry in a way that is 
different, and possibly more severe, than from the complete loss in KOs. Such a 
“cellular interference” or “metabolic interference” mechanism (Johnson, 1980) has 
been observed in other heterozygous X-linked diseases such as ARHGEF9 
dependent ASD (Aarabi et al., 2019), PCDH19 linked epilepsy and mental 
retardation (Dibbens et al., 2008; Hoshina et al., 2021), craniofrontonasal 
syndrome (Twigg et al., 2013; Wieland et al., 2004), and sporadic infantile epileptic 
encephalopathy (Depienne et al., 2009; Dibbens et al., 2008). This hypothesis 
might explain the greater percentage of females affected with NEXMIF variants 
(89%) who demonstrate an epileptic phenotype than affected males (65%) 
(Stamberger et al., 2020). We found that seizures were common in both the male 
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NEXMIF-/y and female NEXMIF+/- mice, but further studies are needed to compare 
the frequency, types, and severity of these seizures in our mouse models.  
While a number of somatic gene mutations are known to lead to ASD in 
heterozygous females (Boccuto et al., 2013; Busch et al., 2019; Courchet et al., 
2018; Dere et al., 2014; Gompers et al., 2017; Jaramillo et al., 2017), only a few 
X-linked genes, including NEXMIF, have been reported to be implicated in ASD 
by haploinsufficiency. For X-linked genes, heterozygous females generally have 
a milder disease phenotype, or are unaffected carriers, due to sufficient gene 
expression from their normal allele, which is not possible in their male 
counterparts. However, there are some cases of manifesting heterozygotes, in 
which heterozygous expression of an X-linked gene results in a more severe 
phenotype (Fuchs et al., 2018; Migeon, 2020; Taherian et al., 2016), such as in 
the heterozygous X-linked neurological disorders Rett syndrome (Gribnau and 
Barakat, 2017), fragile X syndrome (Godler et al., 2015; Marco and Skuse, 2006), 
CASK associated mental retardation (Moog et al., 2011; Patel et al., 2020), and 
loss of Pcdh19 (Hayashi et al., 2017; Pederick et al., 2018). In some cases, the 
disease phenotype results from XCI skewing which leads to biased silencing of 
the X chromosome containing the normal allele, but this seems not to be the case 
for NEXMIF patients. A number of computational studies have attempted to 
identify genes which cannot tolerate the loss of one of the two alleles (Dang et al., 
2008; Huang et al., 2010; Shihab et al., 2017; Steinberg et al., 2015; Yang et al., 
2021). It has been shown that haploinsufficient genes are enriched in several gene 
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ontology categories including transcription factors and phenotypes including 
neurodevelopmental disorders (Dang et al., 2008). Notably, NEXMIF is predicted 
to be a haploinsufficient gene (Steinberg et al., 2015).  
In summary, our results show that the NEXMIF+/- animals recapitulate the 
phenotypes observed in the human disease, making it a useful model for further 
study of NEXMIF and ASD. NEXMIF is expressed in a mosaic pattern in the brains 
of these animals. Therefore, the heterozygous female mice provide a unique 
neural network intertwined by mutual innervation between and among the 
NEXMIF+ and NEXMIF- neurons in a brain. Additionally, the heterozygous female 
model is of particular interest for future study for its potential to rescue the loss of 
NEXMIF from the endogenous normal NEXMIF allele by specific reactivation of 
the X chromosome with the wild type allele, as shown to be a promising strategy 
in Rett syndrome (Przanowski et al., 2018). The NEXMIF+/- line will therefore be 
of great value for further study of the mechanisms underlying NEXMIF-dependent 






Figure 4.1 NEXMIF heterozygous mice show abnormalities in social 
behaviors 
(A) Habituation to the three-chamber apparatus. Mice were released from the 
center chamber, with empty cages in the adjacent chambers, and allowed to move 
freely within the apparatus for 5 min each session for 3 d prior to beginning the 
sociability and social novelty tests. (B) Representative traces of animal track paths 
in the habituation phase for WT and NEXMIF+/- mice. (C, D) Neither WT nor 
NEXMIF+/- animals showed preference for either side chamber (C) (Left vs Right: 
WT: t(32) = 0.7979, KO: t(32) = 0.0977; F(1, 32) = 0.401, p = 0.5311) or either empty 
cage (D) (Left vs Right: WT: t(32) = 0.059, KO: t(32) = 0.849; F(1, 32) = 0.4129, p = 
0.5251) during habituation. (E) Paradigm for the sociability test. An unfamiliar 
mouse (Mouse 1) was placed into either of the side chambers and the test mouse 
was allowed to move freely within the apparatus. (F) Representative traces of 
animal track paths in the sociability test for WT and NEXMIF+/- mice. (G, H) Het 
mice failed to demonstrate the sociability observed in WT mice, which show an 
increase in the time spent in the chamber (G) (Empty vs Mouse 1: WT: t(30) = 
5.354, KO: t(30) = 0.1375; F(1, 30) = 15.92, p = 0.0004) and in proximity to the cage 
(H) (Empty vs Mouse 1: WT: t(30) = 2.452, KO: t(30) = 0.4959; F(1, 30) = 4.514, p = 
0.042) with Mouse 1. (I) Paradigm for the social novelty test. A second mouse 
(Novel Mouse) was placed into the remaining empty chamber opposite to Mouse 
1, and the test mouse was allowed to interact with both mice. (J) Representative 
traces of animal track paths in the social novelty test for WT and NEXMIF+/- mice. 
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(K, L) WT mice showed an increase in the time spent in the chamber (K) (Mouse 
1 vs Mouse 2: WT: t(30) = 3.145, KO: t(30) = 0.5769; F(1, 30) = 7.205, p = 0.0117) and 
in proximity to the cage (L) (Mouse 1 vs Mouse 2: WT: t(30) = 2.818, KO: t(30) = 
1.591; F(1, 30) = 9.526, p = 0.0043) with the Novel Mouse, but the NEXMIF+/- mice 
failed to demonstrate the preference for social novelty. Het, NEXMIF+/-. n = 9 mice/ 





Figure 4.2 NEXMIF heterozygous mice display aberrant marble burying 
behavior, increased repetitive grooming, and hyperactivity 
(A, B) In the marble burying test, NEXMIF+/- animals buried significantly fewer 
marbles (F(1,14) = 7.924, p = 0.0138 between genotypes; F(6, 84) = 31.02, p < 0.0001 
between time points). (C, D) NEXMIF+/- mice spent an increased amount of time 
grooming (C) (t(14) = 2.786, p = 0.0146) and performed an increased number of 
grooming episodes (D) (t(16) = 3.021, p = 0.0081). (E) NEXMIF+/- animals 
demonstrated a reduction in rearing behavior (t(16) = 3.757, p = 0.0017). (F) 
Representative track paths of WT and NEXMIF+/- animals in the open field test. 
(G-K) NEXMIF+/- animals showed increased track lengths (G) (t(16) = 3.132, p = 
0.0064), increased max (H) (t(16) = 2.560, p = 0.0210) and mean (I) (t(16) = 3.132, 
p = 0.0064) speeds, increased mean acceleration (J) (t(16) = 2.966, p = 0.0091), 
and no change in time spent in the central area (K) (t(16) = 0.3870, p = 0.7039) in 






Figure 4.3 NEXMIF heterozygous mice show moderate impairment in 
communication behavior 
(A) Representative vocalizations from P5 recordings for WT and NEXMIF+/- mice. 
Top: the raw USV signals. Bottom: the associated spectrograms; all are 1.5 s in 
length. Dashed line depicts the 30 kHz frequency threshold for eliminating noise. 
(B) Quantification of the number of calls made by NEXMIF+/- animals compared to 
WT controls at each developmental time point recorded (F(1,8) = 5.959, p = 0.0405 
between genotypes; F(2,16) = 0.2021, p = 0.8191 between time points). (C-E) Mean 
number of calls emitted across the 5 min recording period at each developmental 
time point P5 (C) (F(1,8) = 0.7084, p = 0.4244 between genotypes; F(4,32) = 0.1688, 
p = 0.9527 between time points), P7 (D) (F(1,12) = 0.1227, p = 0.7322 between 
genotypes; F(4,48) = 1.353, p = 0.2643 between time points), and P9 (E) (F(1,11) = 
4.040, p = 0.0696 between genotypes; F(4,44) = 0.3459, p = 0.8454 between time 
points). (F-G) Quantification of the mean call syllable duration (F) (F(1,8) = 6.381, 
p = 0.0355 between genotypes; F(2,16) = 0.8940, p = 0.4285 between time points) 
and the total time spent calling (G) (F(1,8) = 14.28, p = 0.0054 between genotypes; 
F(2,16) = 0.4545, p = 0.6427 between time points) between WT and NEXMIF+/- 
mice. (H-I) NEXMIF+/- mice showed no change in peak amplitude of calls (H) (F(1,8) 
= 2.214, p = 0.1751 between genotypes; F(2,16) = 9.698, p = 0.0017 between time 
points), or peak frequency of calls (I) (F(1,8) = 0.1464, p = 0.7120 between 
genotypes; F(2,16) = 1.721, p = 0.2104 between time points). (J) Representative 
calls of each type used in syllable characterization. (K)  WT and NEXMIF+/- mice 
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showed similar ratios of Simple vs Complex call types at each time point (F(1,84) = 
0.0182, p = 0.8931). (L) NEXMIF+/- animals showed no change in frequency of 
particular call syllable types compared to WT animals at P9 (Simple: t(12) = 0.584, 
p = 0.570; Flat: t(12) = 0.733, p = 0.478; Down: t(12) = 0.606, p = 0.556; Up: t(12) = 
0.927, p = 0.372; Chevron: t(12) = 0.295, p = 0.773; “U”: t(12) = 1.90, p = 0.0824; 
Modulated: t(12) = 0.829, p = 0.423; Freq. Jump: t(12) = 1.04, p = 0.318; Multi. Jump: 







Figure 4.4 NEXMIF heterozygous mice display defects in learning and 
memory in the Barnes maze test 
(A) Quantification of the primary latency (s) to find the target hole across all 
training trials (3 trials per day over 4 days) for WT and NEXMIF+/- animals. (B) 
Total track length distance before initial contact with target hole was increased in 
NEXMIF+/- mice 5 d after training (F(1,7) = 15.63, p = 0.0055 between genotypes; 
F(1,7) = 3.519, p = 0.1028 between time points). (C, D) Representative traces of 
track paths to initial contact with target in the Barnes spatial memory maze during 
the 1 d (C) and 5 d (D) memory probe for WT and NEXMIF+/- animals. (E) Primary 
latency to the target hole was increased in the NEXMIF+/- animals in the test 5 d 
after training (F(1,7) = 7.828, p = 0.0266 between genotypes; F(1,7) = 0.7161, p  
= 0.4254 between time points). (F) NEXMIF+/- mice made a significantly higher 
number of nose poke errors in both the 1 d and 5 d memory tests than WT mice 
(F(1,8) = 11.35, p = 0.0098 between genotypes; F(1,8) = 0.2212, p = 0.6507 between 
time points). (G, H) Representative traces of track paths over 3 min test in the 
Barnes spatial memory maze during the 1 d (G) and 5 d (H) memory probe for WT 
and NEXMIF+/- animals. T, target; L, left; R, right; O, opposite. (I, J) NEXMIF+/- 
mice did not spend significantly more time in the target quadrant compared to the 
other maze quadrants, as WT controls do, in the tests at 1 d (I) (WT: Target v Left: 
t(64) = 3.810, Target v Right: t(64) = 4.088, Target v Opposite: t(64) = 3.967; Het: 
Target v Left: t(64) = 0.1492, Target v Right: t(64) = 1.050, Target v Opposite: t(64) 
= 0.0424; F(3, 64) = 3.347, p = 0.0244) and 5 d (J) (WT: Target v Left: t(64) = 2.218, 
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Target v Right: t(64) = 2.442, Target v Opposite: t(64) = 2.716; Het: Target v Left: 
t(64) = 1.182, Target v Right: t(64) = 0.3385, Target v Opposite: t(64) = 1.524; F(3, 64) 







Figure 4.5 Mosaic NEXMIF expression in the NEXMIF heterozygous mouse 
(A-C) Immunostaining of NEXMIF in DIV 6 primary cortical neurons cultured from 
NEXMIF WT or NEXMIF+/- mouse brains shows colocalization with nuclear marker 
Hochest (A) and a lack of NEMXIF expression in some, but not all, neurons from 
NEXMIF+/- brains (B) (t(18) = 13.76, p < 0.0001) with no change in the level of 
NEXMIF in the NEXMIF+ neurons (C) (t(90) = 1.366, p = 0.1752). Scale bar = 5 
μm. n = 10 experiments, 30-100 cells each. (D-I) Immunostaining of NEXMIF and 
neuronal marker NeuN in brain slices of adult female mice shows a reduction in 
NEXMIF-expressing neurons in Het hippocampus (D-F, scale bar = 100 μm; E: 
t(26) = 6.506, p < 0.0001, F: t(14) = 0.5439, p = 0.5951) and L2/3 of the 
somatosensory cortex (G-I, scale bar = 50 μm; H: t(27) = 6.693, p < 0.0001, I: t(18) 
= 0.4492, p = 0.6587). n = 13-16 slices, 60-800 cells each. (J) Representative 
mosaic distribution of NEXMIF-expressing (NEXMIF+; yellow) and NEXMIF 
negative neurons (NEXMIF-; pink) in the somatosensory cortex of WT and 
NEXMIF+/- mice. Scale bar = 50 μm. (K) Ratios of NEXMIF+ and NEXMIF- neurons 
from the cortex of individual NEXMIF+/- mice. *p<0.05, **p<0.01 ***p<0.001, ns = 






Figure 4.6 Mosaic loss of NEXMIF results in a decrease in neurite outgrowth 
in primary neurons 
(A) Representative images (left) and traces (right) of MAP2 immunostained 
primary cortical neurons from WT or NEXMIF+/- brains at DIV 8. Inset is 
immunostaining of NEXMIF, showing a mosaic mixture of NEXMIF+ and NEXMIF- 
neurons. Scale bars = 20 μm. (B) Sholl analysis reveals a decrease in dendritic 
arbor complexity for both NEXMIF+ and NEXMIF- neurons at DIV 8 (F(2,172) = 
6.901, p = 0.0013 between genotypes; F(150, 25800) = 2.197, p < 0.0001 between 
radius). (C-F) The number of dendrites (C), branch points (D), terminal points (E), 
and the sum length of dendrites (F) were decreased in NEXMIF- neurons at DIV 
8. (G) Representative images and traces of cortical neurons at DIV 14. (H) Sholl 
analysis shows reduced complexity for both NEXMIF+ and NEXMIF- neurons at 
DIV 14 (F(2,68) = 27.13, p < 0.0001 between genotypes; F(200, 13600) = 137.7, p < 
0.0001 between radius). (I-L) The number of dendrites (I), branch points (J), 
terminal points (K), and the sum length of dendrites (L) were decreased in both 
NEXMIF+ and NEXMIF- neurons at DIV 14. (No. of Dendrites: F(2,40) = 27.98, p < 
0.0001 between genotypes; F(1,20) = 67.95, p < 0.0001 between time points; No. 
of Branch Points: F(2,40) = 22.04, p < 0.0001 between genotypes; F(1,20) = 27.88, p 
< 0.0001 between time points; No. of Terminal Points: F(2,40) = 28.42, p < 0.0001 
between genotypes; F(1,20) = 34.27, p < 0.0001 between time points, Sum Length: 
F(2,40) = 29.77, p < 0.0001 between genotypes; F(1,20) = 55.22, p < 0.0001 between 
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time points). n = 30-90 cells/ group. Het+, NEXMIF+/NEXMIF-expressing; Het-, 






Figure 4.7 Hippocampal neurons of NEXMIF heterozygous mice show 
abnormal dendritic arborization 
(A) Representative images (left) and traces (right) of MAP2 immunostained 
primary hippocampal neurons from WT or NEXMIF+/- brains at DIV 8. Inset is 
immunostaining of NEXMIF, showing a mosaic mixture of NEXMIF+ and NEXMIF- 
neurons. Scale bars = 20 μm. (B) Sholl analysis reveals a decrease in dendritic 
arbor complexity for both NEXMIF+ and NEXMIF- neurons at DIV 8 (F(2,141) = 
29.35, p < 0.0001 between genotypes; F(150, 21150) = 350.5, p < 0.0001 between 
radius). (C-F) The number of dendrites (C), branch points (D), terminal points (E), 
and sum length of dendrites (F) were decreased in both groups of NEXMIF+/- 
neurons at DIV 8. (G) Representative images and traces of hippocampal neurons 
at DIV 14. (H) Sholl analysis shows reduced complexity for both NEXMIF+ and 
NEXMIF- neurons at DIV 14 (F(2,68) = 27.13, p < 0.0001 between genotypes; F(200, 
13600) = 137.7, p < 0.0001 between radius). (I-L) The number of dendrites (I), 
branch points (J), terminal points (K), and the sum length of dendrites (L) were 
decreased in both NEXMIF+ and NEXMIF- neurons at DIV 14. (No. of Dendrites: 
F(2,38) = 46.72, p < 0.0001 between genotypes; F(1,19) = 25.77, p < 0.0001 between 
time points; No. of Branch Points: F(2,38) = 31.15, p < 0.0001 between genotypes; 
F(1,19) = 20.49, p = 0.0002 between time points; No. of Terminal Points: F(2,38) = 
50.81, p < 0.0001 between genotypes; F(1,19) = 39.64, p < 0.0001 between time 
points, Sum Length: F(2,38) = 40.62, p < 0.0001 between genotypes; F(1,19) = 32.38, 
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p < 0.0001 between time points). n = 20-70 cells/ group. Het+, NEXMIF+/NEXMIF-





Figure 4.8 NEXMIF haploinsufficiency leads to impaired axonal outgrowth 
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(A) Representative images of Tau immunostained primary cortical neurons from 
WT or NEXMIF+/- brains at DIV 3. (B, C) The sum length of axons (B) (F(2,84) = 
7.020, p = 0.0015) and the number of axon branches (C) (F(2,85) = 8.182, p = 
0.0006) were decreased in only NEXMIF- cortical neurons. n = 24-36 cells. (D) 
Representative images of Tau immunostained primary hippocampal neurons from 
WT or NEXMIF+/- brains at DIV 3. (E, F) The sum length of axons (E) (F(2,87) = 
6.495, p = 0.0023) and the number of axon branches (F) (F(2,90) = 4.451, p = 
0.0143) were decreased in both NEXMIF- and NEXMIF+ hippocampal neurons. n 






Figure 4.9 Aberrant dendritic spines and synapses in NEXMIF Het mice 
(A) Representative images of DIV 12 primary cortical neurons from WT or 
NEXMIF+/- mice immunostained for NEXMIF and labelled for actin with Phalloidin. 
Inset is immunostaining of NEXMIF, showing a mosaic mixture of NEXMIF+ and 
NEXMIF- neurons. Scale bar = 5 μm. (B-C) Spine density was decreased in both 
NEXMIF+ and NEXMIF- neurons. (F(2,130) = 20.29, p < 0.0001, n = 19-60 dendrites/ 
group). (D) Quantification of puncta density of synaptic markers. DIV 12 cortical 
cultures of both NEXMIF+ and NEXMIF- neurons were immunostained with 
antibodies against GluA1 (F(2,171) = 12.94, p < 0.0001), PSD95 (F(2,56) = 37.19, p < 
0.0001), VGlut1 (F(2,54) = 9.754, p = 0.0002), GABARα1 (F(2,45) = 9.887, p = 0.0003), 
gephyrin (F(2,123) = 19.17, p < 0.0001), and VGat (F(2,55) = 12.12, p < 0.0001), 
respectively. n = 7-80 cells/ group. (E-P) Spines were analyzed from WT or 
NEXMIF+/- brain slices following Golgi staining. Spine density was decreased in 
L2/3 neurons of the somatosensory cortex (E-G) (t(106) = 6.727, p < 0.0001), L5 
neurons of the somatosensory cortex (H-J) (t(94) = 6.114, p < 0.0001), CA1 neurons 
of the hippocampus (K-M) (t(101) = 2.422, p = 0.0172), and the dentate gyrus 
neurons (N-P) (t(87) = 3.866, p = 0.0002). Scale bar = 5 μm. n = 48-60 dendrites/ 
group. Het+, NEXMIF+/NEXMIF-expressing; Het-, NEXMIF-/NEXMIF lacking. 
*p<0.05, **p<0.01 ***p<0.001.  
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5.1 Summary of findings 
NEXMIF is a novel X-linked ASD gene with loss of its protein product leading to 
autistic behavior and cognitive impairments in humans. This dissertation provides 
an investigation of the cellular and molecular dysregulation and ASD-like 
behavioral impairments that result from loss, and haploinsufficiency of, NEXMIF.  
In Chapter 3, I report findings from the transgenic NEXMIF-/y knockout 
mouse. NEXMIF-/y mice showed autism-like behaviors including deficits in social 
behaviors, increased repetitive self-grooming, impaired communication, and 
deficient learning and memory. The NEXMIF-/y phenotype faithfully replicated the 
symptoms reported in humans with loss-of-NEXMIF (Alarcon-Martinez et al., 2019; 
Charzewska et al., 2015; Kuroda et al., 2015; Lambert et al., 2018; Lorenzo et al., 
2018; Panda et al., 2020; Stamberger et al., 2020). Cultured hippocampal neurons 
from NEXMIF-/y brains, showed a significant decrease in neurite outgrowth, 
synaptic protein expression, spine and synapse density, and synaptic plasticity. 
Additionally, RNAseq after knockdown of NEXMIF demonstrated altered gene 
expression of many genes including those enriched at the synapse and involved 
in neuronal development and function. Among the top downregulated genes, 
neurogranin (Nrgn) and SynDig1 were identified as candidates for investigation 
due to their synaptic enrichment and roles in synaptogenesis and synaptic 
plasticity (Díaz, 2012; Díez-Guerra, 2010; Garrido-García et al., 2019; 
Kalashnikova et al., 2010; Lovero et al., 2013; Ryoo et al., 2015; Zhabotinsky et 
al., 2006; Zhong and Gerges, 2010). I have shown that overexpression of Nrgn or 
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SynDig1 in vitro was sufficient to rescue the decreased density of spines and 
synaptic AMPAR observed from loss of NEXMIF. These studies confirm the value 
of the mouse model for NEXMIF ASD and provide important original knowledge 
regarding the cellular defects that arise from NEXMIF-dependent ASD. Findings 
from the rescue experiments will help with the development of therapeutic 
strategies for clinical intervention of the disorders. 
In addition, I investigated alterations in behavior due to NEXMIF 
haploinsufficiency and the underlying molecular alterations in transgenic 
NEXMIF+/- female mice. In Chapter 4, I discovered that NEXMIF+/- mice display 
reduced social interactions, repetitive behaviors, and impaired memory. 
Interestingly, NEXMIF+/- female mice show more moderate changes in 
communication than their male NEXMIF-/y counterparts, which is consistent with 
reports of milder communication phenotypes in human females affected with 
NEXMIF variants (Athanasakis et al., 2014; Farach and Northrup, 2016; de Lange 
et al., 2016; Moysés-Oliveira et al., 2015; Samanta and Willis, 2020; Stamberger 
et al., 2020; Webster et al., 2017; Wu et al., 2020). Furthermore, I have shown for 
the first time the cellular mosaicism of NEXMIF expression in the brains of 
NEXMIF+/- mice resulting in mixed coexistence of both NEXMIF+ and 
NEXMIF- neurons due to random XCI. Surprisingly, both NEXMIF+ and NEXMIF- 
neurons show impairments in neurite outgrowth and spine density. Additionally, 
both groups of neurons from NEXMIF+/- mice demonstrate reductions in synaptic 
proteins including the GluA1 subunit of AMPARs and PSD95. These findings 
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indicate that the female transgenic mouse of NEXMIF haploinsufficiency 
recapitulates autistic features of the human patients and that loss of NEXMIF 
impaired neuronal development both in cis and trans to neighboring cells. The 
unique neural network of mutually innervated NEXMIF+ and NEXMIF- neurons and 
the potential to restore NEXMIF expression from the endogenous wild type allele 
make the NEXMIF+/- mouse a particularly interesting model for future study of 
NEXMIF and ASD.  
 
5.2 The role of NEXMIF in excitatory/inhibitory balance and epilepsy 
Reports indicate humans with ASD due to loss of NEXMIF show epilepsy as a 
comorbid phenotype (Cantagrel et al., 2004, 2009; Charzewska et al., 2015; 
Farach and Northrup, 2016; Lambert et al., 2018; de Lange et al., 2016; Lorenzo 
et al., 2018; Van Maldergem et al., 2013; Webster et al., 2017). The seizures vary 
in type but include generalized, tonic-clonic, absence, and myoclonic seizures. The 
onset of seizures also varied between patients but began as early as < 1 year old 
and as late as the teens. Some patients don’t demonstrate seizures or have only 
had a single episode, while others could have up to hundreds of episodes per day. 
Our NEXMIF-/y and NEXMIF+/- mice also demonstrate severe seizures, typically in 
response to animal handling. This complex phenotype will require further studies 
for more detailed analysis but suggests dysregulated neuronal networks.  
Several possible mechanisms could explain how loss of NEXMIF leads to 
epilepsy. First, loss of NEXMIF may lead to an abnormal ratio of excitatory to 
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inhibitory (E/I) neuronal activity. Disrupted E/I balance has been hypothesized as 
a mechanism underlying ASD pathology (Nelson and Valakh, 2015; Rubenstein 
and Merzenich, 2003; Sohal and Rubenstein, 2019). Such an imbalance can result 
from developmental changes such as synaptic transmission and plasticity, intrinsic 
neuronal excitability, and ratios of excitatory/inhibitory synaptic inputs or neuronal 
subtypes (Culotta and Penzes, 2020; Gao and Penzes, 2015; Lee et al., 2017). In 
my study, I observed decreases in both glutamatergic and GABAergic synapses 
from loss of NEXMIF. Interestingly, the RNAseq data shows significant 
downregulation of several GABA receptor subunits. Further work investigating the 
E/I ratio more directly, including studies of glutamatergic to GABAergic neuron 
ratios and electrophysiological recordings of excitatory and inhibitory synaptic 
currents, would help clarify whether loss of NEXMIF results in E/I imbalance. 
Second, loss of NEXMIF may lead to hyperexcitability due to altered 
expression and/or distribution of ion channels. Such channelopathies have been 
implicated in the pathogenesis of ASD and over 25% of genes linked to epilepsy 
encode ion channels (Oyrer et al., 2018; Schmunk and Gargus, 2013; Zhang et 
al., 2019c). Our RNAseq dataset revealed downregulation of several potassium 
channels, as well as some chloride and calcium channels, after loss of NEXMIF. 
Loss of potassium channels, in particular, has been shown to increase neuronal 
excitability and enhance susceptibility of seizures (D’Adamo et al., 2013; Guglielmi 
et al., 2015; Köhling and Wolfart, 2016; Villa and Combi, 2016). Further studies 
including biochemical confirmation of reduced potassium channel protein 
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expression and electrophysiological recordings of resting membrane potential and 
action potential firing, would help to determine whether potassium channels play a 
role in hyperexcitability and epilepsy from loss of NEXMIF. 
Third, in the case of NEXMIF haploinsufficiency, mosaic expression of 
NEXMIF may lead to epilepsy as a result of impaired interactions between 
NEXMIF+ and NEXMIF- neurons. Indeed, the presence of two cell populations with 
different genotypes has been shown to lead to epilepsy, depending on the extent 
of mosaicism. For example, in mosaic parents of children with Dravet syndrome, 
parents with <45% mosaic expression of a SCN1A mutation were unaffected, while 
those with >45% expression of the mutation were affected with epilepsy correlated 
to the percent of mosaicism (Depienne 2010). Additionally, there is evidence that 
X-linked cellular mosaicism is an underlying cause of seizures. Mutation of the X-
linked gene PCDH19 causes epilepsy and intellectual disability in heterozygous 
females, but not hemizygous males, due to mismatched interactions between the 
mosaically expressed PCDH19+ and PCDH19- neurons (Depienne 2009, Hoshina 
2021, Hayashi 2017, Dibbens 2008). Further, mutations in the X-linked gene 
CDKL5 cause seizures, autistic features, and neurodevelopmental impairment 
primarily in female heterozygotes and seizure-like events have been observed only 
in female heterozygotes of a transgenic CDKL5 mouse model, not in hemizygous 
knockout males or homozygous knockout females (Terzic 2021). It is possible a 
similar cellular interference mechanism is the underlying cause for NEXMIF 
epilepsy as females heterozygous for NEXMIF seem to have a more severe 
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seizure phenotype than hemizygous males. Further investigations of a mosaic 
neural circuit, including electrophysiological recordings of basal synaptic 
transmission and synaptic plasticity from all four possible pairings of NEXMIF+ and 
NEXMIF- neurons, including mutual innervation between + to +, - to -, + to -, and - 
to + neurons, would help to elucidate the extent to which mosaicism contributes to 
synaptic dysfunction, neuronal hyperactivity, and the epileptic phenotype after loss 
of NEXMIF. 
 
5.3 Diversity in NEXMIF ASD phenotypes between males and females 
Pathogenic variants in NEXMIF have now been reported in dozens of patients 
who demonstrate developmental delay, autistic features, cognitive impairments, 
and epilepsy (Alarcon-Martinez et al., 2019; Athanasakis et al., 2014; Borlot et al., 
2017; Cantagrel et al., 2004; Charzewska et al., 2015; Farach and Northrup, 2016; 
Kuroda et al., 2015; Lambert et al., 2018; de Lange et al., 2016; Lorenzo et al., 
2018; Van Maldergem et al., 2013; Moysés-Oliveira et al., 2015; Panda et al., 
2020; Samanta and Willis, 2020; Stamberger et al., 2020; Webster et al., 2017; 
Wu et al., 2020). Interestingly, males tend to demonstrate more severe language 
and cognitive impairments while females more frequently have epilepsy (Panda 
et al., 2020; Stamberger et al., 2020). The behavioral studies reported in this 
dissertation reveal the transgenic NEXMIF mouse model recapitulates the 
phenotypes observed in humans. Both hemizygous NEXMIF-/y and heterozygous 
NEXMIF+/- mice showed impairments in social behavior, repetitive self-grooming, 
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and deficit spatial memory. However, NEXMIF-/y mice had more dramatic 
impairments in communication than NEXMIF+/- mice, in line with the increased 
severity of language impairment in males than females. Both hemizygous 
NEXMIF-/y and heterozygous NEXMIF+/- mice have seizures although the 
frequency and severity of this phenotype remain to be investigated. It is possible 
that the differences in behavior are due to complete loss of NEXMIF versus 
mosaic loss of NEXMIF. However, XCI patterning does not seem to be a complete 
explanation for this difference as most female patients have random XCI and no 
correlation was found between XCI skewing and disease phenotype. This is in line 
with my data from the brains of NEXMIF+/- mice, which also show no sign of 
significant skewing in NEXMIF expression. 
 Given that males are generally 3-5 times more likely to be diagnosed with 
ASD than females, it is interesting to note that, to date, 72% of reported NEXMIF 
ASD patients are female (Fernell and Gillberg, 2010; Fombonne, 2009; Loomes 
et al., 2017; Nicholas et al., 2009). There are several hypotheses that could 
explain a skewed sex distribution for an X-linked disease. Firstly, mutations in 
NEXMIF could increase the risk of prenatal lethality in males. However, I observed 
that about 22% of pups born from our transgenic line were hemizygous NEXMIF-
/y mice, similar to the expected frequency of about 25% given the wild-type male 
to heterozygous NEXMIF+/- female mating scheme. Second, a higher frequency 
of affected females could also be due to the statistically higher chance female 
have of a de novo mutation in NEXMIF as they have two copies compared to the 
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one copy in males. Or, thirdly, it is possible pathogenic de novo mutations in 
NEXMIF are more likely to occur in male germ cells, resulting in affected 
daughters but not sons (Thomas, 1996). This explanation has been applied to Rett 
syndrome (Girard et al., 2001; Zhu et al., 2010). Indeed, NEXMIF has several 
parallels with MeCP2 as both are X-linked genes whose protein products localize 
to the nucleus and whose variants affect mostly females. However, it is difficult to 
make a conclusion about the inheritance of NEXMIF variants from our mouse 
model as the animals consistently inherited the mutant transgene from their 
mothers rather than de novo. Future work could be done to explore the likelihood 
of pathogenic NEXMIF mutations occurring at various developmental time points. 
 As the majority of affected individuals reported are female, it is reasonable 
to explore potential therapeutic approaches that are unique to haploinsufficiency. 
For example, specific reactivation of NEXMIF from the Xi chromosome in 
heterozygous NEXMIF+/- females would allow expression of wild-type NEXMIF in 
all unsilenced cells. This idea has recently shown promising results for reactivation 
of MeCP2 in Rett Syndrome (Carrette et al., 2018; Przanowski et al., 2018). 
Investigations to confirm the feasibility of NEXMIF reactivation from the Xi 
chromosome in female heterozygous mice will help establish strategies to be used 
in future studies for treatment of the affected female individuals. 
 
5.4 NEXMIF nuclear localization and its role in gene regulation 
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Much remains to be established about the direct function of NEXMIF and the 
mechanistic steps linking it to the structural and synaptic phenotypes I observe. 
NEXMIF has no significant homology with other known proteins (Cantagrel et al., 
2004). Analysis of the NEXMIF protein sequence has only revealed a DUF4683 
domain (Domain of Unknown Function 4683) (Lu et al., 2020) and two predicted 
nuclear localization (NLS) sequences (Kosugi et al., 2009). The presence of NLSs 
is consistent with NEXMIF’s nuclear localization. While the function of NEXMIF 
within the nucleus remains unknown, it is possible NEXMIF acts as a component 
of a gene expression regulatory complex or a transcription factor. Our RNAseq 
analysis revealed significantly altered gene expression of a large number of 
genes, particularly those involved in neuronal and synaptic development, after 
loss of NEXMIF. Additionally, Support Vector Machine classification software tools 
(SVM-Prot and DRNApred) have predicted NEXMIF to be a DNA- and zinc-
binding protein (Cai et al., 2003; Yan and Kurgan, 2017). Future work to confirm 
the DNA-binding capability of NEXMIF, including chromatin immunoprecipitation 
sequencing (ChIPseq), would help to clarify NEXMIF’s role in the regulation of the 
genes identified in the RNAseq. 
 Although no significant homology with other known proteins has been 
identified for NEXMIF, recent studies of Xia-Gibbs syndrome revealed some small 
segments of similarity with the proteins REV3L and AHDC1 (Jiang et al., 2018; 
Khayat et al., 2021; Lange et al., 2016; Murdock et al., 2019). REV3L is the 
catalytic subunit of DNA polymerase zeta, specializing in translesion DNA 
170 
synthesis (Gan et al., 2008; Lange et al., 2016). Interestingly, the conversed 
region between REV3L and NEXMIF is within the DUF4683 of each protein, 
suggesting the function of this unknown domain is something shared between the 
two proteins, perhaps as a docking site for the recruitment of other DNA 
polymerase machinery. AHDC1 is a score 1 gene on the SFARI ASD gene 
database whose de novo truncating variants are linked with Xia-Gibbs syndrome, 
a neurodevelopmental disorder characterized by developmental delay, intellectual 
disability, seizures, hypotonia, and sleep apnea (Jiang et al., 2018; Khayat et al., 
2021; Xia et al., 2014). AHDC1 contains AT-hook DNA binding motifs and is 
nuclear localized, though little is known about its function (Khayat et al., 2021). It 
shares small regions of similarity with both NEXMIF and REV3L and truncating 
mutations including these regions demonstrated unusual aggregation in the 
nucleolus, suggesting a role for these regions in proper localization within the 
nucleus (Khayat et al., 2021).  
 Further, in silico analysis has revealed potential binding partners for 
NEXMIF. A search on the BioGRID database of protein interactions indicated 
predicted interactions with the proteins RNF123, TRF1, and TRF2. RNF123 is a 
RING finger E3 ubiquitin ligase which has been shown to target nuclear envelope 
proteins, such as lamin B1 and LAP2α, for degradation (Chaturvedi et al., 2012; 
Khanna et al., 2018). As the BioGRID database predicts ubiquitination sites on 7 
lysines within NEXMIF, it is possible RNF123 interacts with NEXMIF as the 
responsible E3 ligase for NEXMIF ubiquitination and its subsequent degradation. 
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TRF1 and TRF2 are part of the shelterin complex which binds duplex telomeric 
DNA to regulate telomere length and protect the ends of chromosomes (Arndt and 
MacKenzie, 2016; Giannone et al., 2010; De Lange, 2005; Lee et al., 2018). It is 
possible that the DNA-binding of NEXMIF is also at telomeres where it could 
interact with TRF1 and TRF2. This might indicate a role for NEXMIF in telomere 
maintenance and aging, which could be examined in older NEXMIF-/y mice. In 
addition to the previously mentioned ChIP-seq experiments to identify segments 
of NEXMIF-bound DNA, immunoprecipitation of NEXMIF followed by mass 
spectrometry would confirm RNF123, TRF1, and TRF2 as binding partners and 
possibly reveal other interacting proteins. It would be useful to design experiments 
to disrupt these protein-protein interactions to determine the role of the protein 
complexes and further our understanding of NEXMIF’s function. 
 
5.5 The role of NEXMIF in synapse formation and function 
Altered synaptic structure and function has emerged as a common underlying 
pathology in ASD (Bagni and Zukin, 2019; Bourgeron, 2009, 2015; Carroll et al., 
2021; Gilbert and Man, 2017; Guang et al., 2018; Phillips and Pozzo-Miller, 2014; 
Zoghbi and Bear, 2012). Indeed, I observed decreased synaptic density and 
expression of synaptic related proteins in NEXMIF-/y and NEXMIF+/- neurons. 
Additionally, Ingenuity Pathway Analysis of the dysregulated genes identified from 
NEXMIF knockdown RNAseq showed enrichment of genes involved in key 
synaptic processes, such as glutamatergic signaling, LTP, and LTD. My in vitro 
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studies showed NEXMIF-/y neurons failed to enhance surface AMPAR expression 
in response to either chemical LTP or HSP treatments. It is possible the loss of 
NEXMIF results in dysregulation of AMPAR trafficking or alters AMPAR stability 
at the synaptic surface, thus resulting in decreased surface expression. To assess 
basal AMPAR trafficking in NEXMIF-/y neurons, internalization and insertion 
assays could be performed. Additionally, we have shown that AMPARs are 
subject to acetylation which stabilizes their surface expression (Wang et al., 2017, 
Appendix). The level of AMPAR acetylation, versus its competing modification 
ubiquitination, could be measured in tissue from NEXMIF-/y mice. However, no 
significant change was observed in the gene expression of the related enzymes 
Nedd4, Sirt2, and p300 from analysis of the RNAseq dataset. 
From the top downregulated genes enriched at the synapse in the RNAseq 
dataset, I chose to investigate the role of Nrgn and SynDig1 in synapse 
development after loss of NEXMIF. Nrgn and SynDig1 have been shown to play 
roles in synapse formation and function (Garrido-García et al., 2019; Kalashnikova 
et al., 2010; Zhabotinsky et al., 2006). I was able to show that overexpression of 
Nrgn or SynDig1 could rescue the density of AMPAR puncta and spines after loss 
of NEXMIF expression. This suggests decreased Nrgn and/or SynDig1 
expression play a role in mediating the synaptic deficits observed after loss of 
NEXMIF. To further explore the downstream roles of Nrgn and SynDig1 in exerting 
NEXMIF’s effects on the synapse, studies to measure synaptic plasticity after 
reintroduction of Nrgn and SynDig1 in NEXMIF-/y neurons would be of interest. 
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Furthermore, reintroduction at various time points in development could help to 
determine whether a specific stage is most sensitive to reversal of NEXMIF-
dependent synaptic deficits, providing valuable insight into possible therapeutic 
interventions for future research. 
 In addition to Nrgn and SynDig1, there may be other potential targets 
participating downstream of NEXMIF, particularly those that might act as 
extracellular cues. My findings from in vitro study of NEXMIF+/- neurons revealed 
impaired neurite outgrowth, reduced density, and decreased puncta density of key 
synaptic proteins in both NEXMIF+ and NEXMIF- neurons. This suggests that loss 
of NEXMIF in NEXMIF- neurons results not only in direct changes to those cells, 
but also in impairments to NEXMIF+ neurons, an effect that might be due to altered 
extracellular cues from the NEXMIF- neurons. Indeed, impairments in dendritic 
arborization appeared more severe for NEXMIF+ neurons at DIV 14 than at DIV 
8, suggesting expression of key proteins during this developmental time period, 
such as those involved in synaptogenesis, may play a role in this phenotype. Our 
previous work using shRNA knockdown of NEXMIF proposed the mechanism for 
impaired dendritic outgrowth to be due to increased surface N-cadherin 
sequestering δ-catenin, resulting in increased RhoA activation and decreased 
actin dynamics at the growth cone (Gilbert and Man, 2016). Additionally, N-
cadherin has been shown to stabilize filopodial F-actin, thus promoting maturation 
of dendritic filopodia to mushroom shaped spines (Chazeau et al., 2015). Thus, 
increased surface N-cadherin in NEXMIF- neurons could be the source of aberrant 
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interneuronal communication with NEXMIF+ neurons. Indeed, the proposed 
underlying mechanism to impairments in PCDH19 heterozygotes is that mosaic 
PCDH19 expression results in mismatched PCDH19+ and PCDH19- synapses 
which prevent N-cadherin homophilic adhesion (Hoshina et al., 2021). To further 
investigate this hypothesis in the context of NEXMIF, the pre- and post-synaptic 
expression of N-cadherin, activity of RhoA, and actin dynamics in filopodia could 
be measured in NEXMIF-/y and NEXMIF- neurons from NEXMIF+/- mice. 
Additionally, the RNAseq dataset showed that loss of NEXMIF resulted in 
downregulation of several protocadherins, including PCDH19. It would be 
interesting to explore whether reduced expression of protocadherins, due to loss 
of NEXMIF, could contribute to the observed impairments in synapse formation 
and function, particularly in NEXMIF+/- mice whose brains may not be able to 
properly mediate signals between NEXMIF+ protocadherin-expressing and 
NEXMIF- protocadherin-deficient neurons. 
 
5.6 Conclusions and future perspectives 
In this dissertation, I examined behavioral and molecular phenotypes due to 
NEXMIF deficiency in NEXMIF-/y and NEXMIF+/- mice. I found that the NEXMIF-/y 
and NEXMIF+/- mice faithfully model the behavioral phenotypes observed in 
humans and that NEXMIF-/y and NEXMIF+/- neurons demonstrate impairments in 
neuronal and synaptic development. The work is the first to examine the molecular 
details of haploinsufficient NEXMIF expression, providing new insights into the 
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role of NEXMIF in proper development and maturation of the brain. Future studies 
will be necessary to dissect the detailed molecular mechanisms of NEXMIF 
function in different developmental processes including neuronal morphogenesis, 
migration, synaptogenesis, and network activity. In vitro studies utilizing NEXMIF 
mutants and truncations could help establish the NEXMIF nuclear localization 
signal, sites of post-translational modification, and functional domains, all of which 
would improve our understanding of NEXMIF’s function. The NEXMIF-/y and 
NEXMIF+/- mouse models will also be useful tools for such mechanistic studies, 
as well as for future attempts to develop therapeutics which rescue the 
morphological and behavioral phenotypes. There are some comorbidities in 
humans with NEXMIF-dependent ASD that remain to be characterized in this 
model. Future work to assess the extent of attention deficit/hyperactivity and 
gastrointestinal issues would help to further establish this model. In particular, 
further studies are needed to compare the frequency, types, and severity of 









APPENDIX: ACETYLATION OF AMPA RECEPTORS REGULATES 





In Alzheimer’s disease (AD), decreases in the amount and synaptic localization of 
AMPA receptors (AMPARs) result in weakened synaptic activity and dysfunction 
in synaptic plasticity, leading to impairments in cognitive functions. We have 
previously found that AMPARs are subject to lysine acetylation, resulting in higher 
AMPAR stability and protein accumulation. Here we report that AMPAR acetylation 
was significantly reduced in AD and neurons with Aβ incubation. We identified 
p300 as the acetyltransferase responsible for AMPAR acetylation, and found that 
enhancing GluA1 acetylation ameliorated Aβ-induced reductions in total and cell-
surface AMPARs. Importantly, expression of acetylation mimetic GluA1 (GluA1-
4KQ) in APP/PS1 mice rescued impairments in synaptic plasticity and memory. 
These findings indicate that Aβ-induced reduction in AMPAR acetylation and 
stability contributes to synaptopathy and memory deficiency in AD, suggesting that 
AMPAR acetylation may be an effective molecular target for AD therapeutics.  
 
A.2 Introduction 
Alzheimer’s disease (AD) is the most common form of dementia characterized by 
impairments in learning and memory. A key hallmark of AD is the accumulation of 
amyloid-β (Aβ), which has been shown to cause loss of dendritic spines and 
dysregulation in synaptic functions, such as basal transmission and synaptic 
plasticity (Forner et al., 2019; Palop and Mucke, 2010; Rajmohan and Reddy, 
2017; Selkoe, 2002; Sheng et al., 2012; Yu and Lu, 2012). Evidence suggests 
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these impairments in synaptic function are an early pathology which ultimately lead 
to the cognitive failures observed in AD (Baglietto-Vargas et al., 2018; Chen et al., 
2000; Li et al., 2011; Ma and Klann, 2012; Oddo et al., 2003; Selkoe and Hardy, 
2016).  
AMPA receptors (AMPARs) mediate most of the excitatory synaptic 
transmission that underlies higher brain functions, including learning and memory. 
A change in the synaptic expression of AMPARs is the key mechanism underlying 
synaptic plasticity, the molecular basis for learning and memory. An increase in 
surface AMPARs through exocytosis leads to the expression of long-term 
potentiation (LTP), while internalization of AMPARs causes long-term depression 
(LTD) (Chidambaram et al., 2019; Collingridge et al., 2004; Derkach et al., 2007; 
Ju and Zhou, 2018; Kopec et al., 2006; Lledo et al., 1998; Lüscher et al., 1999; 
Makino and Malinow, 2009; Malinow and Malenka, 2002; Shepherd and Huganir, 
2007; Song and Huganir, 2002). Consistent with impairments in synaptic function, 
a reduction in AMPARs has been observed in the brains of both human AD patients 
and mouse models of AD (Armstrong et al., 1994; Cantanelli et al., 2014; Carter et 
al., 2004; Chang et al., 2006; D’Amelio et al., 2011; Dewar et al., 1991; Du et al., 
2020; Gao et al., 2016; Gong et al., 2009; Jacob et al., 2007; Monteiro-Fernandes 
et al., 2020; Samra and Ramtahal, 2012; Thorns et al., 1997; Wakabayashi et al., 
1999; Yasuda et al., 1995). In line with this, incubation of neurons with Aβ results 
in down-regulation in AMPAR amounts (Guntupalli et al., 2016; Miyamoto et al., 
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2016; Parameshwaran et al., 2008; Thomas et al., 2017; Wisniewski et al., 2011; 
Yu and Lu, 2012; Zhang et al., 2018).  
The abundance of AMPARs in the post-synaptic domain is regulated by 
dynamic receptor trafficking. Enhanced receptor internalization and an ultimate 
reduction in AMPAR synaptic accumulation has been shown to be an early 
pathological feature of AD (Almeida et al., 2005; Baglietto-Vargas et al., 2018; 
Hsieh et al., 2006; Li et al., 2019b; Zhao et al., 2010). Overexpression of amyloid 
precursor protein (APP) or application of soluble oligomeric Aβ results in a 
reduction in surface expression of AMPARs (Alfonso et al., 2014; Gu et al., 2009; 
Miller et al., 2014; Roselli et al., 2005; Tanaka et al., 2019; Zhang et al., 2011) 
likely due to endocytosis of AMPARs from the synaptic surface (Hsieh et al., 2006; 
Miñano-Molina et al., 2011; Wang et al., 2011a; Zhang et al., 2017). The reduced 
stability of AMPARs may be a major contributing factor to the pathology of AD. 
In AD, the reduction in AMPAR seems to result from reduced receptor 
stability. Indeed, treatment with Aβ increased AMPAR mobility(Opazo et al., 2018) 
and, in the presence of cycloheximide, shortened AMPAR half-life (Zhang et al., 
2018). Studies have demonstrated that ubiquitination is a primary regulatory 
mechanism contributing to AMPAR stability (Guntupalli et al., 2017; Rodrigues et 
al., 2016; Zhang et al., 2018). AMPARs are subject to ubiquitination via the E3 
ligase Nedd4 (Hou et al., 2011; Lin et al., 2011; Rodrigues et al., 2016; Schwarz 
et al., 2010) and deubiquitination by the deubiquitinase USP46 (Huo et al., 2015). 
Plasma membrane-inserted AMPARs are preferentially targeted for 
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ubiquitination(Lin et al., 2011), leading to receptor internalization and subsequent 
proteasomal degradation (Goo et al., 2015; Hou et al., 2011; Jarzylo and Man, 
2012; Zhang et al., 2009).  
We have recently demonstrated that AMPARs are also subject to lysine 
acetylation, a regulation that competes with ubiquitination because both processes 
target lysine residues. Acetylation confers AMPARs with higher levels of stability 
due to a suppression in AMPAR internalization and degradation (Wang et al., 
2017). We have shown that inhibition of the AMPAR deacetylase, SIRT2, causes 
enhanced AMPAR acetylation and increased AMPAR accumulation at synapses 
(Wang et al., 2017). Because AMPAR reduction is a crucial first step leading to the 
cognitive deficits in AD, restoration of AMPARs at the synapse is predicted to 
improve synaptic strength and cognitive function in AD.  
In this study, we find that AMPAR acetylation is altered under AD conditions. 
In Aβ-incubated neurons, and in brains of transgenic AD mice and AD patients, 
AMPARs show marked reduction in acetylation. We show that upregulation of 
AMPAR acetylation leads to a suppression in AMPAR internalization and an 
increase in total AMPAR amount. We identify p300 as the acetyltransferase 
responsible for AMPAR acetylation and find that activation of p300, or inhibition of 
AMPAR deacetylase SIRT2, results in an increase in AMPAR acetylation and 
blocks the Aβ-induced reduction in surface AMPAR expression. Importantly, we 
found that hippocampal expression of an acetylation mimetic of GluA1 was able to 
restore synaptic plasticity and rescue cognitive deficits in the 
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Tg(APPswe,PSEN1dE9)85Dbo (APP/PS1) mouse model. Together, these 
findings provide insights into the importance of AMPAR acetylation in the 
pathogenesis of cognitive dysfunction in AD. 
 
A.3 Results 
A.3.1 Aβ Induces a Reduction in AMPAR Acetylation 
Our studies and the work of others have shown that AMPAR levels are reduced in 
AD (Armstrong et al., 1994; Carter et al., 2004; Dewar et al., 1991; Gong et al., 
2009; Thorns et al., 1997; Yasuda et al., 1995; Zhang et al., 2018). In AD brains 
and Aβ-treated neurons, ubiquitination of AMPARs is up-regulated (Guntupalli et 
al., 2017; Rodrigues et al., 2016; Zhang et al., 2018), and studies have 
demonstrated proteasomal degradation of ubiquitinated AMPARs (Huo et al., 
2015; Jarzylo and Man, 2012; Lin et al., 2011).Recently, we found that AMPARs 
are subject to another form of protein modification, i.e., acetylation, a modification 
that opposes receptor ubiquitination and functions to stabilize AMPARs (Wang et 
al., 2017). We therefore wondered whether this modification of AMPARs is altered 
in AD conditions, contributing to the aberrance in receptor expression. To this end, 
we first used immunostaining to confirm the effect of Aβ oligomers on the 
abundance of AMPAR expression. DIV 15 cultured rat hippocampal neurons were 
treated with Aβ (1 μM) for 24 h and labeled with specific antibodies against AMPAR 
subunit GluA1. Immunostaining against the GluA1 N-terminus under non-
permeant conditions showed a reduction in the intensity of surface GluA1 puncta, 
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and antibodies against the GluA1 C-terminus under permeant conditions showed 
a similar reduction in total levels of GluA1 (Fig. A.1A-A.1B). To examine 
specifically the expression level of AMPARs at the synaptic sites, we purified 
synaptosomes from cultured cortical neurons. We found that the Aβ treatment 
resulted in a 62% reduction in the amount of GluA1 in the synaptosome, 
comparable to an overall 65% reduction from total cell lysate (Fig. A.1C-A.1D). In 
addition, we found that Aβ treatment did not affect the levels of PSD95 (Fig. A.1E). 
These findings indicate that Aβ incubation leads to a down-regulation of synaptic 
AMPARs in neurons.  
We wondered whether AMPAR acetylation plays a role in Aβ-induced 
AMPAR down-regulation. Using DIV 15 primary cortical neurons treated with Aβ 
(1 μM) for 24 h, we isolated AMPAR GluA1 subunits via immunoprecipitation, and 
probed western blots with antibodies specific for lysine acetylation (Inuzuka et al., 
2012; Wang et al., 2017). We found that, compared to the control, incubation with 
Aβ resulted in a significant reduction in acetylation signal in precipitated GluA1 
(Fig. A.1F-A.1G). There was no significant difference in PSD95 levels (Fig. A.1H). 
To further determine the state of AMPAR acetylation in AD, we examined lysates 
from postmortem AD patient brains. GluA1 was precipitated from the prefrontal 
cortex lysates from patients and healthy controls. In line with our findings from Aβ-
treated neurons, the AD patient brain homogenates showed a consistent decrease 
in the extent of GluA1 acetylation compared to the non-AD controls (Fig. A.1I-
A.1J). We also observed a dramatic increase in GluA1 ubiquitination (Fig. A.1K). 
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Together these results demonstrate that AMPAR acetylation is decreased in vitro 
in Aβ-treated neurons and ex vivo in human AD brains. 
A.3.2 The Acetyltransferase p300 Causes GluA1 Acetylation† 
Our previous work has identified SIRT2 as the deacetylase responsible for the 
deacetylation of GluA1 (Wang et al., 2017), however, the enzyme(s) responsible 
for AMPAR acetylation remains unknown. We therefore sought to identify the 
acetyltransferase that catalyzes the conjugation of the acetyl group to the lysine 
residues at GluA1 C-terminus (GluA1ct). To this end, we purified GST-tagged 
GluA1ct and incubated it with several acetyltransferases including PCAF, p300, 
CBP, and GCN5, individually (Fig. A.2A). Interestingly, when the GluA1ct was 
probed for lysine acetylation, we observed a marked increase in GluA1 acetylation 
in assays that contained p300 and a trend of increase with the p300 homolog CBP 
(Fig. A.2B). However, this was not observed in assays containing PCAF or GCN5. 
This result indicates a specific role for the p300 family of acetyltransferases on 
AMPAR acetylation. p300 is well known for its role in histone acetylation for the 
regulation of gene expression, but it is also localized in the cytoplasm (Dancy and 
Cole, 2015; Kwok et al., 2006; Rotte et al., 2013; Shi et al., 2009). It is therefore 
possible for the endogenous p300 to acetylate AMPARs in neurons. To confirm 
the effect of p300 on AMPAR acetylation in vivo, we incubated primary cortical 
neurons with either the p300 inhibitor C646 (20 µM) (Bowers et al., 2010) or the 
p300 acetyltransferase activator CTPB (20 µM) (Balasubramanyam et al., 2003), 
for 24 h, and immunoprecipitated GluA1 for acetylation assays. Indeed, inhibition 
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of p300 by C646 caused a decrease in GluA1 acetylation whereas activation of 
p300 by CTPB increased acetylation of GluA1 (Fig. A.2C). Because an acetylation 
event often antagonizes protein ubiquitination due to competition for the same 
lysine residues, we examined changes in GluA1 ubiquitination. As expected, 
inhibition of p300 led to an increase while activation of p300 by CTPB caused a 
decrease in the level of GluA1 ubiquitination (Fig A.2C). 
A.3.3 p300-Mediated Acetylation Leads to AMPAR Stabilization 
Acetylation has been shown to cause stabilization of membrane proteins and 
expansion of protein’s half-life (Alaei et al., 2018; Caron et al., 2005; Drazic et al., 
2016; Mak et al., 2014). To determine whether acetylation by p300 confers AMPAR 
with enhanced stability, we transfected p300, together with GFP, in primary 
hippocampal neurons. Immunostainings showed an overexpression of p300 led to 
an increase in the total GluA1 puncta intensity (Fig. A.2D-A.2E). In addition, we 
transfected p300 with GFP-GluA1 into HEK293T cells and measured the total 
GluA1 levels by Western blotting analysis. In line with our findings in neurons, 
expression of p300 led to an increase in total GluA1 levels compared to the pcDNA 
control, while expression of PCAF did not affect the amount of GluA1 (Fig. A.2F-
A.2G). These results showed that p300 acetyltransferase activity facilitates 
AMPAR acetylation and stabilization, supporting that p300 functions as the 
acetyltransferase for AMPAR acetylation. 
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A.3.4 The Lysine Residues in the GluA1 C-Terminal Tail Are the Targets for 
p300-Mediated AMPAR Acetylation† 
Because the acetyl group is conjugated to lysine residues of the substrate during 
acetylation, the four lysine residues located in GluA1 C-terminal are potential 
candidate sites for p300-mediated acetylation. To confirm the acetylation sites, we 
mutated all four of the lysine residues in GluA1ct to arginine (GluA1-4KR). 
Arginine’s side group mimics the charge of lysine’s side group thus preserving 
structural integrity, but is incapable of being acetylated (Inuzuka et al., 2012). We 
transfected HEK293 cells with GFP-GluA1-4KR, together with either p300, PCAF, 
or control vector pcDNA, respectively and used the cell lysates to assess GluA1 
protein levels to evaluate p300 effects on GluA1-4KR accumulation. Indeed, the 
previously observed increase in GluA1-WT levels from p300 overexpression was 
abolished in cells expressing GFP-GluA1-4KR (Fig A.2F-A.2G), indicating that the 
C-terminal lysine residues are required for p300-mediated GluA1 acetylation and 
stabilization. 
A.3.5 Acetylation of GluA1 Suppresses the Aβ-Induced Reduction of 
AMPAR Amount and Synaptic Accumulation 
Because acetylation reduces the rate of AMPAR turnover and increases AMPAR 
accumulation in neurons (Wang et al., 2017), we hypothesize that acetylation 
should lead to suppression of Aβ-induced AMPAR degradation. To test this idea, 
we incubated DIV 15 hippocampal neurons with Aβ alone, or with the SIRT2 
inhibitor B2, for 24 h. We found that treatment with B2 (2 µM) alone resulted in an 
186 
increase in both total and surface GluA1 (Fig. A.3A-A.3C). Importantly, Aβ-
induced reduction in AMPARs was blocked by co-incubation with B2 (Fig. A.3A-
A.3C). 
To examine the role of acetyltransferase activity in Aβ-induced AMPAR 
reductions, DIV 15 hippocampal neurons were incubated with p300 
acetyltransferase activator CTPB (20 µM), together with or without Aβ, for 24 hr. 
We found that activation of p300 by CTPB resulted in an increase in total and 
surface GluA1 puncta (Fig. A.3D-A.3F). Similar to the effect of Sirt2 inhibition, 
activation of p300 resulted in a blockade of the Aβ-induced AMPAR reduction (Fig. 
A.3D-A.3F). To directly test the effect of the acetyltransferase, primary neurons 
were transfected with p300 at DIV 8, which were then incubated with Aβ at DIV14 
for 24 hrs. Consistently, we found that compared to control neurons expressing 
GFP, which showed a reduction in GluA1 by Aβ treatment, no changes were 
detected on GluA1 puncta intensity in neurons overexpressing p300 (Fig. A.3G). 
A.3.6 GluA1 Acetylation Mimetic Confers AMPAR Resistance to the Aβ-
Induced Down-Regulation 
It has been shown that substitution of lysine with glutamine mimics constitutive 
acetylation as glutamine’s hydrophilic and uncharged structure imitates that of an 
acetylated lysine (Kim et al., 2006). We therefore mutated the four lysine residues 
of GluA1 to glutamine (GluA1-4KQ) and used the construct as a GluA1 acetylation 
mimetic (Wang et al., 2017). We transfected DIV 8 hippocampal neurons with 
GFP-GluA1-WT or GFP-GluA1-4KQ and compared their expression after one 
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week. Consistent with the effect of acetylation, we found that, compared to GFP-
GluA1-WT, GFP-GluA1-4KQ retained significantly higher levels of surface 
expression relative to the total expressed at the synapse (Fig. A.3H-A.3I). To 
determine whether this acetylation mimetic was also able to block the effect of Aβ 
on AMPAR levels, we treated GFP-GluA1-WT or GFP-GluA1-4KQ transfected DIV 
14 neurons with Aβ for 24 h. While Aβ incubation reduced the surface expression 
of GFP-GluA1-WT, the expression of acetyl-mimetic GFP-GluA1-4KQ was not 
changed in the presence of Aβ oligomers (Fig. A.3H-A.3I). These results 
demonstrate that acetylated AMPARs become resistant to Aβ-induced 
downregulation. 
A.3.7  AMPAR Acetylation Suppresses Aβ-Induced Receptor Endocytosis  
Our previous work and studies of others’ have shown that Aβ exposure causes 
AMPAR ubiquitination and internalization (Guntupalli et al., 2017; Miñano-Molina 
et al., 2011; Zhang et al., 2018). We wondered whether the acetylation of AMPARs 
also plays a role in the regulation of Aβ-induced internalization. To test this idea, 
we incubated DIV 14 hippocampal neurons with Aβ alone, or with CTPB, for 24 h 
and performed internalization assays. We found that CTPB treatment (20 µM) 
suppressed AMPAR internalization at basal conditions, indicated by a reduction of 
the ratio of internalized to surface GluA1 (Fig. A.4A-A.4B). Furthermore, while 
treatment with Aβ alone (1 μM) resulted in an increase in AMPAR internalization 
as expected, co-incubation with CTPB abolished the Aβ effect on AMPAR 
trafficking (Fig. A.4A-A.4B). It was possible that CTPB affected AMPAR trafficking 
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via off-target effects of p300 activity. To directly determine the role of AMPAR 
acetylation in Aβ-induced receptor internalization, we examined receptor 
internalization using the GluA1 acetylation mimetic. DIV 8 cultured neurons were 
transfected with GFP-GluA1-WT or GFP-GluA1-4KQ, which were then treated with 
Aβ or vehicle control for 24 h before performing internalization assays on DIV 15. 
We found that the basal internalization of GFP-GluA1-4KQ was reduced compared 
to GFP-GluA1 (Fig. A.4C-A.4D). Importantly, while Aβ treatment enhanced the 
internalization of GFP-GluA1, not significant effect was observed in cells 
expressing GFP-GluA1-4KQ (Fig. A.4C-A.4D). These results indicate that 
modulation of AMPARs by direct acetylation causes suppression of both basal and 
Aβ-induced AMPAR internalization. 
A.3.8  Viral Brain Injection of GluA1-4KQ Restores GluA1 Expression and 
Synaptic Accumulation in APP/PS1 Mice† 
In AD, AMPARs have a facilitated turnover rate, leading to a reduction in the total 
amount and synaptic accumulation of AMPARs. As we found that acetylation was 
able to stabilize AMPARs and rescue the effect of Aβ treatment in vitro, we wanted 
to know the role AMPAR acetylation plays in vivo and in AD conditions. As a widely 
used model of AD, the APP/PS1 mouse produces high levels of Aβ in the brain 
and demonstrates typical molecular and behavioral phenotypes of AD (McClean 
and Hölscher, 2014; Reinders et al., 2016; Reiserer et al., 2007; Sun et al., 2019; 
Trinchese et al., 2004). To determine whether AMPAR acetylation is altered in this 
AD animal model, we isolated GluA1 from hippocampal brain tissues of 11 month 
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old APP/PS1 mouse by immunoprecipitation and probed for acetylation and 
ubiquitination (Fig. A.5A). Indeed, consistent with our findings from rat primary 
neurons and human AD brains, this mouse model showed a significant reduction 
in the level of GluA1 acetylation, as well as an increase in GluA1 ubiquitination 
(Fig. A.5B-A.5C). A reduction in GluA1 acetylation was also observed in APP/PS1 
mice at 5 months old (Fig. A.5D). The APP/PS1 mouse also showed significant 
reduction in the total amount of AMPAR subunit GluA1 (Fig. A.5A and A.5D).  
A reduction in AMPAR synaptic accumulation and the consequential 
suppression in synaptic strength is believed to be an early pathobiology in AD 
(Baglietto-Vargas et al., 2018; Hsieh et al., 2006; Kamenetz et al., 2003; Li et al., 
2019b; Lin et al., 2019; Sun et al., 2019; Ting et al., 2007). We therefore wanted 
to know whether stabilization of AMPARs by acetylation confers positive effects 
towards AD conditions. To examine the role of AMPAR acetylation for memory 
impairments in the AD animals, we injected AAV viruses expressing either GFP-
GluA1-WT or GFP-GluA1-4KQ into the bilateral ventricles of 11-month-old 
APP/PS1 mice. Another group of APP/PS1 mice were injected with a virus 
expressing only GFP as a control (APP/PS1-con). Six weeks after bilateral 
injection of the viruses, brain tissues were collected for examination. Brain slices 
revealed strong GFP signals, indicating efficient viral expression of the constructs 
(Fig. A.5E). Western blots of APP/PS1 hippocampal brain lysates showed a 
significant reduction in synaptic proteins including GluA1, GluA2, synapsin I, and 
PSD95 (Fig. A.5F). These changes in synaptic proteins are consistent with the 
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known loss of synapses in the AD mouse (McClean and Hölscher, 2014; Shi et al., 
2017). In APP/PS1 mice injected with either GFP-GluA1-WT or GFP-GluA1-4KQ, 
we found a specific increase in GluA1 compared to APP/PS1 controls however, 
compared with GluA1-WT, GluA1-4KQ overexpression rescued GluA1 more 
significantly in APP/P1 mice (Fig. A.5F). These results indicate the successful 
expression of the viral GluA1 and GluA1-4KQ AMPAR subunits at the synaptic 
sites of these brain regions. 
A.3.9 Expression of GluA1 Acetylation Mimetic Rescues Deficits in Synaptic 
Plasticity in the APP/ PS1 Mice† 
Synaptic plasticity serves as the molecular basis for learning and memory 
(Humeau and Choquet, 2019; Lüscher and Malenka, 2012; Nabavi et al., 2014; 
Parkinson and Hanley, 2018), which is known to be impaired in AD conditions 
(Colom-Cadena et al., 2020; Lambert et al., 1998; Li and Selkoe, 2020; Sánchez-
Rodríguez et al., 2019; Shankar et al., 2008; Styr and Slutsky, 2018; Walsh et al., 
2002). We wanted to know whether the improved synaptic expression of AMPARs 
by viral injection of GluA1-4KQ had any effect on synaptic function. Using 
hippocampal brain slices, we examined the expression of long-term potentiation 
(LTP) by recordings of field excitatory postsynaptic potentials (fEPSPs). 
Consistent with previous reports, recordings from APP/PS1 mice showed a 
significant reduction in LTP expression when compared to the wild type mice 
(Gelman et al., 2018; Gengler et al., 2010; Da Silva et al., 2016; Trinchese et al., 
2004; Vargas et al., 2014; Vyas et al., 2020) (Fig. A.6A-A.6B). However, APP/PS1 
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mice expressing viral GFP-GluA1-4KQ had substantially improved LTP, while 
expression of GFP-GluA1-WT showed some rescue but to a lesser extent (Fig. 
A.6A-A.6B). These results indicate that restoration of AMPAR stability and 
synaptic accumulation rescues synaptic plasticity. 
A.3.10 Expression of GluA1 Acetylation Mimetic Rescues Visual Episodic 
Memory Deficits in APP/ PS1 Mice† 
To examine the effect of GluA1 expression on cognitive function in the AD mice, 
we first performed the novel object recognition test to assess visual episodic 
memory in the virally-injected APP/PS1 mice.  Animals were first habituated to the 
apparatus by allowing them to explore the cage prior to the test. The animals were 
then allowed to familiarize themselves with the initial objects A and B. The 
preference index from the familiarization period showed a lack of preference for 
either of the objects (data not shown). 1 h and 24 h later, animals were brought 
back to the cage with object B being replaced with object C and then object D (Fig. 
A.6C). As measured by the discrimination index, APP/PS1 mice struggled to 
remember the familiar object and thus failed to discriminate between the objects 
(Fig. A.6D). In the familiarization stage, none of the animals showed a particular 
preference of either of the objects (Fig. A.6E). During the 1 h and 24 h tests, 
APP/PS1 mice spent similar amounts of time with familiar object A and either of 
the novel objects C or D, respectively, indicating impairments in short-term and 
long-term memory (Fig. A.6F-A.6G). APP/PS1 mice expressing viral GluA1 spent 
significantly more time with the novel object compared to the familiar object in both 
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the 1 h and 24 h tests (Fig. A.6F-A.6G).  While viral expression of GluA1-WT led 
to modest improvements in memory, more robust rescue effects were observed in 
animals expressing the acetylation mimetic GluA1-4KQ, at both 1 h and 24 h after 
training (Fig. A.6D). These findings indicate that addition of acetylated and thus 
stabilized AMPARs is capable of correcting the impairments in memory capacity 
in AD mice. 
 
A.4 Discussion 
One of the earliest pathological features of AD is an impairment in synaptic function 
partly due to a reduction in AMPA receptors at the synapse (Almeida et al., 2005; 
Baglietto-Vargas et al., 2018; Chang et al., 2006; Dong et al., 2015; Li et al., 2019b; 
Marttinen et al., 2018). It has been shown that soluble Aβ oligomers promote 
AMPAR internalization and degradation (Guntupalli et al., 2017; Miñano-Molina et 
al., 2011). This is consistent with studies of our own, and those of others, which 
show an increase in ubiquitination of AMPARs in AD (Guntupalli et al., 2017; 
Rodrigues et al., 2016; Zhang et al., 2018) (as reviewed by (Harris et al., 2020; 
Moraes et al., 2020; Zhu and Tsai, 2020)). Findings from our recent work have 
revealed for the first time that AMPARs are also subject to acetylation, a new form 
of AMPAR regulation that antagonizes receptor ubiquitination due to competition 
for the same lysine residues (Wang et al., 2017). In this study, we further 
investigated the molecular mechanism involved in AMPAR acetylation and 
examined the role of AMPAR acetylation in cognitive deficits in AD.   
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We found that in brain lysates from AD patients, a reduction in total AMPAR 
amount is accompanied with a decrease in acetylation of AMPARs. The change in 
AMPAR acetylation was also observed in the brains of APP/PS1 AD mice. 
Consistently, treatment of neuronal cultures with soluble Aβ oligomers led to a 
significant reduction in the level of AMPAR acetylation.  
In our previous work, SIRT2 was identified as the deacetylase for AMPAR 
deacetylation (Wang et al., 2017) however, the related acetyltransferase remained 
unknown. In this study, we discovered that p300 functions as the acetyltransferase 
responsible for AMPAR acetylation. Though p300 is generally known for its role in 
acetylation of nuclear histone proteins, it also localizes in the cytosol where it 
acetylates various substrates (Aslan et al., 2015; Dancy and Cole, 2015; Kwok et 
al., 2006; Rotte et al., 2013; Sebti et al., 2014; Shi et al., 2009). Our results 
demonstrate that p300 acetyltransferase activity triggers acetylation of AMPARs, 
resulting in a reduced rate in receptor internalization and degradation, leading to 
an increase in AMPAR cell-surface expression and elevated accumulation at the 
synapse.  
The implication of AMPAR acetylation in brain function may vary depending 
on the basal levels of AMPAR protein amount and the extent of AMPAR 
acetylation. In this study, an increase in AMPAR acetylation led to improvements 
in memory in the APP/PS1 AD mice. Under AD conditions, a dramatic reduction in 
overall AMPAR amount is a major factor in causing synaptic weakening and 
impairments in cognition. Therefore, reintroduction of the acetylated and stabilized 
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AMPARs restores the level of AMPARs and synaptic activity, leading to rescue of 
AD-related memory deficits. Interestingly, over-stabilization of AMPARs via 
enhanced receptor acetylation seems to have different effect on brain function. 
Indeed, wild type mice expressing the stabilized acetylation mimetic GluA1, as well 
as knockout mice lacking the deacetylase SIRT2, showed impairments in synaptic 
plasticity and memory (Wang et al., 2017). This memory impairment likely results 
from excessive over-stabilization of acetylated AMPARs at synapses. In normal 
non-AD animals, a dramatic increase in AMPAR acetylation disrupts receptor 
trafficking and turnover, which is probably the cause for synaptic dysregulation and 
memory deficits (Wang et al., 2017).  
Given their crucial role in interneuronal communication and brain function, 
AMPARs have been identified as a therapeutic target for several neurological 
disorders, (Hettinger et al., 2018; Lee et al., 2016; Lynch, 2006; Paula-Lima et al., 
2013; Swanson, 2009; Zhang et al., 2019b). Our findings provide further support 
for potential strategies targeting AMPARs for the treatment of AD-related cognitive 
dysfunctions. Thus far, the main treatment focus has been the use of positive 
allosteric modulators of AMPARs known as Ampakines (Bernard et al., 2010; 
Black, 2005; Fernandes et al., 2018; Ward et al., 2010), a few of which have gone 
to clinical trial. However, while compounds showed some success in animal 
models (Bretin et al., 2017; Giralt et al., 2017; Lauterborn et al., 2016), they have 
had low clinical success (Bernard et al., 2019; Trzepacz et al., 2013; Wezenberg 
et al., 2007). Due to a lack of chemical diversity among the Ampakines, alternative 
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strategies for AMPAR-based treatment are being considered (Chang et al., 2012; 
Hao et al., 2015; Lee et al., 2016; Zhao et al., 2019). Our results provide a basis 
for pharmacological manipulation of AMPAR acetylation as a potential therapeutic 
strategy. On a broader level, because ubiquitination, a modulation antagonizing 
acetylation and resulting in receptor degradation, is enhanced in AD (Gadhave et 
al., 2016; Liu et al., 2019; Tramutola et al., 2018), manipulation of both of these 
opposing processes should be considered for more efficient management of AD.  
In conclusion, our results show that the acetylation of AMPARs leads to a blockage 
of Aβ induced reduction of AMPARs at the synapse by preventing receptor 
internalization, resulting in significant improvements in memory for the transgenic 
AD mice. These findings encourage future efforts to identify novel compounds that 





Figure A.1. Aβ treatment induces a reduction in AMPAR acetylation 
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(A) Hippocampal neurons were treated with Aβ (1μM) for 24 h and probed for 
synaptic GluA1 using immunocytochemistry (Total GluA1: Green; Surface GluA1: 
Red) (scale bar, 5 µm). (B) Quantitative analysis of the GluA1 puncta intensity 
showed a decrease in both surface (Ctrl, n = 10 cells, 548 puncta; Aβ, n = 11 cells, 
511 puncta; t(34) = 3.453, p = 0.0015) and total intensities (Ctrl, n = 10 cells, 597 
puncta; Aβ, n = 11 cells, 652 puncta; t(34) = 3.539, p = 0.0012). (C) Synaptosome 
purification of cultured cortical neurons incubated with Aβ (n = 3 experiments). (D) 
Quantification showed a decrease in synaptically localized, as well as total, GluA1 
levels. (Synaptic: t(8) = 12.30, p < 0.0001; Total: t(8) = 12.85, p < 0.0001). (E) 
Quantification shows no change in PSD95 levels. (Synaptic: t(8) = 1.186, p = 
0.2695; Total: t(8) = 1.940, p = 0.0883). (F) GluA1 acetylation levels were assessed 
via acetylation assays using cultured cortical neurons incubated with Aβ (n = 4 
experiments). (G) Quantitative analysis showed that application of Aβ reduced 
acetylated and total GluA1 levels. GluA1 acetylation was measured by normalizing 
the acetyl-lysine signal to the amount of GluA1 in IP. (Acetylated: t(12) = 1.93, p = 
0.0018; Total: t(12) = 2.87, p = 0.031). (H) Quantification shows no change in PSD95 
levels.  (t(4) = 0.4946, p = 0.6468). (I)† Acetylation assays from prefrontal cortical 
brain homogenates from AD patient and healthy control brains (n = 3 brains). (J)† 
Quantification showed reduced acetylation of GluA1 in AD patients’ brains 
compared to those of controls. (Acetylated: t(4) = 8.014, p = 0.0013; Total: t(8) = 
2.478, p = 0.038). (K)† Quantification showed a significant increase in GluA1 
ubiquitination in AD brains compared to those of controls. (t(4) = 5.0352, p = 
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0.00731). * p < 0.05, **p < 0.01, *** p < 0.001. Data are mean ± SEM. † With 





Figure A.2. Acetyltransferase p300 acetylates and stabilizes AMPARs 
(A)† Acetylation assays from in vitro reactions with purified acetyltransferases. (B)† 
Quantification shows that incubation with p300, but not CBP, PCAF, or GCN5 
increased GluA1 acetylation. (F(4,10) = 4.263, p = 0.0286, n = 3 experiments). (C)† 
Inhibition of p300 acetyltransferase activity by C646 (40 μM, 4 h) led to reduced 
acetylation while activation by CTPB (20 µM, 4 h) led to increased acetylation. (D) 
GluA1 puncta levels were assessed by immunocytochemistry following 
overexpression of p300 (Total GluA1: Red) (scale bar, 5 µm). (E) Quantitative 
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analysis showed overexpression of p300 increased total GluA1 puncta intensity. 
(Ctrl, n = 25 cells, 2407 puncta; p300, n = 23 cells, 2164 puncta; t(46) = 4.539, p < 
0.0001). (F-G)† In HEK293T cells, overexpression of p300 increases GluA1 
intensity. Additionally, expression of GluA1-4KR mutant abolishes p300-induced 
GluA1-WT up-regulation, indicating the lysine-dependence of p300 effect (WT: 
pcDNA v p300: t(12) = 3.255, p = 0.0205, pcDNA v PCAF: t(12) = 0.3032, p = 0.9873; 
4KR: pcDNA v p300: t(12) = 1.230, p = 0.5648, pcDNA v PCAF: t(12) = 0.630, p = 
0.9145; F(2,12) = 5.601, p = 0.0191; n = 3 experiments). * p < 0.05, **p < 0.01, *** p 







Figure A.3. Acetylation stabilizes AMPAR synaptic localization 
(A) Cultured hippocampal neurons were treated with B2, to inhibit SIRT2 (Total 
GluA1: Green; Surface GluA1: Red) (scale bar, 5 µm). (B-C) Quantification 
showed B2 treatment increased GluA1 puncta localization and blocked Aβ induced 
reduction in GluA1 as measured by GluA1 (B) total and (C) surface puncta 
intensity. (Ctrl, n = 17 cells, 21,486 puncta; Aβ, n = 19 cells, 25,742 puncta; B2, n 
= 17 cells, 14,838 puncta; B2 + Aβ, n = 17 cells, 11,524 puncta; Total: F(3, 70) = 
12.22, p < 0.0001; Surface: F(3, 68) = 36.33, p < 0.0001). (D) CTPB treatment, to 
activate acetyltransferase activity of p300, followed by immunocytochemistry 
probing of GluA1 (Total GluA1: Green; Surface GluA1: Red) (scale bar, 5 µm). (E-
F) Quantification showed CTPB treatment increased GluA1 puncta localization 
and blocked Aβ induced reduction in GluA1 puncta intensity as measured by 
GluA1 (E) total and (F) surface puncta intensity. (Ctrl, n = 10 cells, 2615 puncta; 
Aβ, n = 11 cells, 3964 puncta; CTPB, n = 8 cells, 4383 puncta; CTPB + Aβ, n = 8 
cells, 3363 puncta; Total: F(3, 36) = 21.78, p < 0.0001; Surface: F(3, 35) = 19.80, p < 
0.0001).  (G) Overexpression of p300 increased total GluA1 puncta intensity and 
blocked Aβ induced reduction. (Ctrl, n = 7 cells, 336 puncta; Aβ, n = 10 cells, 332 
puncta; p300, n = 10 cells, 337 puncta; p300 + Aβ, n = 9 cells, 351 puncta; F(3, 32) 
= 24.44, p < 0.0001). (H) Aβ treatment of hippocampal neurons overexpressing 
GluA1-WT-GFP or GluA1-4KQ-GFP acetylation mimetic (Surface GluA1: Red) 
(scale bar, 5 µm). (I) Quantitative analysis of surface expressing exogenous GluA1 
normalized to total puncta expressing exogenous GluA1 showed GluA1-4KQ-GFP 
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increased GluA1 surface expression and blocked Aβ induced decrease in surface 
GluA1 levels. (GluA1-WT, n = 8 cells, 798 puncta; GluA1-WT + Aβ, n = 9 cells, 943 
puncta; GluA1-4KQ, n = 9 cells, 901 puncta; GluA1-4KQ + Aβ, n = 8 cells, 862 
puncta; F(3, 40) = 17.75, p < 0.0001). * p < 0.05, **p < 0.01, *** p < 0.001. Data are 




Figure A.4. Acetylation blocks Aβ induced receptor internalization 
(A) Internalization assay of hippocampal neurons treated with CTPB, to activate 
acetyltransferase activity of p300, or CTPB with Aβ (Surface GluA1: Green; 
Internalized GluA1: Red) (scale bar, 5 µm). (B) Quantification of the puncta 
intensity of internalized GluA1 to initial surface total GluA1 (internalized + 
remaining surface) showed CTPB treatment blocked Aβ induced internalization of 
GluA1. (Ctrl, n = 19 cells, 2095 puncta; Aβ, n = 19 cells, 2124 puncta; CTPB, n = 
19 cells, 6230 puncta; CTPB + Aβ, n = 19 cells, 3341 puncta; F(3, 72) = 20.91, p < 
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0.0001). (C) Internalization assay of hippocampal neurons overexpressing GluA1-
WT or GluA1-4KQ with or without Aβ (Internalized GluA1: Red) (scale bar, 5 µm). 
(D) Quantitative analysis of the puncta intensity of internalized GluA1-GFP or 
GluA1-4KQ-GFP to total GluA1-GFP or GluA1-4KQ-GFP expressed at that 
puncta. Quantification showed Aβ induced internalization of GluA1 is suppressed 
by overexpression of GluA1-4KQ. (GluA1-WT, n = 26 cells, 2637 puncta; GluA1-
WT + Aβ, n = 20 cells, 2161 puncta; GluA1-4KQ, n = 20 cells, 1897 puncta; GluA1-
4KQ + Aβ, n = 20 cells, 3018 puncta; F(3, 76) = 14.01, p < 0.0001). * p < 0.5, ** p < 





Figure A.5. Viral brain injection of GluA1-4KQ restores GluA1 expression and 
synaptic accumulation† 
 (A) Hippocampal tissue from 11-month wild type and APP/PS1 mouse brains was 
homogenized and immunoprecipitated with antibody against GluA1. GluA1 
acetylation and ubiquitination levels were detected through probing the 
immunoprecipitated GluA1 with anti-Acetyl-Lysine or ubiquitin antibodies, 
respectively. (B) Quantitative analysis of the GluA1 acetylation levels showed a 
reduction in AMPAR acetylation in APP/PS1 mice. (t(4) = 6.652, p = 0.0027, n = 3 
experiments). (C) Quantification analysis of the GluA1 ubiquitination levels showed 
an increase in AMPAR ubiquitination in APP/PS1 mice (t(4) = 3.594, p = 0.0229, n 
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= 3 experiments). (D) GluA1 acetylation and ubiquitination levels were detected 
through probing GluA1 immunoprecipitated from hippocampal tissue from 5-month 
old wild-type mice or APP/PS1 mice with anti-Acetyl-Lysine or ubiquitin antibodies, 
respectively (n = 3 brains). (E) AAV expression was observed (green) 6 weeks 
after injection. Cell nuclei were stained with Hoechst (blue) to show the cortex and 
hippocampus (scale bar, 500 µm). (F) GluA1, GluA2, synapsin I, and PSD95 were 
detected by Western blotting in whole cell lysates, cytosolic fractions and 
synaptosomal fractions of mouse hippocampus. * p < 0.05, ** p < 0.01, *** p < 





Figure A.6. Overexpression of GluA1-4KQ rescues hippocampal LTP and the 
visual episodic memory deficit in APP/PS1 mice† 
(A) LTP recordings of fEPSP in acute hippocampal slices from AAV- injected wild-
type mice or APP/PS1 mice. (B) Quantitative analysis of the normalized fEPSP 
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slope. (F(3, 8) = 95.08, p < 0.0001, n = 2 animals per condition, 3 brain slices per 
animal). (C) The experimental design of novel object recognition test (NOR). One 
day before the memory acquisition, the mice were habituated to the arenas for 5 
min, as indicated in the first box. The second box showed the acquisition trial. The 
third and fourth box showed the test trial conducted 1 h and 24 h after the 
acquisition trial. (D) The discrimination index of 1 h test trial and 24 h test trial. (n 
= 5 animals). (E) The recognition index between objects A and B in the acquisition 
trial. (WT: t(32) = 0.3497, p = 0.99, APP/PS1 Con: t(32) = 0.5760, p = 0.97, APP/PS1 
GluA1-WT: t(32) = 0.2057, p = 0.99, APP/PS1 GluA1-4KR: t(32) = 0.0206, p = 0.99; 
F(3,32) = 1.023, p = 0.3953) (F) The recognition index between objects A and C in 
the test trial 1 h after the acquisition trial. (WT: t(32) = 7.083, p < 0.0001, APP/PS1 
Con: t(32) = 0.1026, p = 0.99, APP/PS1 GluA1-WT: t(32) = 2.207, p = 0.1314, 
APP/PS1 GluA1-4KR: t(32) = 4.363, p = 0.0005; F(3,32) = 31.77, p < 0.0001) (G) The 
recognition index between objects A and D in the test trial 24 h after the acquisition 
trial (WT: t(32) = 7.275, p < 0.0001, APP/PS1 Con: t(32) = 0.2735, p = 0.99, APP/PS1 
GluA1-WT: t(32) = 3.555, p = 0.0048, APP/PS1 GluA1-4KR: t(32) = 5.196, p < 0.0001; 
F(3,32) = 1.061, p = 0.3793). * p < 0.05, ** p < 0.01, *** p < 0.001. Data are mean ± 
SEM. † Contribution from Yang-Ping Shentu and Rong Liu.  
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